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Photodynamic therapy (PDT) is an emerging therapy for the treatment of 
cancer and various other human disorders. 5-Aminolaevulinic acid (ALA) is a 
simple natural product that is of great interest for PDT because it can be 
converted within cells via the haem biosynthetic pathway to the 
photosensitiser, protoporphyrin IX (PpIX). ALA-PDT has become a first line 
clinical approach for the treatment of cancerous and precancerous skin lesions 
(e.g Bowen’s disease, basal skin carcinomas, and actinic keratosis) that would 
otherwise require significant conventional surgery. However, ALA being a 
zwitterion suffers from poor lipid solubility and at the same time has stability 
issues at physiological or alkaline pH.   
The work herein describes some novel strategies to enhance the delivery of 
ALA to specific cell types using targeted ALA dendrimeric prodrugs. 
Specifically, it describes the synthesis of molecules consisting of branched 
units with 3 or more copies of ALA attached to a central core structure (e.g. 
gallic acid) using copper-catalysed azide-alkyne click chemistry (CuAAC). 
Selective delivery of the dendrimeric ALA cargo was achieved by attachment 
of a homing peptide to an independently addressable functional group on the 
prodrug core. As proof of concept of this approach, systems were prepared 
containing a peptide that allows selective targeting of the epidermal growth 
factor receptor (EGFR) which is overexpressed in a variety of tumours. 
Targeted ALA delivery and PpIX production was studied with these prodrugs 
in EGFR-expressing breast adenocarcinoma cells (MDA-MB-231 cells) and a 
peptide-targeted derivative with 9 ALA units was found to have enhanced PDT 
efficacy compared to an equimolar dose of ALA. Other targeting units that have 
been attached to these dendrimeric ALA prodrugs include biomolecules such 
as vitamin E, thymidine (a nucleoside) and a glucose derivative. Additionally, 
strain-promoted azide-alkyne cycloadditions (SPAAC) of the same EGFR-
targeting peptide with some classical photosensitisers were also investigated 
and biological studies in EGFR-overexpressing cell lines were carried out. 
Lastly, a group of cell penetrating peptide-ALA conjugates have been 
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CHAPTER 1: INTRODUCTION 
1.1 Brief history of Photodynamic therapy (PDT) 
Therapeutic approaches involving light (visible and non-visible) have long 
been applied in ancient Egypt, India and China to treat various diseases  such 
as psoriasis, rickets, vitiligo, cancer and psychosis.1 The Greek physician 
Herodotus in 600 BC reported the benefits of sunlight (heliotherapy) on the 
restoration of health, which was further supported by Hippocrates                   
(460-375 BC) who also reported the use of heliotherapy to treat human illness.2 
In the eighteenth and nineteenth centuries, the use of sunlight was applied to 
treat a range of disorders, including tuberculosis, rickets, scurvy, rheumatism, 
paralysis, edema and muscle weakness, but it was the Danish physician Niels 
Rydberg Finsen who provided the first scientific evidence for the potential use 
of other forms of light in therapy. Finsen used red light for the amelioration of 
suppuration and scarring from smallpox, however his most important findings 
were for  the treatment and cure of lupus vulgaris (a tubercular condition of 
skin causing reddish brown plaques) by using ultraviolet light from a carbon 
arc.3 Finsen was later awarded a Nobel Prize for Physiology-Medicine in 19032 
in recognition of this work.   
Photochemotherapy combines the use of both a chemical agent                            
(or photosensitizing agent) and light. In such an approach, light of an 
appropriate wavelength is focussed  on the target tissues where the chemical 
is localized in order to generate a therapeutic effect.1  The principle of 
photochemotherapy has been known for over 3000 years and it was applied 
in ancient India for the treatment of the skin disease vitiligo using extracts from 
the plant Psoralea corylifolia followed by exposure to sunlight. In the 1970s, 
the combination of UVA light and psoralen (1) (Figure 1), which is derived from 
the seeds of P. corylifolia, began to be used clinically to treat psoriasis, which 
became known as PUVA therapy.  More recently, PUVA has also been used 
for the treatment of other dermatological conditions such as mycosis fungoides 




Figure 1. Structures of psolaren, acridine orange and eosin. 
The concept of photodynamic action started taking shape in the late 1800s 
when one of Prof. Herman von Tappeiner’s medical students, Oscar Raab, at 
Ludwig-Maximillian University, Munich, observed some inconsistencies in his 
data while working on the antimalarial properties of acridine orange (2)    
(Figure 1).5  He noticed that a specific concentration of acridine orange was 
able to kill paramecia within 60-100 min compared to 800-1000 min from 
previous experiments. This made Raab and von Tappeiner thoroughly analyse 
their experimental protocols and led to the discovery that the tenfold decrease 
in time was due to differences in the lighting conditions between the two sets 
of experiments. They subsequently went on to prove that a combination of light 
and acridine orange is required to kill paramecia, however the role of oxygen 
in such photodynamic processes was still unknown at this stage.6 
Following the publication of these results in 1900, further research was initiated 
by von Tappeiner in collaboration with Albert Jesionek from the University of 
Munich. They investigated topical application of the dye eosin (3) (Figure 1) 
together with sunlight or arc-lamp light for the treatment of facial basal cell 
carcinoma and observed total tumor resolution and a 12 month relapse-free 
period in two-thirds of the patients.7  
In 1904, von Tappeiner  and Jodlbauer investigated the application of aniline-
based dyes and light in protozoa and reported for the first time that  oxygen 
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was required for photosensitization.8 The results from the above experiments 
were collated into a book in which the word ‘photodynamic therapy’ was coined 
to describe this oxygen-dependent photosensitization process.9  
Herman von Tappeiner is thus considered to be one of the pioneers of 
photobiology. However, another important phase in the field of photodynamic 
therapy came with the discovery and subsequent investigation of 
haematoporphyrin (4) (Figure 2).10  
 
Figure 2. Structure of haematoporphyrin. 
Haematoporphyrin was isolated in 1841 by Scherer in an impure form by 
treating dried blood with concentrated sulfuric acid and washing the resulting  
precipitate free of iron.11 Further treatment with ethanol gave a residue with a 
blood-red colour, indicating that iron was not essential for the colour of the 
blood. Later in 1867, Thudichum described the absorption spectrum and 
fluorescence of this purple-red substance, while Hoppe-Seyler (1871) was the 
first to describe the same purple-red substance by its original name 
‘Haematoporphyrin’.9, 12, 13 The first report on the biological properties of 
haematoporhyrin came in 1908 when Walter Hausmann investigated the effect 
of this photosensitiser on paramecia and red blood cells.14 This was followed 
by Pfeiffer’s work in 1911 and Hausmann (1911) who reported sensitisation on 
guinea-pigs and white mice with haematoporphyrin (4), describing fairly acute, 
sub-acute, and chronic photosensitivity changes and some phototoxicity with 
intense light.15 The first study on the photosensitizing effects of 
haematoporhyrin in humans was attempted by a German doctor, Friedrich 
Meyer-Betz, who in 1913 decided to self-administer 200 mg of 
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haematoporhyrin, followed by exposing himself to sunlight.16 Following the 
injection, Meyer-Betz suffered from erythema and oedema on the areas of his 
body which were exposed to sunlight, and remained photosensitive for more 
than two months.  
The next important stage in the study of haematoporphyrin as a 
photosensitizing agent was the observation of its tumour-localizing properties.9 
Policard in 1924 investigated the selective localization of haematoporphyrin in 
experimental rat sarcomas, which were exposed to light from a Wood lamp  
following administration of the sensitizer (a Wood lamp is a low-output mercury 
arc covered by a Wood filter (barium silicate and 9% nickel oxide) that emits 
wavelengths 320–450 nm (peak 365 nm). The resulting red fluorescence 
which was observed from the tumours was attributed to the accumulation of 
sensitizer.17 Another major finding was reported by Auler and Banzer in 1942 
who were the first to observe photodynamic action involving the selective 
uptake of haematoporphyrin (4) in primary and metastatic tumours as well as 
in lymph nodes in comparison to the normal surrounding tissue.18 However, in 
all the above experiments, consistent uptake of sensitizer was not possible 
without administering large doses of haematoporhyrin. Further investigations 
into the chemical nature of haematoporhyrin studied previously revealed that 
it was not in fact a pure compound but a variable mixture of a number of 
porphyrins.9 Subsequent attempts to isolate the active component gave rise to 
the discovery of haematoporphyrin derivative (HpD) which is discussed in 
further detail in Section 1. All these studies helped to lay the foundations for 
the development of the technique of photodynamic therapy (PDT) into the 
clinical technique that is used today. Photodynamic therapy (PDT) in general 
can be described as a non-thermal therapeutic technique in which targeted 
destruction of diseased tissue is achieved by exposure to light after selective 
administration of a light-activated photosensitising drug (photosensitiser).19 
The major advantage of PDT is that the therapeutic effect is highly controlled 
as it is limited to the illuminated area, and takes place only during illumination, 




The three key components of PDT are: 
1. Photosensitiser (PS)   
2. Light source (preferably red light)  
3. Molecular oxygen 
Each of the three key components above are harmless (inert) on their own but, 
in combination, they may give rise to lethal cytotoxic agents causing cell death. 
1.2 Photochemical and photophysical basis of PDT 
The photochemical and photophysical basis of PDT can be explained by a 
modified Jablonski diagram as illustrated in Figure 3.2  
 
Figure 3. Modified Jablonski diagram showing type 1 and type 2 photooxygenation processes 
(adapted from Bonnett et al.2). 
A photosensitiser molecule upon absorption of light of the appropriate energy 
is excited from the ground state (So, electrons with opposite spins) to an 
excited single state (S1). This state is unstable and loses its energy either 
through fluorescence (by emission of light) or by producing heat                 
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(internal conversion).  However through a process of intersystem crossing, the 
excited singlet state photosensitiser may also form a stable excited triplet state 
(electrons with parallel spins). The excited triplet state is much more stable in 
comparison to the excited singlet state and has a lifetime of microseconds.         
It has been noted that the slower the decay of this triplet state, the longer is 
the PDT effect.19  
The excited state of a photosensitiser may initiate a chemical reaction in a 
substrate causing  damage to the living tissue by two different mechanisms.2  
Type 1 mechanism: This is based on electron transfer and generates free 
radicals by either electron transfer to (or from) substrates or by hydrogen atom 
abstraction from the substrate (Figure 4). The resulting radicals or radical ions 
then react with ground state oxygen to produce oxygenated products such as 
superoxide ion (O2
-
), hydrogen peroxide (H2O2) and hydroxyl radical (OH
.
). 
These may then go on to react with biomolecules in targeted tissue. 
 
Figure 4. Overview of type 1 reactions during PDT (derived from Bonnett et al.).2 
Type 2 mechanism: This involves transfer of electronic excitation energy from 
the excited triplet state of a sensitizer (T1) to ground state molecular oxygen 
(3O2) to give the sensitizer in its ground state, S0, and singlet oxygen (1O2) 




Figure 5. Overview of type 2 reactions during PDT (derived from Bonnett et al.).2
1.3 Photosensitisers in PDT  
A photosensitiser in PDT is a chemical agent which absorbs light of a specific 
wavelength and generates lethal cytotoxic agents such as singlet oxygen.19      
A photosensitiser for clinical use should ideally possess the following 
properties:19, 20  
1. Chemical stability. 
2. Selectivity towards the target tissue. 
3. Rapid clearance from a patient’s body. 
4. Efficient production of singlet oxygen. 
5. No dark or systemic toxicity. 
6. Easily synthesised and no toxic by-products upon light activation. 
7. Strong absorption and high extinction coefficient in the red/near infrared 
region of the electromagnetic spectrum (600–850 nm) to allow 
activation at deeper levels of tissue. 
Many photosensitiser molecules have been identified or developed and are 
mainly classified as first and second generation photosensitisers. A detailed 
description of some of these follow below. 
8 
 
1.3.1 First-generation photosensitisers 
Photosensitisers such as acridine orange, eosin, psoralen, haematoporphyrin 
and haematoporphyrin derivative (HpD) were the first group of compounds that 
were tested for their PDT activities, and are hence termed first-generation 
photosensitisers. These molecules are either natural products, or early 
synthetic dye molecules that were not developed specifically for 
phototherapies. This section focuses mainly on haematoporphyrin and its 
derivatives as these molecules have been investigated in some detail for PDT 
and have shown clinical real clinical potential.21 As noted earlier, the 
fluorescent properties of haematoporphyrin were first reported as early as 
1867, and it was only later shown to be a potent photosensitiser by 
Hausmann.1, 9 However, Schwartz et al. in 1955 while investigating the nature 
of haematoporphyrin found the sensitizer to be a crude mixture of various other 
porphyrins, most of which had different biological properties.22 Partial 
purification gave pure haematoporphyrin with the structure shown in Figure 4, 
which itself was found to have poor tumour-localizing properties, and it was as 
also shown to be only a weakly phototoxic agent. Schwartz later developed a 
general purification system (Scheme 1) in which haematoporphyrin 
dihydrochloride was subjected to a series of acid and base treatments before 
obtaining a purified fraction, which was later identified by the name 
haematoporhyrin derivative (HpD).2 HpD was found to be a powerful 
photosensitiser and had better affinity for tumour cells than the parent 




Scheme 1.  Isolation procedure for the production of HpD and its commercial variants from 
impure haematoporphyrin dihydrochloride. 
Following up on Schwartz’s work on HpD, Lipson from the Mayo Clinic along 
with Baldes investigated the effect of HpD on malignant tissue and found that 
HpD had enhanced localization in malignant tissue with improved PDT 
properties.23-26 Lipson et al. later in 1966 conducted the first human PDT 
studies using HpD in a female patient with extended recurrent ulcerated cancer 
of the mammary gland.27 The results showed recurrence of cancerous lesions 
after several weeks, however the study gave substantial evidence of 
neoplastic tissue death by HpD-mediated PDT.  
Another early in vivo PDT study with HpD was carried out by Diamond et al. in 
1972 using glioma cells that had been implanted subcutaneously in rats.28 It 
was found that cells that were treated with HpD and light suffered a growth 
arrest for up to 20 days post-photosensitization along with a reduction in 
tumour volumes. A few years later, Kelly and Snell also demonstrated that light 
activation of HpD eliminated bladder carcinoma in mice.29 At around the same 
time, Thomas J. Dougherty and co-workers at the Roswell Park Cancer 
Institute, New York also began a pioneering set of investigations into HpD-
mediated PDT.  They initially purified HpD by removing the monomers to form 
a product which was later called Photofrin®. This then led to an extensive 
clinical survey by Dougherty and his colleagues in 1978, which involved            
Haematoporphyrin dihydrochloride 
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25 patients with cutaneous and sub-cutaneous malignancies.30 The results 
were promising and the majority of the patients showed complete or partial 
response in cutaneous or sub-cutaneous malignant lesions. HpD received its 
first regulatory approval (marketed as Photofrin (5) by QLT Phototherapeutics 
Inc, Vancouver) (Figure 6) in 1995. The initial approval in Canada was limited 
only to papilloma of the bladder, but subsequent approvals worldwide were 
obtained for other indications in France (oesophagus, bladder), Germany 
(lung), Japan (lung, oesophagus, stomach, and cervix), Netherlands (lungs, 
oesophagus) and for palliative use (bronchus, oesophagus) in the UK in 1999. 
Other commercial variants of HpD were also developed e.g Hematodrex 
(Bulgaria), Photocarcinorin (China), Photosan (Germany) and Photogem 
(Russia). After its original FDA approval, HpD has since received regulatory 
approval in more than 40 countries.2  
 
Figure 6. Structure of Photofrin (5). 
1.3.2 Second-generation photosensitisers 
Although HpD showed some promising clinical activity and subsequently 
received a number of regulatory approvals, it suffers from various drawbacks 
such as: 
1. Difficulty in reproducing the complex mixture of dimers and oligomers 
of HpD. 
2. Modest PDT effect vs cancer cells. 
3. Limited selectivity between tumour and normal tissue. 
4. Long clearance time leading to prolonged skin photosensitivity in 
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patients for several weeks. 
To overcome the shortfalls of first generation photosensitisers like HpD, a new 
generation of photosensitising agents have therefore been developed, based 
on porphyrin or porphyrin-like macrocyclic structures such as chlorins, 
bacteriochlorins, pheophorbides, bacteriopheophorbides, texaphyrins, 
porphycene and phthalocyanins (Figure 7).  
These photosensitisers are all single substances with a fixed composition that 
are typically available by straightforward and high-yielding syntheses.      
Second-generation photosensitisers have also been designed specifically to 
have significant absorption at wavelengths in the far red (660-700 nm) or near 
infrared regions (700-850 nm) of the electromagnetic spectrum.                        
Such wavelengths allow deeper penetration of the light up to 20 mm into tissue, 
compared to 5-10 mm at 630 nm.31, 32 
 
Figure 7. Basic structures of porphyrin-based second-generation photosensitisers. 
A brief overview of some of these second generation photosensitisers is given 





Figure 8. Core structure of porphyrin derivatives (porphin). 
Porphyrins are a group of heterocyclic and macrocyclic organic compounds 
consisting of four modified pyrrole sub-units joined by methine bridges (=C-) in 
a cyclic arrangement (Figure 8). The simplest unsubstituted tetrapyrrole ring 
arrangement is known as porphin, while substituted compounds are known as 
porphyrins.33, 34 The porphyrin system is aromatic with 18π electrons and are 
generally planar with low solubility in organic solvents and water. However 
substitution at the periphery increases their solubility in organic solvents.         
For example 5, 10, 15, 20-tetraphenylporphyrin (6) (TPP) is insoluble in water 
whereas modification with polar groups on the phenyl rings (7) increases the 
solubility in water (Figure 9). 
 





Porphyrins readily form complexes with metal ions which modifies their 
fluorescent and photodynamic properties. For example, the Al, Zn and Si 
complexes of phthalocyanines have been used in clinical studies and have 
shown enhanced PDT activities.35 Porphyrins also have characteristic UV 
spectra with an intense band at around 400 nm called the Soret or B band, and 
four distinct bands in the region 500-600 nm called the Q bands (Figure 10).2 
 
Figure 10. UV-Vis spectrum of a typical synthetic porphyrin showing the Soret band and            
Q bands. 
Over the years, many second-generation porphyrin-type photosensitisers 
have been synthesized and developed. Two important examples are meta-
tetra(hydroxyphenyl)porphyrin (8) (m-THPP) and protoporphyrin IX (9)     
(Figure 11). 
 























m-THPP (8) is one member of a large possible family of tetrahydroxyphenyl 
porphyrins. The hydroxyl functional group makes this group of molecules 
amphiphilic and causes small hyperchromic and bathochromic effects on Q 
Band 1. m-THPP (8) has been shown to be 25-30 times more potent compared 
to HpD in tumour photonecrosis upon irradiation at 648 nm.36 Amongst the 
other different isomers studied, the all-ortho derivative was found to cause 
severe skin photosensitivity and clinical trials were subsequently 
discontinued.2, 36   
Protoporphyrin IX (9) is actually a natural product and is an important precursor 
in haem biosynthesis. Its use in PDT and diagnosis is via its biosynthetic 
precursor, 5-aminolevulinic acid (5-ALA or ALA), or prodrugs thereof.             
ALA-induced protoporphyrin IX (9) was approved by the US FDA (Levulan) in 
1999 for the treatment of actinic keratosis. The methyl ester of ALA (Metvixia) 
received FDA approval in 2004 for treatment of actinic keratosis, whereas its 
hexyl ester (Hexvix) received approval in 2010 for bladder cancer diagnosis 
and was shown to produce PpIX 50-100 times more efficiently than ALA at an 
equivalent dosage.19, 37 The methyl ester of ALA is also an active component 
of Visonac, which is currently in phase 2 clinical trials (NCT01347879) in the 
USA for the treatment of acne vulgaris.38    
1.3.2.2 Chlorins and bacteriochlorins 
 
Figure 12. Basic structure of chlorins and bacteriochlorins. 
Chlorins and bacteriochlorins are β-dihydroporphyrins and                                         
β-tetrahydroporphyrins respectively that are formed by reduction of one or two 
peripheral double bonds in the porphyrin skeleton (Figure 12).31 These 
macrocycles play an important role in nature. Chlorin is the chromophore of 
15 
 
chlorophyll a and b (10, 11), while bacteriochlorin is the chromophore of the 
bacterial photosynthetic pigment, bacteriochlorophyll a (12) (Figure 13). 
Compared to a porphyrin, a chlorin has a much more intense Q Band I and it 
is shifted to a longer wavelength. The intensity of this band is further increased 
in the case of bacteriochlorins.2 
 
Figure 13. Structure of chlorophyll a (10), chlorophyll b (11) and bacteriochlorophyll a (12). 
Several photosensitisers from the chlorin group have been evaluated for their 
PDT efficacy. This includes the benzoporphyrin derivative monoacid ring A 
(13) (BPD-MA, verteporfin, Visudyne®), meta-tetra(hydroxyphenyl)chlorin (14) 
(m-THPC, Foscan®), tin ethyl etiopurpurin (15) (SnET2, Rostaporfin, 
PurlytinTM) and N-aspartyl chlorin e6 (16) (NPe6, Talaporfin, Ls11).35 
Verteporfin (13) is activated by light at 689 nm and was approved by the FDA 
in 1999 for the treatment of age-related macular degeneration (Figure 14). 
Verteporfin also causes less skin photosensitivity than Photofrin® due to the 
rapid clearance of the drug from the body.39, 40 
 
Figure 14. Structure of verteporfin (13). 
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m-THPC (14) (Temoporfin, Foscan®), which is formed by reduction of one of 
the pyrrole rings in m-THPP (8), has a red-shifted Q band absorption compared 
to photofrin (5) λmax (652 nm vs 630 nm) and a significantly higher molar 
absorption coefficient (15 fold) (Figure 15). 
 
Figure 15. Structure of m-THPC (14). 
It was the first sensitizer that was used in a clinical study for PDT of prostate 
cancer in 2002.41 It has received regulatory approval in Europe for the 
treatment of neck and scalp cancer and is also used successfully in the 
treatment of breast and pancreatic cancer.35, 42, 43 A water-soluble formulation 
of m-THPC has also been developed under the name of Fospeg® and showed 
lower dark toxicity when tested in the epidermoid carcinoma cell line, A431, 
over a wide range of fluences. The only drawback that has been reported for 
m-THPC is high skin photosensitivity, which was similar to that of       
Photofrin.19, 44, 45 
Other chlorin derivatives such as SnET2 (15) (Rostaporfin, PurlytinTM) have 
completed phase 2 clinical studies for cutaneous AIDS-related Kaposi’s 
sarcoma (Figure 16).46 Rostaporfin may be activated at a much greater depth 
in tissue compared to Photofrin® by irradiation at 664 nm, but has problems of  
possible dark toxicity and skin photosensitivity.47 N-Aspartyl chlorin e6 (16) 
(NPe6, Talaporfin, Ls11) was approved in Japan in 2003 for the treatment of 
lung cancer and has also shown potential for the treatment of fibrosarcoma, 
liver, brain and oral cancer. Unlike Photofrin®, NPe6 causes minimal skin 




Figure 16. Structures of SnET2 (15) and NPe6 (16). 
Several clinically important photosensitisers from the bacteriochlorin group like 
TOOKAD and its water-soluble derivative TOOKAD Soluble have been tested 
against prostate cancer.50, 51 LUZ11 is another derivative which recently 
completed phase 2 clinical trials for head and neck cancer.52 The key features 
for photosensitisers of the bacteriochlorin group are that near IR light between 
700-800 nm may be used for activation, and this has been found to be effective 
against pigmented tumours which are coloured and can absorb longer 
wavelengths.53   
1.3.2.3 Phthalocyanines and naphthalocyanines 
 
Figure 17. Basic structures of phthalocyanines and naphthalocyanines. 
Phthalocyanines (Pc) also fall into the tetrapyrrole group of photosensitisers, 
but have the carbon atoms at the meso positions (6, 13, 20 and 27) replaced 
by N. The presence of multiple meso-nitrogens and fused benzene rings 
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results in the formation of stable metal complexes from these photosensitisers. 
Unlike porphyrins, the Q bands (650-750 nm) of phthalocyanines are much 
more intense than the Soret bands, a property which is ideal for PDT.2, 41 
The complexes of phthalocyanines with Zn, Al, and Si (17)-(19) have been 
used in clinical studies, however due to the hydrophobic nature of these 
compounds, a formulation modification (e.g liposomes) was required         
(Figure 18).35 The aluminium complex of phthalocyanine (18) (Photosens) was 
approved in Russia in 2001 for the treatment of stomach, skin, lip, oral and 
breast cancer, however it showed prolonged photosensitivity for several 
weeks.54 Silicon phthalocyanine (19) (Pc4) has undergone in vivo and clinical 
studies along with completion of phase 1 trials for actinic keratosis, Bowen’s 
disease, skin cancer and mycosis fungoides (NCT00103246).55  
 
Figure 18. Structures of some clinically used phthalocyanine photosensitisers (17)-(19). 
1.3.2.4 Non-porphyrin based photosensitisers 
Over the years many non-porphyrin photosensitisers have been developed 
and include among others anthraquinones, phenothiazines, xanthenes, 
cyanines and curcuminoids (Figure 19). Hypericin (20) is an anthraquinone 
derivative extracted from St. John’s Wort and has a peak absorption at 600 
nm. It has been shown to release ROS to target cancer cells, however clinical 
trials against squamous cell carcinoma and basal cell carcinoma have yielded 
unsatisfactory results.56, 57 Phenothiazinium dyes such as methylene blue (21) 
(absorbs at 660 nm) and toluidine blue (22) (absorbs at 630 nm) have been 
studied for their antimicrobial applications as well as for anti-cancer 
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properties.58, 59 Methylene blue (21) has been included in clinical PDT 
treatments for basal cell carcinoma and Kaposi’s sarcoma as well as 
completed clinical trials for chronic periodontitis (NCT01535690).60, 61 
Toluidine blue (22) is currently undergoing Phase 3 clinical trials for chronic 
periodontitis (NCT01330082).35, 58, 60, 62 Rose Bengal (23) comes from the 
xanthene class of photosensitiser and absorbs at 549 nm. The presence of a 
heavy atom such as iodine has been shown to increase the triplet yield of the 
molecule by intersystem crossing leading to an enhanced singlet oxygen yield. 
Rose Bengal (23) has entered clinical trials for allogeneic stem cell 
transplantation.63 Curcumin (24) is a well-known component of the spice 
turmeric and is a new entry in the PDT field. It absorbs at 420 nm and is a 
hydrophobic molecule requiring a formulation vehicle in order to be used as a 
photosensitiser. Curcumin (24) has found most applications so far in 
antimicrobial PDT for the destruction of oral pathogens.64, 65 
Apart from the photosensitisers discussed above, which have been studied in 
some detail and in some cases have undergone clinical trials, there are some 
further miscellaneous photosensitisers that have been investigated for in vitro 
anti-microbial applications. These include cationic riboflavin (25) (flavin-based, 
natural product-derived)), ASQI (26) (squaraines, synthetic dye), DIMPy-
BODIPY (27) (BODIPY, synthetic dye), hypocrellin (28) (natural product) and 




Figure 19. Structures of some non-porphyrin photosensitisers (20)-(29). 
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1.3.3 Third-generation photosensitisers  
Recently, much work in the PDT field has been focused on the so-called 3rd 
generation of photosensitising agents, with the aim of increasing the selective 
accumulation of photosensitisers in targeted tissue, usually tumours. Some of 
the strategies adopted towards this approach are the conjugation of 
photosensitisers with biologically active elements such as peptides, anti-
tumour monoclonal antibodies, proteins such as transferrin or epidermal 
growth factor, folic acid and carbohydrate derivatives.53, 66  
For example, You et al. in 2015 investigated the synthesis and evaluation of 
derivatives of the non-selective photosensitiser, pheophorbide-a (30), 
conjugated to folic acid (31) and three specific targeting peptides, 
CRGDLASLC (32), cyclo(RGDfK) (33) and leuprorelin (34) (Figure 20).67  
 
Figure 20. Structures of pheophorbide-a (30) and different targeting units (31)-(34). 
Folic acid (31) is a ligand which targets the folate receptor which is 
overexpressed on the surface of many malignant cells. On the other hand, the 
CRGDLASLC (32) peptide binds to the αvβ6 integrin receptor, which is 
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overexpressed in head and neck cancer cells, whereas cyclo(RGDfK) (33) 
recognises the αvβ3 integrin receptor which plays an important role in tumour 
angiogenesis, progression and metastasis of various cancer cells. Leuprorelin 
(34) has been approved for the treatment of advanced stage prostate cancer 
and can be used as a targeting unit for the luteinizing hormone-releasing 
hormone (LHRH) receptor that is overexpressed in ovarian, breast and 
prostate cancer cells. Biological evaluation showed enhanced cellular uptake 
followed by PDT activity for all the pheophorbide-a (30) conjugates in cells 
expressing the receptors of corresponding targeting units.  
Stuchinskaya et al. have reported antibody-phthalocyanine gold nanoparticle 
conjugates in which anti-HER2 antibodies were attached to the nanoparticles 
to enhance the drug targeting.68 The 4-component system (anti-HER2 
antibody–phthalocyanine photosensitiser–PEG–gold nanoparticle) was tested 
in SK-BR-3, MDA-MB-231 and MCF-10A cell lines and the in vitro studies 
revealed enhanced selectivity towards breast cancer cells overexpressing the 
HER2 epidermal growth factor receptor, with enhanced PDT activity in these 
cell lines also. 
Ligand-targeted PDT with verteporfin (13) has been attempted by conjugation 
with the factor VII (fVII) protein.69 fVII has a high affinity and specificity for 
tissue factor (TF), which has been shown to be overexpressed in many types 
of cancer cells including solid cancers and leukaemia, and has also has 
selective expression in pathological neovascular endothelial cells in cancer. 
Results with a fVII-verteporfin conjugate showed it to have better selectivity 
and a stronger PDT activity in the MDA-MB-231 breast cancer cell line 
compared to verteporfin itself. 
Finally, Kascakova et al. have investigated the cell line-specific uptake and 
photodynamic activity of two conjugates (36) and (37) containing chlorin e6 
(35) and the somatostatin analogue [Tyr3]-octreotate (Figure 22). 70 Biological 
evaluation in human erythroleukemic K562 cells showed enhanced uptake for 
conjugate (36)  in cell lines overexpressing the neuropeptide somatostatin 
receptor compared to wild-type cells. Compared to non-conjugated Ce6 (35), 
PDT activity for (36) was lower, however it had higher photostability than Ce6 
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(35) which could compensate for its lower phototoxicity. Conjugate (37) did not 
show any receptor-mediated activity, possibly due to its high hydrophobicity.  
 
Figure 21. Chemical structures of Ce6 (35) and its [Tyr3]-octrotate conjugates (36) and (37). 
24 
 
1.4 Novel PDT techniques 
1.4.1 Nanotechnology 
There have been many applications of nanotechnology in the development of 
photosensitising agents for PDT. Nanoparticles are in general sub-microscopic 
particles made from naturally occurring or synthetic materials and can carry 
multiple copies of theranostic agents (Section 1.4.4) in a targeted manner.20 
The development of nanoparticles for PDT has the following advantages: 
1. Nanoparticles have a large surface to volume ratio. A large number of 
photosensitiser molecules can thus be delivered to the target cells.71 
2. Diffusion of photosensitiser molecules into tumour tissue is facilitated, 
as is their retention, due to the enhanced permeability and retention 
effect (EPR).72  
3. Premature release of photosensitisers and their inactivation by plasma 
components is prevented, thus reducing their overall photosensitivity.73 
4. Nanoparticle encapsulation can give photosensitisers amphiphilic 
properties which thus allows them to travel unhindered through the 
blood stream.74 
5. Nanoparticles allow surface modification with functional groups or 
targeting groups which further improves the biodistribution, 
pharmacokinetics, cell uptake and targeting potential.75 
Nanoparticles for PDT applictions can be classified into active and passive 
carriers based on the functional roles they play in enhancing PDT activity.      
The active carriers can be further sub-classified based mechanism of 
activation into photosensitiser nanoparticles, upconversion nanoparticles and 
self-lighting nanoparticles. The passive carriers can be further sub-classified 
into biodegradable and nonbiodegradable nanoparticles based on the material 
composition.76 For example, Khdair et al. investigated dioctyl sodium 
sulfosuccinate (Aerosol-OT) and sodium alginate for the encapsulation of the 
photosensitiser methylene blue and evaluated these nanoparticles in two 
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breast cancer cell lines: MCF-7 and 4T1.77 Following PDT, the level of 
intracellular reactive oxygen species was significantly increased and a higher 
incidence of necrosis was observed in both cell lines. Nuclear localization of 
methylene blue from the nanoparticles was also observed in the tumour cells, 
whereas free drug treatment resulted in accumulation of the drug in 
endolysosomal vesicles.  
1.4.2 Two-photon PDT (TP-PDT) 
In a single-photon PDT experiment, the photosensitiser absorbs a photon of 
light and moves to an excited singlet state which on intersystem crossing leads 
to a triplet state. The duration of this triplet state allows its interaction with 
molecular oxygen and the formation of singlet oxygen which is highly reactive 
and causes almost instantaneous cell damage (Type 2 reaction).                        
The minimum energy required in this process makes only visible light of 
wavelengths below 850 nm suitable. Two-photon PDT (TP-PDT) involves 
absorption of two low energy photons simultaneously by the photosensitiser 
and leads to a total energy absorption which is twice that of each absorbed 
photon (Figure 22).78  
 
Figure 22. Representation of a two-photon excitation process. 
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TP-PDT is thus advantageous compared to single photon PDT, in that 
wavelengths longer than 850 nm can provide enough energy to produce 
singlet oxygen. This in turn means that longer wavelengths (IR) could be used 
which will penetrate deeper into the targeted tissue.79  Also, since this process 
is highly dependent on the intensity of light, parameters can be altered in such 
a way that the event of TP-PDT occurs only in the focal plane of light delivered 
from a pulsed laser, thus achieving a precise spatial targeting. For example 
Collins et al. in 2008 reported the synthesis and evaluation of a series of 
photosensitisers derived from porphyrin-based molecular wires (38a-e) which 
had high two-photon cross-sections (Figure 23).79  
 
Figure 23. Structure of conjugated porphyrin dimers used in a two photon PDT study.79 
These compounds were evaluated in vitro in human ovarian adenocarcinoma 
cells (SK-OV-3) and the results were compared with a commercial 
photosensitiser, verteporfin. (38a) was found to be the most promising 
candidate amongst other derivatives (Figure 23) based on its PDT activity, cell 
uptake and high two-photon cross-section, and was taken further for in vivo 
studies to test selective closure of blood vessels using the dorsal skinfold 
window chamber model for non-invasive visualization of blood vessels.           
The results were encouraging and the authors were able to demonstrate the 
feasibility of two-photon photodynamic therapy as a new strategy for targeted 
occlusion of blood vessels. 
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1.4.3 Metronomic PDT 
The term metronomic was introduced to describe continuous low-dose 
administration of chemotherapeutic agents after it was found that low-dose 
chemotherapy is more anti-angiogenic than the conventional high-dose 
therapy.80, 81 Metronomic PDT (mPDT) involves delivering both the light and 
the photosensitiser over an extended period of time at a very low dose, thus 
improving the tumour-specific response via cell-specific apoptosis.82 However 
mPDT presents two technical challenges:82 
1. Continuous delivery of photosensitiser over an extended period of time 
(days or weeks) to ensure a high concentration of drug within the tumour 
and avoiding systemic toxicity. 
2. Continuous delivery of light to the tumour in a minimally invasive way. 
Davies et al. in 2007 reported a study which involved the delivery of ALA via 
mPDT for up to 4 days to CNS-1 tumour-bearing female Lewis rats. Results 
from bioluminescence imaging showed that there was no sign of any tumour 
regrowth at 26 days post-tumor implantation.83  
1.4.4 Theranostics 
Theranostics refers to the combination of therapeutics and diagnostics and is 
a term introduced by Funkhouser in 2002.84 Such systems can deliver both 
imaging and therapeutic agents within the same dose, the functionality of 
which could be switched between either thus leading to improved detection 
and treatment of disease (Figure 24). Theranostics can thus help in 
understanding the phenotype and heterogeneity of a tumour before the 




Figure 24. Representation of concept for theranostics.85 
Kopelman et al. (2005) reported a theranostic system which consisted of a 
photosensitiser (Photofrin) and MRI contrast agents encapsulated into a 
polyacrylamide core.86 The surface of the nanoparticle was further 
functionalized with PEG groups an integrin receptor- targeting peptide     
(Figure 25). Encapsulation of Photofrin within the nanoparticle was 
advantageous as it prevented the direct exposure of the sensitiser to the 
physiological environment and also allowed a significant reduction in the time 
interval between administration of Photofrin and light illumination (from 24 h        
to 1 h). Biological evaluation indicated selective accumulation of the 
nanoparticles in an αvβ3-overexpressing cell line (MDA-435) compared to 
MCF-7 cells (αvβ3 negative). The in vivo therapeutic activity of the Photofrin-
containing nanoparticles was evaluated in rats bearing intracerebral 9L 
tumours, and gliomas treated with the nanoparticles produced massive 
regional necrosis which resulted in shrinkage of tumour mass. Tumour kill was 
also established by increased mobility of water molecules, which was 
monitored by spatially resolved magnetic resonance around the tumour cells, 




Figure 25. Schematic representation of a theranostic system containing photosensitiser, MRI 
agent, targeting peptide and PEG group.86 
Other novel strategies have also been adopted to bring imaging and 
therapeutic agents together such as nanoagents (carbon nanotubes), quantum 
dots (QDs) and liposome-like porphysomes.87  
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1.5 Light sources in PDT 
To achieve a required PDT effect, the target tissue needs to be irradiated with 
light of an appropriate dose and wavelength which in turn generates enough 
singlet oxygen.88 Many light sources have been used clinically in PDT        
(Table 1) with further types currently under investigation.89 Lamps and lasers 
are the two most commonly used types of light source for PDT, and the choice 
of one over the other depends on the location of the tumour, dose of light 
required and the type of photosensitiser used.  
Lasers (light amplification by stimulated emission of radiation) provide light 
which is easily focussed and give a single colour (monochromatic).90 A major 
advantage of using lasers is that they produce monochromatic light which can 
be injected directly into fibres and delivered to the target site using specially 
designed fibre optics.89 Lamps on the other hand, provide a broad range of 
wavelengths and can be combined with different photosensitisers having 
different absorption maxima. Hence a common type of lamp could be used for 
PDT treatment with Foscan, Photofrin or ALA (eg. Dye laser).89 
Different light sources have been approved clinically for ALA-PDT. Blu-U® light 
has been approved for Levulan® emitting at 400 nm, whereas Aktilite® has 
been approved for Metvixia® emitting at 630 nm.91 
In recent years light emitting diodes (LED) have shown potential in PDT. LEDs 
offer some advantages over their counterparts; they are more affordable, 
stable, require low maintenance and can be arranged in a number of 









Table 1. Clinically used light sources in PDT (adapted from Brancaleon et al.).89 
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illumination 












1.6 Singlet Oxygen 
Molecular oxygen has a triplet electronic configuration in its ground state with 
two unpaired electrons occupying two degenerate antibonding π -orbitals 
(Figure 26). The excited singlet state however, which exists in two forms 
(1∑gO2 and 1ΔgO2), has electrons with opposite spins.92 The 1ΔgO2 form (also 
known as 1O2) is involved in the process of photosensitization, while 1∑gO2 is 
too short-lived (10−11–10−9 s in solution) to show any biologically activity.93  
 
Figure 26. Molecular orbital diagram for molecular oxygen (adapted from Josefsen et al.).92 
Unlike other reactive oxygen species, singlet oxygen is generally produced 
only when exogenous or endogenous photosensitisers absorb light energy. 
However, reactive oxygen species such as H2O2 and O2
−
 are produced under 
normal physiological conditions inside cells and can readily interconvert to 
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other ROS species. This can make it difficult to identify which ROS is 
responsible for a particular cellular response. 
The reaction between 1O2 and proteins has multiple effects and includes 
oxidation of side-chains, backbone fragmentation, dimerization/aggregation, 
unfolding or other conformational changes, enzymatic inactivation, and 
alterations in cellular handling and turnover. The most common targets for 1O2-
mediated oxidations are lipids (cholesterol and phospholipids), aromatic and 
heteroaromatic amino acids (Trp, Tyr, His), sulfur-containing amino acids     
(Cys, Met), and nucleic acid bases (guanine and guanosine).  
Tryptophan (39) is a highly sensitive towards various oxidizing agents 
including singlet oxygen. In general, tryptophan undergoes photooxidation to 
give an unstable primary intermediate, 3-hydroperoxyindolenine (39a), which 
then further rearranges to form N-formylkynurenine (39c) (FMK).94 At least 
three different pathways have been proposed for this transformation to FMK 
(39c) (Scheme 2). The first pathway involves heterolysis of the O-O 
hydroperoxide bond, followed by ring expansion to yield (39h) which then 
breaks down into FMK (39c).95, 96 Another pathway involves homolysis- or 
heterolysis-induced decomposition of O-O bond of the tricyclic hydroperoxide 
(39e). This gives an 8-membered hydroxyketone intermediate (39f) followed 
by decomposition to FMK (39c).97 Finally, a dioxetane (39b) that is derived 





Scheme 2. Proposed reaction pathways for singlet oxygen-mediated oxidation of 
tryptophan.94 
1.7 Photodynamic action 
A photosensitiser on exposure to light of a specific wavelength can deliver a 
PDT effect mainly through the following mechanisms: 
1. Direct cytotoxic effects  
2. Vascular damage  
3. Immunological responses 
The biological substrates typically involved are mitochondria, lysosomes, 
plasma membranes and nuclei, and their oxidative damage ultimately leads to 
cell death (Figure 27). A number of factors may govern the importance of one 
mechanism over another, such as the type of photosensitiser, its extracellular 
and intracellular localization, dose of photosensitiser or light, type of tumour 





Figure 27. Overview of the PDT effect. Targeted generation of 1O2 in tumour tissue leads to a 
selective photodynamic effect. 
A detailed description for each of the biological mechanisms of PDT is given 
below. 
Direct Cytotoxic effects  
1O2 has a very short lifetime and hence the site of photodamage is generally 
considered to coincide with the location of accumulation of the photosensitiser 
in tumour cells. Once activated, 1O2 oxidises amino acid residues (Trp, His, 
Cys, and Met),102 lipids and proteins thus causing irreversible damage to the 
sub-cellular targets such as lysosomes, Golgi apparatus, mitochondria and 
endoplasmic reticulum (ER). The extent of photodamage however depends 
upon the type of photosensitiser used, dose of light or photosensitiser, and 
time interval between the photosensitiser being administered and light 
exposure. Hydrophobic photosensitisers easily diffuse across plasma 
membranes, while ones which are less hydrophobic, due to their polar nature, 
are taken up by endocytosis.103 In general, cell death induced by PDT can 






































administration of high doses of photosensitiser or light, thus causing swelling 
of the cytoplasm and disruption of the plasma membrane, leading to release 
of the intracellular contents, and triggering an inflammatory response. 
Apoptosis, also known as programmed cell death, is the most common 
pathway for PDT. It involves shrinkage of cells, membrane blebbing, nuclear 
fragmentation and formation of apoptotic bodies which are scavenged by 
phagocytes.104 
Vascular damage 
Through the process of angiogenesis, solid tumours inside a body grow by 
inducing growth of blood vessels. This enables them to have a constant supply 
of oxygen and nutrients.105 However, due to leaky blood vessels and the 
incomplete cell borders of the tumour cells, this may allow accumulation of a 
photosensitiser in the tumour. When photosensitisers are activated with light 
localized either in the endothelial cells or bound to blood vessel walls, a series 
of events are triggered which ultimately leads to complete or partial vascular 
shutdown, severe hypoxia, absolute blood stasis and ultimately 
haemorrhage.106  
Immunological responses 
The third type of mechanism for biological damage by PDT involves the 
presence of immune mediators such as leukocytes and macrophage invasion 
which lead to tumour destruction (immunogenic cell death, ICD).107 The 
inflammatory process releases inflammatory mediators such as proteinases, 
peroxidases, cytokines, growth factors, and other immune-regulators which in 
turns stimulate various white blood cell components (neutrophils and 
macrophages).108 These macrophages remove damaged cancer cells through 
phagocytosis, which presents the proteins from the tumour cells to CD4 helper 
T lymphocytes. This is followed by activation of CD8 cytotoxic T lymphocytes 
which induces both necrosis and apoptosis wherever a new tumour cell is 
located, thus leading to long term effect.108 PDT thus tends to be immune-
stimulatory whereas chemotherapy and surgery are immunosuppressive.20 
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1.8 Applications of PDT 
1.8.1 Anticancer PDT 
Clinical applications of PDT in cancer date back to the 1970s when Dougherty 
and co-workers used HpD against bladder cancer.29 Since then PDT has found 
widespread application to treat various types of cancer, some of which are 
described below: 
Skin Cancer 
PDT has been extensively applied clinically for the treatment of both malignant 
and non-malignant skin tumours.109, 110 Actinic keratoses are dry scaly patches 
of skin formed as a result of damage due to years of exposure to solar 
radiation.111 ALA hydrochloride as a solution (Levulan, DUSA, USA) has been 
approved for the treatment of actinic keratoses along with blue light (Blu-U 
lamp, DUSA, USA). The methyl ester of ALA (Metvix in Europe and Metvixia 
in USA; Photocure ASA in Norway and Galderma S.A in France) has also 
received regulatory approval in Europe and Australia for the treatment of basal 
cell carcinoma (BCC), actinic keratoses and Bowen’s disease, in combination 
with red light.112  
Head and Neck cancer 
Photofrin, ALA and Foscan have been evaluated against head and neck 
tumours.112 Biel et al. conducted clinical studies using Photofrin against 
squamous cell carcinomas of the oral cavity, pharynx or larynx and Kaposi’s 
sarcoma, along with melanoma and squamous cell carcinoma in the head and 
neck area. Complete clinical response in patients with early stage oral cavity, 
larynx, pharynx and nasopharynx lesions monitored over 15 years was 
observed.113 Second-generation photosensitisers, such as Foscan, have also 
been clinically tested against advanced stages of head and neck cancer.            
In one study with 128 patients, the results showed that there was a complete 
tumour mass reduction in approximately 40% of lesions, whereas the 
remaining lesions showed at least 50% reduction.114 Foscan (Biolitech Pharma 
Ltd, Dublin, Ireland) was approved by the EU in 2001 for the treatment of head 
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and neck cancer.115 
Digestive system cancers 
Applications of PDT in the gastrointestinal tract include treatment of Barrett’s 
oesophagus and various grades of dysplasia and oesophageal cancer. Corti 
et al. conducted clinical studies using HpD against oesophageal cancer and 
concluded that PDT is an effective therapy for early stage cancer, however 
due to limitations of tissue depth penetration, it was not successful with T2 
tumours.116 Further investigations comparing Photofrin to omeprazole showed 
that PDT treatment was favoured for the elimination of high grade dysplasia 
(77% vs 39% with omeprazole).117 This led to FDA approval in 2003 for 
Photofrin-mediated PDT in patients who do not undergo surgery.112 Other 
applications of PDT in the GI tract include studies against 
cholangiocarcinoma118 non-resectable pancreatic cancer119 and 
hepatocellular carcinoma.120 
Urinary system cancers 
Porphyrin derivatives have been used both as therapeutic and diagnostic tools 
for tumours of the urinary system which include prostate cancer and bladder 
cancers. PDT has been used in the treatment of bladder cancer and the first 
reported study was with HpD for the treatment of 50 superficial bladder 
transitional cell carcinomas (TCC) which achieved a 74% complete response 
rate from a group of 37 patients.121 The study was also repeated for treatment 
of refractory carcinoma in situ (CIS) of the bladder, but in spite of the 74% of 
complete response observed, a significant percentage of patients showed 
disease recurrence after 2 years.121, 122 A better response to PDT was 
observed in bladder CIS and superficial TCC by working on dosimetry and 
changing the photosensitiser to Photofrin.123, 124 Studies were also performed 
with ALA-induced PpIX and similar results were observed, but without the 
prolonged photosensitivity which was seen with Photofrin.125 The hexyl ester 
of ALA has also been shown to accumulate preferentially in neoplastic bladder 
tissue and produce fluorescence when illuminated. It has been approved for 
fluorescence diagnosis of bladder cancer (Hexvix, Photocure ASA in Norway 
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and Cysview, Photocure Inc in USA).126 
Non-small cell lung cancer (NSCLC) 
Hayata et al. in 1982 were the first to report the use of PDT for NSCLC using 
HpD to effect tumour necrosis and reopening of the airway. This has since 
been found to be more specific and lesion-oriented compared to other 
available treatments.127 Studies using Photofrin-mediated PDT were 
conducted in 54 patients with 64 lung carcinoma lesions and an 85% complete 
response rate was observed.128 These results were confirmed by similar 
studies done by other groups.128, 129  
Brain tumours 
PDT has been utilized as a supporting treatment in various clinical 
investigations for brain tumours. The photosensitisers that have been used are 
HpD, ALA and Foscan along with light sources such as lamps, dye lasers, gold 
vapour potassium titanyl phosphate (KTP) dye lasers, and diode lasers. Stylli 
et al. in 2005 reported a study with HpD on patients diagnosed with 
glioblastoma multiforme and anaplastic astrocytomas.130 The results showed 
that more than 30% of the glioblastoma patients survived for more than two 
years, whereas in the case of anaplastic astrocytomas, around 60% of the 
patients treated survived for more than 3 years. Studies were also reported by 
Muller et al.131 in 2006 and Stummer et al.132 in 2006 using HpD                           
(for supratentorial gliomas) and ALA (for malignant gliomas) respectively, 
however the results obtained were not statistically significant in comparison to 
control groups.  
1.8.2 Antimicrobial PDT 
Antimicrobial PDT also known by the term photodynamic inactivation (PDI), 
lethal photosensitization, photo-activated disinfection (PAD) or photodynamic 
antimicrobial chemotherapy (PACT) is seen as a promising alternative 
treatment for infections associated with multi-drug resistant pathogens. In the 
past few years, it has been found that by altering the physicochemical 
properties of certain photosensitisers (e.g. imparting positive charge), they can 
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be used to inactivate almost all classes of micro-organisms including gram 
positive and negative bacteria, fungi, viruses and other parasites.133 Figure 28 
below shows a range of human infections that have been clinically treated by 
PDT. 
 
Figure 28. Clinical applications of PDT on a range of human infections (adapted from 
Kharkwal et al.).133 
Viral Lesions 
Clinical studies in the area of viral lesions were initially directed towards the 
human papilloma virus (HPV). Abramson et al. in 1992 reported a study of the 
use of dihematoporphyrin ether against respiratory papillomatosis caused by 
HPV, and found that the growth of papilloma decreased significantly in 
comparison to control patients.134, 135 Another application of PDT against 
cutaneous warts caused by the virus was reported by Schroeter et al, wherein 
ALA was administered to patients and complete response with minimum side 
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effects was observed after PDT.136  
Dermatological infections 
Acne vulgaris is one of the most common non-viral dermatological disorders, 
and is caused by Propionibacterium acnes.133 Over the years, many PDT 
studies have been conducted against acne with encouraging results being 
obtained with either ALA or MAL. Hongcharu et al. in 2000 was the first to 
report a clinical study involving ALA and since then many other clinical studies 
have been reported involving different light sources or regimens in order to 
improve the specificity of treatment, as well as to reduce the incubation time of 
the drug.137-139  
Dental Infections 
PDT has found wide application in the field of dentistry for treatment of 
common bacterial diseases such as dental caries and periodontal diseases. 
Periodontitis is an inflammatory disease involving progressive loss of alveolar 
bone and can cause loosening and loss of teeth. Oliveira et al. in 2007 
conducted a study involving toluidine blue O and 660 nm laser illumination in 
patients with aggressive periodontitis, and reported encouraging clinical 
effects.140 Ge et al. repeated the same study by replacing toluidine blue with 
methylene blue, and observed less bleeding in the PDT group compared to 
control group.141 Other applications of PDT in dentistry include treatment for 
necrotic pulp and periapical lesions.133  
Other applications of PDT to treat infections include treatments for 
leishmaniasis and peptic ulcer disease. Leishmaniasis is a disease caused by 
protozoan parasites and is usually spread by the bite of certain types of 
sandflies. There are three main types of this disease: cutaneous (most 
common), mucocutaneous and visceral leishmaniasis.133 Asilian et al. reported 
a placebo-controlled randomized clinical trial comparing the efficacy of ALA-
mediated photodynamic therapy with topical paronomycin for treatment of old 
world cutaneous leishmaniasis in a total of 57 patients with 95 lesions.142 
Results showed approximately 94% complete improvement in patients treated 
with ALA as compared to 41% with paranomycin. Peptic ulcer disease is a 
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common gastric infection and is found to be commonly associated with 
Helicobacter pylori (H. pylori). Wilder-Smith et al. conducted the first ever 
clinical trial involving humans using ALA and blue light (410 nm) and found a 
marked reduction in H. pylori numbers in comparison to the control.143
1.9 Aminolevulinic acid-PDT (ALA-PDT) 
5- Aminolevulinic acid (40) (ALA) is an intermediate in the haem biosynthetic 
pathway and has been a point of interest for many researchers in the field of 
PDT (Scheme 3).  
 
Scheme 3. Bioconversion of ALA (40). 
ALA (40) is not a photosensitiser as such, but can induce the intracellular 
synthesis of a photosensitiser, protoporphyrin IX (9) (PpIX) by entering into the 




1.9.1 Haem biosynthesis  
 
Scheme 4. Bioconversion of ALA to haem (adapted from Pottier et al.) 126. 
Scheme 4 shows the pathway of haem biosynthesis. The haem biosynthetic 
pathway begins with a condensation reaction between glycine (41) and 
succinyl-CoA (42) in the mitochondrion to form ALA (40) which becomes the 
source of C and N atoms for the construction of the haem macrocycle. This 
reaction is catalysed by ALA synthase and involves pyridoxal-5-phosphate as 
the cofactor. The synthesized ALA then enters the cytosol and a condensation 
reaction between two units of ALA mediated by the enzyme ALA dehydratase 
(ALAD) forms monopyrrole porphobilinogen (43) (PBG). Four units of PBG 
(43) oligomerize to a linear tetrapyrrole intermediate, followed by cyclisation 
by the enzyme uroporphyrinogen III co synthase to give the cyclic tetrapyrrole 
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intermediate, uroporphyrinogen III (44). The tetrapyrrole intermediate now 
undergoes a decarboxylation of the four acetate side chains to methyl groups 
(catalysed by uroporphyrinogen decarboxylase) to form coproporphyrinogen 
III (45), which is then carried to the intermembrane space of the mitochondrion. 
Subsequent steps in the mitochondrion lead to formation of protoporphyrin IX 
(9) and later haem (47), by insertion of iron by the enzyme ferrochelatase.  
1.9.2 Advantages of ALA-PDT 
Administration of exogenous ALA (40) bypasses the rate-limiting step in the 
biosynthesis of haem, and thus can produce photosensitising amounts of PpIX 
(9) in malignant, premalignant, and certain other abnormal tissues.                    
The metabolic conversion of exogenous ALA into a photosensitising 
concentration of PpIX is relatively fast, requiring only 1-3 h. Furthermore, since 
PpIX is part of a biosynthetic pathway, it has a built-in clearance mechanism 
that restricts possible systemic patient photosensitivity to less than 2 days.         
In comparison to other photosensitisers, ALA can be administered both 
topically and systemically and when applied topically, the photosensitized area 
is restricted to the site of application with no systemic effects. An additional 
and an important advantage of ALA-PDT is its rapid photobleaching.              
PpIX molecules react with singlet oxygen and are converted to products which 
are no longer photosensitive.126  
1.9.3 Clinical applications of ALA-PDT 
ALA and simple ester derivatives have received clinical approval both for PDT 
and diagnostic applications. The methyl ester of ALA (Metvix) has been 
approved in Europe and Australia for treatment of various skin disorders such 
as actinic keratosis and basal cell carcinoma (see Section 1.3.2.1). The hexyl 
ester of ALA, also known as Hexvix, was approved in Europe for endoscopic 
fluorescence diagnosis of bladder cancer, whereas the US-FDA approved ALA 




1.9.4 Drawbacks of ALA-PDT and strategies to improve its effectiveness 
ALA is a zwitterion at physiological pH, which results in poor lipid solubility and 
limits its passage through biological barriers such as cellular membranes.145 
As a result, ALA has a poor penetration through the stratum corneum.146 One 
of the most common approaches to influence the drug penetration into the skin 
is to alter the composition and structure of the stratum corneum by employing 
formulation-based chemical permeation enhancers.146-148 In the case of ALA, 
many permeation enhancers have been investigated such as dimethyl 
sulfoxide (DMSO),148 1-[2-(decylthio)-ethyl]azacycpentan-2-one (HPE-101),149 
glycerol monooleate,150 6-ketocholestanol (2% w/w)151 and oleic acid152. 
Experimentally, penetration enhancers, such as DMSO, have shown relatively 
higher concentrations of ALA up to a certain depth in skin, however ALA 
delivery was not significant when compared to control.146   
At physiological or alkaline pH, ALA is also unstable with respect to self-
condensation through formation of Schiff bases. Buffered solutions of ALA at 
physiological pH discolour even at low temperature due to decomposition of 
ALA, thus stock solutions for clinical use need to be freshly prepared.153 The 
instability of ALA under neutral and alkaline conditions has been investigated 
in some detail. Under alkaline conditions, ALA (40) has been shown to undergo 
dimerization and forms 2, 5-dicarboxyethyl-3,6-dihydropyrazine (50) (DHPY), 
which oxidises spontaneously to 2,5-dicarboxyethylpyrazine (51)                      
(PY, Scheme 5).154, 155 Other degradation pathways of the ALA dimer (48) to 






Scheme 5. Degradation pathway of ALA under alkaline conditions (adapted from Bunke               
et al.).155 
Significantly, simple N-acylated ALA derivatives such as (52) and (53) have 
been shown to be completely stable at physiological pH, but they do not 
generate PpIX in cells, presumably due to the lack of suitable enzymes 
activities required to release ALA (Figure 29).158, 159  
 
Figure 29. Structures of simple N-acylated ALA derivative (52) and (53). 
Over the years, many prodrugs of ALA have been suggested to overcome 






The synthesis of ALA esters has been the most exploited prodrug strategy, 
and several of these have been shown to give a quicker, more homogeneous, 
and more effective PpIX production than ALA itself. Many ALA ester-based 
prodrugs have been synthesized with linear, branched, or cyclic alkyl ester 
groups, as well as examples with aromatic, heteroaromatic, perfluorinated 
hydrocarbon, or ethylene glycol-type moieties (Figure 30).161, 163-166 At pH 5, 
ALA and simple esters have comparable stability.167 
A number of n-alkyl esters (54a-h) and (55a-i) of ALA have been synthesized 
to improve the lipophilicity as well as to increase diffusion across cell           
membranes.158, 163-165 Some of these are shown in Figure 30.   
 
Figure 30. Linear and non-linear aliphatic esters of ALA. 
Peng et al. (1996) were the first to report a comparative study on the 
effectiveness of ALA esters vs ALA. This showed that ALA-methyl, ethyl and 




human tissues as compared to free ALA.165 Similar results were also obtained 
by Kloek et al. (1996) and Gaullier et al. (1997) while evaluating ALA esters 
(54a-f) (Figure 30).163, 164, 168 Gaullier also observed that enzymatic hydrolysis 
was faster for the case of long chain ALA esters (54f-h) in comparison to short 
chain ester prodrugs. In some cases, PpIX production was 30-150 times more 
efficient than for free ALA, thus indicating faster cellular uptake of the prodrugs 
and ALA-induced PpIX formation.163 However some variations in terms of PpIX 
production have been observed from ALA esters having similar lipophilicity. 
For example, Uehlinger et al. (2000) noted that the hexyl ester of ALA (54f) 
showed PpIX fluorescence which was an order of magnitude higher than cyclo-
hexyl ester (56e) even though both the conjugates had similar log P values.166 
These results were further confirmed by Whitaker et al. (2000) in a report on 
the synthesis and in vitro biological evaluation of a series of linear, non-linear 
aliphatic and cyclic-ALA esters in pancreatic tumour cells (Figure 30 and 
31).169 Lower PpIX production was found for conjugates (55a,d,g-h) which 
shared the common feature of having a branch point next to the site of ester 
cleavage. This presumably inhibits the interaction of the prodrug ester unit with 
the active site of cellular esterases.169, 170  
A range of ALA prodrugs have also been synthesized based on cyclic, 
aromatic or halogen-substituted benzyl esters and the production of PpIX 
compared to that obtained with equimolar doses of ALA                                     
(Figure 31).162, 164, 169, 171  
Kloek et al. (1996) reported the synthesis and biological evaluation of 
tetrahydrofuranyl (56c) and tetrahydropyranyl (56d) esters of ALA and found 
enhanced PpIX fluorescence for both the conjugates in vitro (Figure 31).      
Godal et al. reported the synthesis of cyclic (56e) aromatic (57a-i) and halogen 
substituted benzyl esters (58a-f) of ALA, and biological evaluation in vitro/ in 
vivo showed significantly enhanced PpIX fluorescence compared to ALA (40) 
for aromatic esters, especially the benzyl and ring-alkylated benzyl esters               
(57a-b,g-i). In contrast, the cyclohexyl ester (56e) produced the least PpIX 
fluorescence amongst all the prodrugs tested and was only as effective as ALA 




fluorescence, and amongst them the mono-halogenated esters showed higher 
PpIX fluorescence than the di- or penta-substituted esters.171  
 
Figure 31. Cyclic, aromatic and halogen-substituted benzyl esters of ALA. 
Although aliphatic ALA esters have been shown to induce higher PpIX 
production with an increase in carbon chain length, increasing ALA prodrug 




which are derived from long-chain alcohols.164, 172 In contrast, poly(ethylene 
glycol) derivatives, which have been used for a large number of 
pharmaceutical applications, potentially offer the advantage of both improved 
water and lipid solubility.162  
Berger et al. (2009) reported the synthesis of ethylene glycol esters of ALA    
(59a-c) and tested their biological efficacy in human and rat cell lines of 
carcinoma and endothelial origin (Figure 32). It was found that a high PpIX 
fluorescence compared to free ALA was observed in endothelial cells in 
comparision to tumour cells, especially for long-chain ethers.172 Godal et al. 
also reported the synthesis of ethylene glycol esters (59d-e), but biological 
evaluation in vivo showed that a lower PpIX fluorescence was produced 
compared to the simple hexyl ester (Figure 32).171 
 
Figure 32. Ethylene glcol esters of ALA. 
As already noted, the use of ALA esters can result in increase PpIX production 
in various cell types, but with a greater enhancement in tumour cells.             
Brunner et al. (2001) also proposed that a reduction in the concentration for 
ALA esters (54f) and (57a) followed by shorter incubation time would be 







It has been observed that differences in the accumulation of PpIX in healthy 
cells and malignant cells are due to differences in the activity of enzymes in 
the haem biosynthetic pathway such as porphobilinogen deaminase and 
ferrochelatase. This forms the basis of a therapy combining iron chelators with 
ALA PDT where cells are deprived of Fe2+ in the last step of haem synthesis, 
thus leading to higher levels of PpIX.174 Iron chelators such as EDTA, 
desferrioxamine (DFO), 2-allyl-2-isopropylacetamide and 1,10-phenanthroline 
have indeed shown potential in preclinical studies for increasing PpIX levels 
upon ALA administration.175-181 
Berg et al. demonstrated that administration of EDTA (60) (Figure 33) in 
combination with ALA in epithelial skin tumours moderately increases 
intracellular PpIX levels.175  
 
Figure 33. Structure of EDTA (60). 
However, EDTA is a non-specific chelator which chelates other metal ions. It 
also has a lower affinity for iron compared to that of CP94 and DFO (see 
below).175   
Desferrioxamine (61) DFO is a hexadentate siderophore which has been 
shown to have anti-proliferative activities against various tumour cell lines 
(Figure 34).176 It has also been shown to have medical applications by acting 
as chelating agent and removing excess iron from the body.177 However, due 
to its hydrophilic nature it is unsuitable for topical application. It has also been 
shown that long exposure to DFO (61) leads to iron starvation from healthy 






Figure 34. Structure of DFO (61). 
1,2-Diethyl-3-hydroxypyridin-4-one (62) (CP94) is a low molecular weight 
lipophilic chelator which has high specificity for iron (Fe2+) and has perhaps 
shown the most promise in ALA-PDT (Figure 35).179 Blake et al. investigated 
the combination of CP94 (62) with ALA and MAL in human glioma cells,180 and 
observed that CP94 (62) significantly enhanced PpIX accumulation and 
subsequent PDT cytotoxicity. This combination may therefore be useful both 
in photodiagnosis and /or PpIX-induced PDT treatment of glioma. 
 
Figure 35. Structure of CP94 (62). 
Most recently, Mrozek-Wilczkiewicz et al. reported the synthesis of some novel 
thiosemicarbazone iron chelators and evaluated them for their PDT activity in 
combination with ALA (Figure 36).181 Biological evaluation in HCT 116 
colorectal carcinoma cells with a wild-type (+/+) or deleted (−/−) tumour 
suppressor TP53 gene showed significant photocytotoxicity for compounds 
(63)  and (64)  when combined with ALA (40), whereas a much weaker activity 





Figure 36. Chemical structures of thiosemicarbazone derivatives (63)-(66). 
Peptide prodrug derivatives 
Peptide derivatives of ALA have also been synthesized to provide prodrugs 
with improved physicochemical properties relative to ALA itself.182-192              
This approach also provides the possibility of achieving selective ALA release 
in particular cell lines.182 Berger et al. investigated the synthesis of ALA peptide 
prodrugs by two different approaches and evaluated them for their PpIX 
production (Figure 37).172, 183 The first approach involved synthesizing acidic, 
basic and neutral amino acid ALA-derivatives (67a-e) as potential substrates 
for cellular peptidases APA, APB or APN/M (Figure 37).172 Biological 
evaluation in endothelial and carcinoma cell lines A549, HCEC and EC219 
showed that prodrugs containing a neutral amino acid sidechain (67c) induced 
the highest PpIX production, however basic amino acid derivative (67d) or 
acidic derivative (67e) did not show any favourable results (minimal PpIX  
production). The second approach involved the synthesis and evaluation of 
pseudo di- and tripeptide derivatives (Gly-Gly and Gly-Pro) of ALA (68a-f) as 
potential substrates for cellular di/tripeptidases or peptide transporters at the 
cell surface, to target human endothelial cells or carcinoma cells in cancer       
(Figure 37).183 Biological evaluation in human endothelial (HCEC) and human 
lung carcinoma cells (A549) showed the peptide derivatives of ALA to be 
substrates for Gly/Pro-specific cellular transport systems and enzymatic 
activities. The dipeptide derivatives were also less cytotoxic in the absence of 





Figure 37. Pseudopeptide derivatives of ALA (67) and (68). 
A significant feature in the synthetic approaches used by Berger et al. was that 
an excess of the activated amino acid components or ALA derivative was used 
for the formation of the critical amino acid-ALA peptide bond, presumably to 
compensate for the instability of ALA under the basic coupling conditions. 
Rogers et al. developed an alternative approach by employing only one 
equivalent each of an acylated amino acid active ester and ALA.HCl.184            
The instability of ALA under basic conditions was avoided by slow 
neutralisation of ALA.HCl in the presence of the active esters (Scheme 6).  
 
Scheme 6. Synthesis of urethane and acetyl-protected ALA-dipeptide ester derivatives. 
Bourré et al. in 2008 reported the synthesis of some N-acetyl prodrugs based 
on phenylalanine and tested their biological efficacy in transformed PAM212 
keratinocyte cells and pig skin explants (Figure 38).186 The synthesized 
prodrugs were uncharged, more lipophilic than ALA, but at the same time 
remained water soluble. These were also stable in solution, unlike the 
corresponding ALA peptides with a free N-terminus.183 Fluorescence 
spectroscopy revealed both (69) and (70) to be efficiently taken up by cells and 
converted to PpIX, however better results were obtained with compound (69) 
(methyl ester) in comparison to  (70) (free carboxy terminus). PDT studies with 




fluorescence pharmacokinetics, and the cell survival was significantly reduced 
in comparison to equimolar doses of ALA (40). 
 
Figure 38. ALA peptide-prodrugs (69) and (70) based on phenylalanine. 
Giuntini et al. reported a series of 27 dipeptide prodrugs of ALA with the 
general structure Ac-Xaa-ALA-OR where Xaa was an α-amino acid providing 
appropriate lipophilicity and water solubility to the prodrug (Figure 39).187          
All the ALA prodrugs were taken up effectively in PAM212 keratinocytes as 
compared to ALA itself, however only the L-amino acid derivatives produced 
PpIX.185 This clearly demonstrated the potential of desgning peptide prodrugs 
of ALA which are cleaved by a disease-specific/cell-line specific enzyme 
activity. In a subsequent study, Bourré et al. showed that compounds of the 
general structure in Figure 39 are substrates for the enzyme acylpeptide 
hydrolase (ACPH). D-amino acid derivatives are not substrates, and PpIX 
production is also limited in cell lines with a low expression of this enzyme.185 
Further in vivo studies with these compounds provided support for their 
potential use in topical treatment of basal cell carcinomas and for systemic 
administration.188 
 
Figure 39. Dipeptide derivatives of ALA. 
Several studies have reported the synthesis and biological evaluation of more 
complex ALA peptide prodrugs, designed to provide improved and selective 
delivery. Dixon et al. (2007) reported the synthesis of a 9-residue ALA-




chemistry (Figure 40).189 The synthesized peptide was based on a 
heptapeptide fragment of the cell penetrating peptide, penetratin. Biological 
results showed effective uptake and intracellular conversion of the peptide to 
protoporphyrin IX in PAM212 cells.  
 
Figure 40. Structure of a cell penetrating peptide conjugate with ALA (71). 
Johnson et al. in 2012 reported a series of pH sensitive ALA-poly(L-histidine) 
prodrugs (72) and their activity in the human colon cancer HCT116 cell line 
(Figure 41).190 The results showed that the phototoxicity and selectivity of the 
synthesized prodrugs were higher than ALA itself, especially for the conjugate 
having 15 L-histidine residues.  
 
Figure 41. Structure of ALA-poly(L-histidine) prodrugs (72). 
Abd-Elgaliel et al. have also described the synthesis and selective activity of a 
cathepsin E-cleavable ALA peptide prodrug (73) (Figure 42).191 Biological 
evaluation showed that ALA was liberated in cathepsin E-positive pancreatic 
tumour cells, but not in normal pancreatic tissue, thus allowing delivery of 
selective photodynamic therapy (PDT) to cancerous tissues. 
 




Guaragna et al. in 2015 reported the synthesis of a novel folic acid-based 
photosensitiser delivery system in which the prodrug 5-aminolevulinic acid 
methyl ester (MAL) was conjugated to folic acid via a polypeptide spacer (74) 
(Figure 43).192 The peptide spacer consisted of four consecutive β-Ala units 
linked to an α-Asp residue, with the aim of improving the water solubility and 
cellular stability of the final conjugate. However the biological and stability 
studies are yet to be reported. 
 
Figure 43. Folic acid-conjugated with MAL via a peptide spacer (74). 
Other targeting derivatives 
Various groups have reported bioconjugates of ALA with vitamins, nucleosides 
and glycosides (Figure 44) with the rationale of overcoming the stability issues 
of ALA as well as improving its targeting potential. Vallinayagam et al. reported 
the attempted synthesis of novel bioconjugates of ALA with vitamin E (75), 
vitamin D3 (76) and biotin (77).193 Vitamin E (or α-tocopherol) is known to 
incorporate easily into natural membranes which might facilitate the transport 
of ALA into the interior of cancer cells, whereas it has been shown that 
pretreatment with vitamin D may improve the efficacy of ALA-PDT in a variety 
of tumour models.193-195 All the conjugates were synthesized in moderate yield, 
except vitamin D3-ALA (76), where degradation was observed in the final acidic 





Figure 44. Structures of vitamin-ALA conjugates (75)-(77). 
Nucleoside analogues have long being studied for their tumour activity and 
they act by inhibiting cellular division.196 Gurba et al. reported the synthesis of 
nucleoside-ALA bioconjugates (Figure 45) with adenosine (mono, bis and tris 
bioconjugate) and thymidine (bis-bioconjugate).197 The conjugates were tested 
in various cell lines including human colon (SW480), breast (MCF7), lung 
(A549), ovarian (A2780) and cervix (HeLa). The thymidine conjugate of ALA 
(81) was found to show enhanced PpIX production (approx. 1.5 times) in all 
the cell lines except SW480 as compared to equimolar ALA (40). However the 
adenosine conjugates (78)-(80) were found to show poor PpIX production as 
compared to ALA in all the cell lines, suggesting that they may not be 
substrates for adenosine receptors.  
 
Figure 45. Structures of nucleoside-ALA conjugates (78)-(81). 
Glycosylated porphyrins and chlorins have been previously synthesized and 
shown the potential to improve the uptake of these photosensitisers into 
cells.198-200 Vallinayagam et al. also reported the synthesis and biological 
evaluation of glycoside esters of ALA with α-glucose (82), α-mannose (83), or 




of ALA showed better selectivity in producing PpIX in human cancer and 
angiogenic endothelial cells as compared to free ALA. 
 
Figure 46. Structures of glycoside-ALA conjugates (82)-(84). 
Very recently, Tong et al. reported novel 5-aminolevulinic acid (ALA) 
pseudopolyrotaxane prodrug micelles that have dual pH-responsive properties 
(Figure 47).201  
 
Figure 47. Illustration of a ALA pseudopolyrotaxane prodrug micelles for PDT (adapted from 




As shown in the Figure 47, ALA was conjugated to α-cyclodextrin (CD) through 
an acid-labile hydrazone bond, while the pH-responsive CPP, R6H4 
(RRRRRRHHHH) was conjugated to PEG to form PEG–R6H4. The two 
elements were combined to give a pseudopolyrotaxane prodrug via inclusion 
complexation between α-CD and PEG. Once internalised within tumour cells 
through endocytosis, ALA was released by cleavage of the hydrazone bond in 
response to the lowered endo-/lysosomal pH followed by conversion to 
protoporphyrin IX for PDT activity. 
Dendrimers 
Polyvalent drug carriers such as dendrimers are a promising new strategy for 
the delivery of high payloads of photosensitisers in PDT.202 In ALA-PDT eight 
molecules of ALA are required to build the tetrapyrrole structure of PpIX 
(Scheme 3), hence delivering multiple units of ALA on a single core would 
boost the synthesis of PpIX. Battah et al. in 2001 reported the synthesis of a 
series of novel ALA-containing dendrimers bearing 6 to 18 ALA residues       
(85)-(89) and their biological evaluation in the keratinocyte cell line, PAM 212. 
Enhanced PpIX fluorescence was observed for (88) in comparison to ALA at 
an equimolar dose, along with higher phototoxicity upon irradiation of cells 
(Figure 48).203  
 




In order to identify improvements in the basic structure of ALA dendrons which 
would allow effective design of larger ALA dendrimers with 6, 9 or 18 ALA 
copies, low molecular weight dendritic derivatives were also investigated by         
Battah et al. (2006) with three copies of ALA conjugated as esters via 
methylene or propylene linkers to a quaternary carbon, functionalised with an 
aminobenzyloxycarbonyl (90), nitro (91) or amino group (92) (Figure 49).204 
Biological evaluation in the PAM212 keratinocytic cell line showed enhanced 
PpIX fluorescence for all the three ALA dendrimers in comparison to equimolar 
free ALA, while (91) (with a propylene linker) was found to be the most active 
amongst the three dendrimers. The study concluded that lipophilicity and steric 
hindrance within the dendritic structure are key factors that can influence the 
efficacy of dendrimeric ALA conjugates which would potentially restrict the 
access of intracellular esterases for liberation of ALA. The conjugate (92) was 
also studied for in vitro efficacy in LM3 cells and was found to produce similar 
porphyrin levels compared to free ALA.205 However in vivo studies in tumour-
bearing mice showed lower porphyrin levels from the dendron (92) as 
compared to free ALA after topical administration, which may be due to the 
retention of the lipophilic conjugate within the stratum corneum at the 
application site. 
 
Figure 49. Structures of ALA dendrimers (90)-(92). 
Following the preliminary studies with low molecular weight ALA dendrons and 
some second generation dendrons having 18 copies of ALA, Battah et al. 
(2007) investigated another 18-ALA dendrimer (93) which was built on a 
tripodal aromatic core with oligoamidoamine branches. The ability of (93) to 
enter the tumorigenic cell lines PAM 212 and A431 and the resulting PpIX- 
induced phototoxicity was studied (Figure 50).206 Fluorescence 




(93) in comparison to free ALA, across a range of concentrations between 0.01 
to 0.1 mM. These results were further supported by a higher phototoxicity post-
irradiation of the cells. An important result highlighted in this study was that the 
internalisation of the high molecular weight ALA dendrimer (93) occurred 
through an endocytic route and mainly via the micropinocytosis pathway. This 
mechanism would be expected for a non-targeted macromolecular prodrug 
such as (93). 
 
Figure 50. Reported dendrimeric prodrugs of ALA (93). 
The enhancement in PpIX production observed with the 18 ALA dendron (93) 
in in vitro studies was also confirmed by in vivo evaluation in a murine tumour 
model. Here, (93) showed a sustained release of PpIX for over 24 h, and the 
basal values were not reached until 48 h post-intraperitoneal administration of 
(93).207 In contrast, PpIX production for ALA was observed for only 3-4 h.  
An additional application of the ALA dendron (93) was reported by             
François et al. (2012) for fluorescence diagnosis of bladder cancer, and where 
a sustained release of PpIX was observed even after 24 h post-administration 
of the prodrug intravesically.208 A significantly lower dose of the prodrug was 
required to produce the same effect in comparision to free ALA                            
(0.7 vs 180 mM) and the hexyl ester of ALA (0.7 vs 8 mM). Significant tumour 
specificity vs muscle and normal urothelium was also observed as compared 





Recently Rodriguez et al. (2015) investigated ALA dendrimers (94)                     
(6-ALA units) and (95) (9-ALA units) for their PDT effect in mammary LM3 
carcinoma cells. In vitro studies showed enhanced PpIX production                   
(ca. 4 times) for ALA dendrimers (94) and (95) at a lower concentration as 
compared to free ALA (Figure 51).209 Topical application of these dendrimers 
(94) and (95) on the skin overlying a subcutaneous LM3 implanted tumour 
showed lower amounts of PpIX in distant skin as compared to free ALA, which 
induced similar profiles of PpIX in distant skin and skin overlying tumour. This 
suggests a promising use of these dendrimers in superficial cancer models.    
A possible application in vascular PDT was also investigated for the 
dendrimers (94) and (95) by assessing their selectivity towards macrophages 
over endothelial cells. Biological evaluation in Raw 264.7 macrophages and 
HMEC-1 microvasculature cells showed enhanced porphyrin synthesis by the 
dendrimers (95) (6 fold) and (94) (4.6 fold) in macrophages as compared to 
endothelial cells. Free ALA in comparison to the ALA dendrimers (94) and (95) 
had only a slight selectivity towards macrophages (1.7 fold) thus showing a 
possible application of these dendrimers in vascular PDT.  
 





1.10 Objectives of the project 
5-Aminolevulinic acid photodynamic therapy has been successfully used 
clinically both as a therapeutic and diagnostic tool for treatment of cancer. 
However it suffers from various drawbacks such as stability, low lipid solubility 
and targeting effect. As discussed in section 1.10.3, various strategies have 
been explored to overcome these drawbacks. These includes ALA-esters to 
improve its lipophilicity, conjugation with a peptide sequence or a biomolecule 
(nucleoside, vitamin, glycoside and folic acid) to improve its targeting effect 
and synthesizing ALA-dendrimers to deliver multiple copies of ALA. 
The overall aim of this project was to build upon some of these strategies to 
develop novel prodrug systems for the targeted delivery of multiple ALA units. 
Our specific objectives were to: 
 Develop an efficient synthetic route to ALA dendron derivatives, suitable 
for application in copper-catalysed azide-alkyne cycloaddition (CuAAC) 
chemistry. 
 Apply these building blocks for the preparation of simple biomolecule-
targeted ALA prodrugs. 
 Apply these building blocks for the preparation of a novel peptide-
targeted delivery system for ALA, in which multiple ALA dendrons 
(effectors) are attached to a peptide-targeted core unit via CuAAC 
chemistry. The general model structure of such a targeted dendrimeric 
ALA prodrug system is outlined in Figure 52. 
 Evaluate the ability of peptide-targeted ALA dendrimers to generate 
PpIX in a cancer cell line, and assess the potential of these prodrugs 
for PDT. 
 Explore other peptide-based strategies for the targeted delivery of ALA 















CHAPTER 2: RESULTS AND DISCUSSION (Preparation of 
effector units) 
2.1 Introduction to dendrimers  
Dendrimers in general are well-defined, highly branched, globular 
macromolecules with multiple arms arising from a central core.210 Such 
architecture provides many advantages for drug delivery. Dendrimers are 
multivalent and allow attachment of several copies of drug molecules, targeting 
groups and solubilizing groups in a well-defined manner. They also give 
reproducible pharmacokinetic behaviour due to their low polydispersity.211 
Dendrimers can be chemically synthesized either by divergent or convergent 
approaches (Scheme 7). 
 
Scheme 7. Convergent and divergent routes of synthesis for dendrimers (adapted from 
Klajnert et al.)212. 
A divergent approach involves synthesis from the core and moves outwards 
through a series of reactions which must be driven to completion to avoid any 
defects in the dendrimers.213 Convergent approaches, which were developed 
by Hawker and Frechet, involve assembling small synthesized molecules on 




core.214, 215 Since the convergent approach involves functionalisation of a 
smaller number of reactive sites, the chances of any side reactions as 
compared to the divergent approach are minimal. In recent years, dendrimers 
have also been synthesized via click chemistry involving azide-alkyne 
cycloaddition.216-218 The high efficiency and simplicity of such reactions are 
very suitable for both chemical strategies of dendrimer synthesis. 
The terminal groups of dendrimers allow multiple drug molecules to be 
attached which can lead to an enhanced therapeutic effect, whereas 
dendrimers which allow localization of unstable drug molecules deeper within 
the dendrimer structure can shelter them from the environment. The size and 
structure of dendrimers may also be favourable for carrying a high payload of 
therapeutic agents to tumours, as it favours their entry into the highly 
permeable tumour vasculature, and the abnormal tumour lymphatic system 
retains the dendrimers due to the enhanced permeability and retention effect 
(EPR) (Figure 53).219  
 
Figure 53. Representation of an EPR effect (adapted from Kumar et al.220). The figure shows 
that the normal endothelium has tightened cell-cell junctions resulting in less drug entry. In the 
case of tumours, the vascular endothelium has cell-cell junction with a wider gap opening, thus 




2.1.3 Dendrimers in Photodynamic therapy 
One of the recent developments in the field of dendrimers is their application 
to photodynamic therapy.202 Dendrimers containing multiple copies of ALA      
(3 to 18) have been synthesized and evaluated in vitro and in vivo for their 
ALA-mediated PpIX release and for their PDT activity (Section 1.9.4). It was 
found that by attaching multiple copies of ALA, efficient and sustained release 
of PpIX from ALA was observed as compared to free ALA at equimolar 
doses.207 Since the terminal amino group of each copy of ALA is protonated in 
vivo, this also led to increased water solubility for the ALA-dendrimer 
conjugate.209 Attempts have also been made to synthesize dendrimer 
conjugates with porphyrins acting as a core unit. For instance, Nishiyama             
et al. in 2003 reported the synthesis and biological studies of third-generation 
aryl ether dendrimers having Zn-porphyrin as the core photosensitiser 
surrounded by either 32 positively charged groups (C(O)N(H)(CH2)2NMe3) 
[32(+)DPZn] or negatively charged (COO-) [32(-)DPZn] groups on its periphery 
(Figure 54).221  
 






Biological studies revealed both type of dendrimers to be internalized into 
Lewis lung carcinoma cells, however the PDT effect of the positively charged 
dendrimers was found to be 230 times higher than its negative counterpart. 
This is possibly due to strong adsorption of the positively charged dendrimer 
to the negatively charged membrane components (glycoproteins) through 
electrostatic interactions.221  
2.2 Synthesis of ALA dendrons 
The objectives of this project required the preparation of a series of ALA 
dendron derivatives which could be attached to a core molecule or targeting 
unit via copper catalysed azide-alkyne cycloaddition (CuAAC) (Figure 55). The 
current section discusses the stepwise synthesis of such ALA dendrons 
(effector units) which involved attachment of multiple copies of ALA on to a 
multifunctional building block by controlled synthesis via ester linkages       
(Figure 55). 
 
Figure 55. Application of ligatable ALA dendrons. The effector units are attached to the core 
by CuAAC chemistry .
2.2.1 Synthesis of first-generation ALA dendrons 
Tris(hydroxymethyl)aminomethane, Tris (97) and 4-amino-4-(3-
hydroxypropyl)-1,7-heptanediol, Ext-Tris (98) were chosen as the intitial 





Figure 56. Structures of the building blocks Tris and Ext. Tris (97) and (98). 
The choice of these building blocks was based on their simple structure, 
multiple hydroxyl groups for attachment of effector units (ALA) and the terminal 
amino group which could be acylated with an alkyne derivative (4-pentynoic 
acid, 4-PA) to generate ligatable building blocks. The effector units were 
synthesized by modification of the procedures reported by Battah et al.203, 204 
The first step was the Boc protection of ALA (99). Here, a suspension of 
ALA.HCl (40) in THF was treated with di-tert butyl dicarbonate, followed by 
slow addition of base, DIEA. This released the ALA slowly into the solution so 
that it could be intercepted by the excess acylating agent in solution before 
competing self-condensation could intervene (Scheme 8).222 The product (99) 
was obtained in a higher yield (80% vs 60%) than the originally reported 
procedure which uses aq NaOH/dioxane as the solvent, without slow 
neutralisation of ALA.203  
 
Scheme 8. Synthesis of Boc-ALA (99). Reagents and conditions: a. Di-tert butyl dicarbonate, 
THF, DIEA, 16 h, 78%. 
Boc-protection of ALA was followed by the stepwise assembly of the first 
generation ALA dendrons (90) and (102) (Scheme 9). The building blocks (97) 
and (98), as discussed earlier, have multiple attachment sites (for N and O 
acylation) and hence the next step in the scheme of synthesis involved 
selective Z-protection of the amino groups of the building blocks (97) and (98). 
In the case of (97), benzyl chloroformate (Z-Cl) was used for the protection of 




EtOAc/H2O and sodium bicarbonate at RT to give (100) in 47% yield. The 
protection of the amino group of the extended dendron (98) was carried out 
using N-(benzyloxycarbonyloxy) succinimide (Z-OSu). Previous work in our 
laboratory has shown that both N and O acylation occurs when Z-Cl is used 
for the preparation of (98), and hence the less reactive Z-OSu was used.223 
Purification of the crude product by silica gel chromatography gave (101) 
which, however showed, an additional peak in 1H-NMR at δ 2.74 ppm, 
probably due to N-hydroxysuccinimide. Subsequent purification by 
precipitation of the crude product from the minimum quantity of cold water, 
followed by centrifugation gave the expected purified product (101) in 42% 
yield. The resulting Z-protected derivatives (100) and (101) were then 
esterified with Boc-protected ALA (99) via EDC.HCl/DMAP activation. 
EDC.HCl was used as a coupling agent over DCC as reported by Battah et 
al.203 for better separation of the urea by-product (water soluble), and the 
reactions were carried out in dry DCM at 30 °C for 48 h to give the expected 
Z-protected conjugates (90) and (102) in good yields (Scheme 9).  
 
Scheme 9. Synthetic route adopted for preparation of first generation ALA dendrons (Initial 
approach). Reagents and conditions: a. Z-Cl, EtOAc/H2O, NaHCO3, RT, 5 h, 47% (100);           
Z-OSu, THF, RT, 20 h, 42% (101); b. Boc-ALA, EDC.HCl, DMAP, DCM, 30 °C, 48 h, 43% 
(90), 40% (102);  
In order to transform (90) and (102) into ligatable derivatives, the next step 
involved cleavage of the Z group. Deprotection of (90) was first attempted via 
transfer hydrogenolysis in order to avoid the inconvenience of using H2 gas         
(Scheme 10). Treatment of (90) with ammonium formate (hydrogen donor) and 
Pd/C in MeOH according to the method of Baldoli et al.224 showed the 
presence of a new ninhydrin-positive spot on the TLC baseline. However, work 




also ninhydrin positive, but with higher Rf values compared to the original 
baseline spot. When conventional hydrogenolysis of (90) was attempted 
replacing ammonium formate with H2 gas, similar results were obtained.   
 
Scheme 10. Initial attempts for hydrogenolysis of (90). Reagents and conditions: a. Pd/C, 
ammonium formate, MeOH, RT, 1.5 h; b. Pd/C, H2, MeOH, 1.5 h, RT.  
Due to the conversion of the initial polar ninhydrin-positive product to less polar 
materials, it was suspected that the free amine initially formed on 
hydrogenolysis of (90) was undergoing acylation via intra or intermolecular 
reaction with the ALA ester units. This is consistent with a report by Newkome 
et al. who observed intramolecular rearrangement of the ester derivative (97a) 
via a five-membered cyclic intermediate to form the amide (97b)               
(Scheme 11).222, 224 Such a side reaction was not reported by Battah et al. 
when carrying out the hydrogenolysis of (90) with Pd/C in EtOAc/MeOH.203 
 
Scheme 11. Mechanism of intramolecular rearrangement of amino Tris esters. 
In order to suppress such a rearrangement, the hydrogenolysis of (90) was 
repeated under acidic conditions (Scheme 12). In this way the final product 
thus obtained would be a salt and unreactive towards any possible O to N-acyl 
migration. Two conditions were attempted: either with AcOH/MeOH as solvent, 




product (92) was isolated as the salt in both the experiments (Scheme 12), 
however the procedure involving AcOH was favoured over methanolic HCl to 
avoid the risk of any additional Boc cleavage.  
 
Scheme 12. Hydrogenolysis of (90) and (102) under acidic conditions. Reagents and 
conditions: a. (90), Pd/C, H2, MeOH, 2M HCl in dioxane; b. (90) or (102), 10% Pd/C, H2, 
MeOH/AcOH (3:1, v/v), RT, 30 min, 90% (92), 96% (103). 
The last step for the preparation of ligatable ALA dendrons (Scheme 13) 
involved attachment of an alkyne handle to the intermediates (92) and (103). 
4-Pentynoic acid (104) was chosen as the alkyne spacer due to its simple 
structure and ready availability. For the preparation of (105), 4-pentynoic acid 
(104) was first activated with EDC.HCl/HOBt followed by addition of (92) and 
dropwise addition of DIEA (Scheme 13). The reaction proceeded to give the 
expected product (105), but in low yields (11%).  
 
Scheme 13. Acylation of (92) with 4-pentynoic acid (104). Reagents and conditions:                        
a. EDC.HCl, HOBt.hydrate, DIEA, DMF, RT, 32 h, 11%. 
A similar outcome was obtained using the succinimido ester of 4-pentynoic 
acid (106) (prepared by treatment with N-hydroxysuccinimide and EDC.HCl), 
but for the extended dendron (107), an acceptable yield (40%) of the expected 





Scheme 14. Acylation of (92) and (103) with 4-pentynoic acid succinimido ester (106). 
Reagents and conditions: a. N-hydroxysuccinimide, EDC.HCl, DMF, RT, 16 h, 71% b. (106), 
DIEA, DMF, RT, 48h, 7% (105) and 40% (107). 
The low yield for (105) showed that it is apparently difficult to neutralise the 
acetate derivative (92) with DIEA for acylation without competing 
intramolecular rearrangement or other side reactions observed previously. 
To overcome the issues encountered during the synthesis of ALA dendrons 
(105) and (107), an alternative route of synthesis was investigated which 
involved N-acylation of Tris (97) with 4-pentynoic acid (104) in the first step. 
This would provide a conjugate having only free hydroxyl groups available for 
acylation with Boc-ALA (99) and thus avoid any inter/intramolecular acyl group 
migrations later in the synthesis. Scheme 15 gives an overview of the different 
experimental conditions that were attempted with (97). 
 
Scheme 15. Strategies adopted for the effective N-acylation of Tris (97). Reagents and 
conditions: a. (106), THF, DIEA, RT, 48 h; b. (106), EtOAc, H2O, DIEA, RT, 48 h; c. 4-pentynoic 
acid, DCC, HOBt.hydrate, DIEA, DMF, RT, 48 h. 
Initial attempts to acylate the amino function of (97) with (106) gave a mixture 
of N- and O- acylated products as shown by 1H NMR analysis. Changing the 




similar results. To avoid competitive N- and O-acylations, a modification in the 
synthetic route was therefore made (Scheme 16), and the three hydroxyl 
groups in (97) were initially silylated using TIPS-Cl and imidazole according to 
the procedure of Cunico et al.225        
 
Scheme 16. Silylation strategy for acylation of Tris compounds. Reagents and conditions:       
a. TIPS-Cl, imidazole, DMF, 50 °C, 60 h, quant (110); 48 h, 94% (111); b. 4-pentynoic acid, 
EDC.HCl, HOBt.hydrate, DIEA, 30 °C, 24 h, 82% (112), 81% (113); c. TBAF, THF, Dowex 
(50WX8, hydrogen form, 200-400 mesh), CaCO3, MeOH, 3 h, 70% (108), 16 h, 65% (114).  
TIPS-Cl was chosen for the protection due to its low cost and ready availability. 
The TIPS group can also be readily removed with fluoride ion under mild 
conditions.  The reaction proceeded smoothly and the expected product (110) 
was obtained in quantitative yield. This was followed by acylation with                
4-pentynoic acid (104) using EDC.HCl/HOBt activation, which gave the 
expected product (112) in excellent yield (82%). The next step involved 
removal of the silyl protecting groups using TBAF. The reaction was monitored 
by TLC and after 3 h, complete disappearance of the starting material was 
observed along with the appearance of a new spot. However the expected 
product (108) was highly water-soluble and hence a conventional work up 
procedure involving aqueous phase extraction could not be followed. Avoiding 
aqueous extraction did not permit removal of excess tetrabutylammonium 
fluoride, which otherwise is difficult to remove by column chromatography.      




TBAF-promoted desilylation which involves treatment with sulfonic acid ion 
exchange resin and calcium carbonate (Scheme 17).226 The treatment results 
in a tetrabutylammonium-resin complex and calcium fluoride which are 
insoluble and can be removed by simple filtration of the reaction mixture.  
 
Scheme 17. Work-up strategy to remove excess TBAF post-desilylation (adapted from 
Kaburagi et al.).226 
This strategy was applied for the isolation of (108). The work-up was carried 
out by treating the residue from the desilylation reaction with DOWEX ion 
exchange resin (50WX8, hydrogen form, 200-400 mesh) and CaCO3 in MeOH 
as solvent. The reaction was initially monitored for 16 h (to ensure complete 
desilylation) and showed appearance of a new spot at the end of 3 h along 
with disappearance of starting material. However, multiple spots were 
observed on TLC at the end of 16 h, and hence the reaction time was 
subsequently restricted to 3 h, which resulted in a very good yield of (108) 
(70%). The modified steps followed in Scheme 16 were also applied for the 
extended dendron (98) and similar results were obtained leading to formation 
of (114) in a yield of 65%.  
The overall approach compares very favourably to a recently reported direct 
synthesis of (108) via EEDQ activation of 4-pentynoic acid.227 Our approach is 




(discussed in section 2.2.2). 
Finally, intermediates (108), (114) with free hydroxyl groups were esterified 
with Boc-ALA (99) via EDC.HCl/DMAP activation, as previously (Scheme 18). 
This gave (105) and (107) in excellent yields (89% and 77% respectively).   
 
Scheme 18. Coupling of Boc-ALA (99) with (108) and (114). Reagents and conditions: a. (99), 
EDC.HCl, DMAP, dry DCM, 30 °C, 48 h, 89% (105); 32 h, 77% (107). 
2.2.2 Synthesis of second-generation ALA dendrons 
The successful synthesis of ligatable first-generation ALA dendrons was 
followed by the investigation of synthetic strategies for building a second-
generation ALA dendron. Such an ALA dendron would have 9 copies of Boc-
ALA within the same building block (115) as compared to 3-ALA units in the 
first generation ALA dendrons (105) and (107) (Figure 57).  
 





An initial approach involved synthesizing a triacid component (Scheme 19) 
which would serve as a building block for the attachment of a first generation 
ALA intermediate (92). The first step of this synthetic route was to generate a 
triester derivative based on a method described by Cardona et al.228                 
1,4- Addition of Tris (97) to tert-butyl acrylate (116) in a mixture of DMSO/H2O 
(9:1) with NaOH as base gave (117) in 26% yield. The yield of the reaction was 
lower (26%) than that reported in the literature (54%), possibly due to some 
loss at the stage of evaporation of DMSO under vacuum. This reaction was 
followed by acylation of the amino group with 4-pentynoic acid using 
EDC.HCl/HOBt activation to obtain the expected alkyne derivative (118) in 
good yield (63%). The last step of this scheme involved cleavage of the               
t-butylester groups using TFA at 0 °C, to give the required triacid (119), which 
was used for the next step without any further purification. 
 
Scheme 19. Synthesis of a triacid (119) from Tris (97). Reagents and conditions: a. NaOH, 
DMSO/H2O, RT, 24 h, 26%; b. 4-pentynoic acid, EDC.HCl, HOBt.hydrate, DIEA, DMF, RT,    





A modified first-generation ALA dendron intermediate for attachment to triacid 
(119) was synthesized as follows (Scheme 20):  
 
Scheme 20. Synthesis of ALA dendron (124). Reagents and conditions: a. (110), EDC.HCl, 
HOBt.hydrate, DIEA, RT, 36 h, 49%; b. TBAF, THF, Dowex, CaCO3, MeOH, 3 h, 74%;                 
c. (99), EDC.HCl, DMAP, DCM, 32 ˚C, 36 h, 72%; d. Pd/C, H2, MeOH:AcOH (3:1), 20 min, 
79%.  
Silylated Tris derivative (110) was first acylated with Z-β-ALA-OH (120) using 
EDC.HCl/HOBt activation to give (121) in 49% yield. The β-ALA spacer was 
expected to provide a more reactive amino function for acylation with the triacid 
(119), as well as avoiding problems of N, O-migration on N-deprotection 
(Section). The next step was the removal of the silyl groups using a similar 
strategy as above which gave (122) in good yield.229 Esterification of (122) with 
Boc-ALA using EDC.HCl and DMAP then gave (123) in 72% yield.                         
Z-deprotection using PD/C and H2 as previously yielded (124) as the acetate 
salt. 
The acylation of triacid (119) with (124) was then explored. Initially the reaction 
was carried out using EDC.HCl/HOBt activation and the reaction was 
monitored by TLC (Scheme 21). However, TLC showed no trace of any new 
spots nor disappearance of the starting material (124). The acylation was also 






Scheme 21. Attempted coupling of triacid (119) with ALA dendron (124). Reagents and 
conditions: a. (124), EDC.HCl, HOBt.hydrate, DIEA, RT, HATU, DMF, 32 h. 
An alternative strategy was explored by using 5-aminoisophthalic acid as the 
dendron core. The choice of this core was based on the fact that the two 
carboxylic acid groups are held in a fixed spatial arrangement on the aromatic 
ring, which might thus favour attachment of bulky ALA dendrons. The attached 
amino group can also be acylated with an alkyne derivative to generate 
ligatable building blocks (Figure 58).  
 
Figure 58. Proposed structure of a 2nd generation ALA dendron (125) synthesized from 
isophthalic acid. 
The first step of the synthesis involved acylation of 5-aminoisophthalic acid 
(126) with 4-pentynoic acid (104) using EDC.HCl/HOBt activation           




multiple spots were observed. This suggested the possible formation of 
coupled products derived from the desired conjugate (127) and isophthalic 
acid, which was supported by NMR of the crude product. 
 
Scheme 22. Initial attempt to conjugate (126) with 4-pentynoic acid. Reagents and conditions: 
a. 4-pentynoic acid, EDC.HCl, HOBt.hydrate, DIEA, RT, 36 h. 
The synthetic strategy was modified and (126) was esterified by treatment with 
EtOH and in the presence of catalytic amount of H2SO4 to yield the bis-ethyl 
ester (128) in good yield (Scheme 23). This reaction was followed by the 
acylation of (128) with 4-pentynoic acid under EDC.HCl/HOBt activation 
forming the expected alkyne derivative (129) in excellent yield (97%). The ethyl 
ester groups were then hydrolysed with NaOH/MeOH to obtain (127) as a 
white solid.  
 
Scheme 23. Synthesis of ligatable 5-aminoisophthalic acid derivative (127). Reagents and 
conditions: a. EtOH, Conc. H2SO4, reflux, 20 h, 77%; b. 4-pentynoic acid, EDC.HCl, 




The intermediate (127) was then acylated with (111) using EDC/HOBt 
activation to give the expected silyl protected derivative (130) (Scheme 24).  
 
Scheme 24. Synthesis of 2nd generation ALA dendron (125). Reagents and conditions:              
a. (111), EDC.HCl, HOBt.hydrate, DIEA, DMF, RT, 36 h, 64%; b. TBAF.H2O, AcOH, THF, RT,    
4 h; c. (99), EDC.HCl, DMAP, DCM, RT, 36 h. 
Following the successful preparation of (130), the conversion to (131) was 
attempted on a trial scale. The silyl groups of (130) were removed using TBAF 
using the same conditions as previously to obtain (114). Although 1H-NMR of 
the product obtained after column chromatography showed traces of silyl 
groups, esterification with Boc-ALA using EDC.HCl and DMAP gave the 







In summary, two synthetic routes were investigated for the synthesis of first-
generation ALA dendrons (105) and (107), which involved either N- (via Z) or 
O- (via silyl) terminal protection of the building blocks (97) and (98) prior to 
attachment of multiple copies of Boc-ALA. In the second approach, initial 
protection of the three hydroxyl groups of (97) and (98) proved to be 
advantageous as it avoided completely the problem of O- and N- acyl group 
migration. This gave a high-yielding route to both (105) and (107). In contrast, 
the initial approach involving the Z-protection gave problems of acyl group 
migration for the Tris derivative (90) which resulted in low overall yields. The 
dendrons (105) and (107) thus obtained bearing three Boc-protected ALA units 
then served as key intermediates for all the targeted and non-targeted ALA 
dendrimers discussed in the current work (Figure 59). 
Synthesis of second-generation ALA dendrons involved initially an attempt to 
attach ALA dendrons (124) to triacid component (119); however, no successful 
outcome was observed under different coupling conditions. An alternate 
strategy with 5-aminoisophthalic acid as the dendron core proved to be 
successful, and a second-generation ALA dendron with 6 copies of ALA (125) 
was successfully synthesized on a trial scale and confirmed by mass 
spectrometry. 
 





CHAPTER 3: RESULTS AND DISCUSSION (Preparation of 
core molecules) 
Having developed a successful synthesis of alkyne-functionalised ALA 
dendrons, the next step was to investigate the synthesis of complementary 
azide-containing core molecules, suitable for attachment to various targeting 
units (Figure 60).  
 
Figure 60. Model for targeted-ALA dendron showing the core unit and its conjugation to 
effector units via copper-catalysed azide-alkyne cycloaddition. 
The following section discusses the different strategies that were explored for 
the preparation of core units followed by their conjugation to effector units.  
3.1 Choice of core unit 
Gallic acid and p-hydroxybenzoic acid were chosen as the central core units 
for the synthesis of 1st generation targeted ALA dendrimers. Gallic acid has 
three hydroxyl groups to load spacer arms with an azido function, which in turn 
may participate in coupling with the effector units through azide-alkyne 
cycloaddition. In the specific gallic acid derivative chosen for this study,230 the 
spacer arms consist of triethylene glycol units that were designed to aid water 
solubility and to counteract the hydrophobic effect of the aromatic nucleus. The 




targeting group such as a peptide (Figure 61). p-Hydroxybenzoic acid 
derivative (133) was chosen as a test model to explore different reaction 
conditions for attaching multiple ALA units. 
 
Figure 61. Multifunctional GATG core (132) and simplified model core (133). 
Roy and co-workers have reported the synthesis of gallic acid triethylene glycol 
(GATG)-based dendrimers derived from (132), but faced a common issue of 
low yields in synthesising the repeating unit of GATG, via a four-step sequence 
from triethylene glycol.231-233 The procedure was later modified by Amaral           
et al. using a commercially available chlorohydrin as one starting material, 
providing a high yielding and large-scale route to the GATG derivative (132).230   
3.1.1 Synthesis of core unit 
The azido-chloro derivative required for the spacer arm in (132) and (133) was 
prepared according to the method of Amaral et al. as outlined in Scheme 25.230  
 
Scheme 25. Synthesis of azido-PEG-chloro derivative (135). Reagents and conditions: a. 
NaN3, H2O, 75 °C, 48 h, 99% b. SOCl2, BTEAC, 65 °C, 3 h, 74%. 
Herein the chlorohydrin derivative (133) was treated with sodium azide in water 




chloride and benzyltriethylammonium chloride (BTEAC) to give the required 
azido-chloro derivative (135) in 74% yield.  
The basic building block for the initial model prodrug structure was                          
p-hydroxybenzoic acid (136) which was first esterified with MeOH in the 
presence of sulfuric acid to give (137) in moderate yield (33%) (Scheme 26). 
(137) was then alkylated according to the procedure of Amaral et al.30 with 
(135) in the presence of 18-crown-6 to give the expected model structure (138) 
in 75% yield. 18-Crown-6 was used as it is able to complex potassium ions 
effectively, thus increasing the nucleophilicity of the phenoxide from (137). 
Amaral’s procedure230 was also applied for the gallic acid core structure, and 
the expected derivative (140) was also obtained in very good yield (72%).  
 
Scheme 26. Synthesis of core molecules (138) and (140). Reagents and conditions:                      
a. MeOH, Conc. H2SO4, 20 h, 40% b. (137) or (139), K2CO3, 18-Crown-6. DMF, DMF, 80 °C, 






3.2 Bioorthogonal ligations and click chemistry 
3.2.1 Basic concept 
Bioorthogonal ligations are a type of chemical reaction involving two mutually 
reactive functional groups or handles which react with each other under 
physiological conditions without interfering or interacting with any biomolecules 
present.234 The term bioorthogonal chemistry was first introduced in 2003 by 
C. Bertozzi235 and  since then many such chemical reactions which meet the 
specific requirements of bioorthogonal ligations have been developed. These 
requirements include:236 
1. Both the functional groups should be bioinert and non-toxic. 
2. The rate of the reaction should be high, even at low concentrations of 
the starting material. 
Various types of bioorthogonal ligations have been reported including copper 
(I) catalysed azide-alkyne cycloadditions (CuAAC), strain-promoted azide-
alkyne cycloadditions (SPAAC), tetrazine ligations and photoclick reactions 
(between a tetrazine and alkene component).236-238 An overview of chemical 





Figure 62. Overview of recently developed biorthogonal ligation chemistries.236-238 
3.2.2 Cu (I) catalysed azide-alkyne cycloaddition/click chemistry 
Copper-catalysed azide alkyne cycloaddition (CuAAC) is a widely used 
synthetic technique for the assembly of multifunctional molecules through the 




Huisgen cycloaddition reaction between an organic azide and alkyne occurs 
at elevated temperature for several hours resulting in a mixture of 1,4- and 1,5-
triazoles.240, 241 However, it was found by Sharpless et al. that the involvement 
of a catalytic amount of Cu(I) accelerates the reaction at low temperature to 
form 1,4-triazole products only (Scheme 27).239 The advantages of CuAAC are 
that it is stereospecific, robust, and product isolation is usually simple. CuAAC 
typically involves inexpensive reagents and catalysts, and proceeds with high 
efficiency and minimal by-products, under mild reaction conditions. Polar 
solvents such as water may also be used.216 
 
Scheme 27. Proposed mechanism of CuAAC.216 
The reaction begins with the formation of a complex between an alkyne and copper, followed 
by the coordination of an organic azide with the copper centre. The mechanism then proceeds 
via a six-membered metallocycle transition state to the copper triazolide species, which 
undergoes reductive elimination to give the 1,4-disubstituted triazole. 
In recent years, CuAAC has been applied to PDT in order to generate a variety 
of novel photosensitiser structures.242-244  
3.2.3 Synthesis of non-targeted ALA dendrons 
For the synthesis of the simplified model ALA dendron derivative (141), a 
CuAAC click coupling was first attempted between azide (138) (1 eq) and 




CuSO4 and sodium ascorbate (reducing agent) with DMSO/H2O (9:1) as the 
solvent (Scheme 28). The use of CuSO4 as a source of Cu(I) and a reducing 
agent (in this case sodium ascorbate) is one of the most commonly applied 
conditions in CuAAC.216 Both the starting materials (138) (azide) and (105) 
(alkyne) had good solubility in DMSO, whereas stock solutions of CuSO4 and 
sodium ascorbate were prepared in water. 
 
Scheme 28. Preparation of (141) via Cu(I)-catalysed click coupling of azide (138) and alkyne 
(105). Reagents and conditions: a. CuSO4, sodium ascorbate, DMSO/H2O (9:1), 16 h. 
The reaction was monitored by analytical HPLC, and after 16 h although there 
was a significant amount of unreacted azide (138) (Rt = 9.4 min) remaining, a 
new peak at 10.1 min was observed (Figure 63). The reaction was 
subsequently repeated changing the stoichiometry of alkyne:azide (2:1)245 
which resulted in complete disappearance of the starting material (azide) and 
the appearance of a distinct product peak on HPLC. Mass spectrometry 





Figure 63. HPLC for click coupling reaction of (138) and (105) after 16 h. 
Having established the general feasibility of preparing clicked dendrons such 
as (141), the synthetic scheme was modified. Firstly the methyl ester of the 
(138) was hydrolysed to give the free acid (142) using aq. KOH/THF         
(Scheme 29). This would allow the attachment of a targeting unit, either after 
or before the click coupling. Secondly, the reaction solvent for the click reaction 
was changed to DMSO/H2O/tBuOH (90:5:5 v/v/v), as this has been shown to 
limit potential side reactions in various CuAAC.246  
 
Scheme 29. Modified click strategy for the preparation of model compound (143). Reagents 
and conditions: a. aq. KOH, THF, 50 °C, 24 h, 87% b. (105), CuSO4, sodium ascorbate, 







When azide (142) was coupled with alkyne derivative (105), using the modified 
solvent mixture (Scheme 30), after 1 h reaction a single peak was observed 
on HPLC (Rt = 9.43 min), together with a very small amount of unreacted (142)                           
(Rt = 7.89 min) (Figure 64). No further change was observed on prolonged 
reaction (12 h). The product was isolated by semi-preparative HPLC and was 
confirmed to be the expected triazole (143) by NMR and mass spectrometry. 
The final yield of (143) was 46%. A similar strategy was adopted for Ext Tris 
dendron (107) and the Boc protected clicked product (144) was isolated by 
semi-preparative HPLC with a yield of 44%. 
 
Scheme 30. Click strategy for the preparation of model compound (144). Reagents and 
conditions: a. CuSO4, sodium ascorbate, DMSO/H2O/t-BuOH (9/0.5/0.5 v/v/v), RT, 12 h, 44%. 
Figure 64 shows the HPLC chromatograms for crude reaction mixtures for 
(143) and (144) showing the presence of new species at 9.43 min (143) and 






Figure 64. HPLC chromatogram for click coupling reaction of (143) and (144) after 1h. 
A. Crude reaction mixture showing Boc-protected clicked product (143). 
B. Crude reaction mixture showing Boc-protected clicked product (144). 
The Boc protecting groups from dendrimers (143) and (144) were removed by 
treatment with 50% TFA in DCM (Scheme 31). The deprotection reactions 
were monitored by analytical HPLC with complete disappearance of starting 








30 min. The final conjugates (145) and (146) were freeze-dried from H2O and 
obtained as TFA salts. The trifluoroacetic acid (TFA) salts of the resulting ALA 
dendrimers were prepared in preference to the hydrochloride salts as the 
former has an intrinsic buffering capacity,247 and so would mitigate possible 
acidification of cell culture media and a consequent reduction in porphyrin 
yield, which is optimal between pH 7.0 (for the enzyme uroporphyrinogen 
decarboxylase) and 7.5 (for the enzyme coproporphyrinogen oxidase).204 The 
final structures of the conjugates were confirmed by 1H NMR, 13C NMR and 
mass spectrometry.  
 
Scheme 31. Deprotection of model ALA dendrons (143) and (144). Reagents and conditions: 
a. TFA: DCM (1:1, v/v), 30 min, 0 °C then RT, 92% (145), 94% (146).  
Figure 65 (A and B) shows an overlay of HPLC chromatograms for the two 
dendrimer systems. In each case the final clicked-ALA dendron (145) and 
(146) is shown along with the peaks for the Boc-protected clicked prodrugs 
and the starting azide (142). The respective retention times for (145) and (146) 
were 4.80 and 4.98 min, i.e the extended Tris derivative (146) as expected was 









Figure 65. Overlay of HPLC chromatograms for clicked ALA dendrons (145) and (146). 
A. Overlay showing the product (145) and the starting azide (142) and Boc protected clicked 
prodrug (143). 














Click couplings were then attempted on the trivalent azide (147) using the 
optimised reaction conditions above with both alkyne derivatives (105) and 
(107) (Scheme 32).  
 
Scheme 32. Click couplings between (147) and ALA dendrons (105) and (107). Reagents and 
conditions: a. aq. KOH, THF, 50 °C, 24 h, 94% b. (105) or (107), CuSO4, sodium ascorbate, 
DMSO/H2O/t-BuOH (9/0.5/0.5 v/v/v), RT, 72 h, 50% (148), 52% (149). 
The reactions were carried out for 72 h and monitored by HPLC (Figure 66). 
In both cases a major product peak was observed with disappearance of the 
starting material (147) (azide). The product peaks eluted at 10.5 min for (148) 






Figure 66. HPLC chromatograms for click coupling reaction of (148) and (149) after 72 h. 
A. Crude reaction mixture showing Boc-protected clicked prodrug (148). 
B. Crude reaction mixture showing Boc-protected clicked prodrug (149). 
The final products were isolated by semi-preparative HPLC in yields of 50% 
and 52% for (148) and (149), respectively, and their structures were confirmed 
by 1H NMR (which showed the expected integration of 3 x CH signals for the 
triazole units), 13C NMR and mass spectrometry.The Boc protecting groups 
from dendrimers (148) and (149) were removed by treatment with 50% TFA in 








(Scheme 33). The conjugates obtained were once again characterized by            
1H NMR, 13C NMR and mass spectrometry. 
 
 
Scheme 33. Boc cleavage for model ALA dendrons (148) and (149). Reagents and conditions: 
a. TFA: DCM (1:1, v/v), 30 min, ice-cold then RT, 88% (150), 90% (151).  
Figure 67 shows an overlay of the HPLC chromatograms for the two gallic 
acid-derived dendrimer systems. Once again, as expected, the final 
deprotected conjugates (150) and (151) are relatively hydrophilic due to the 










Figure 67. Overlay of HPLC chromatograms for clicked ALA dendrons (150) and (151).  
A. Overlay showing the product (150) and the starting azide (147) and the Boc-protected 
clicked prodrug (148). 
B. Overlay showing the product (151) and the starting azide (147) and the Boc-protected 












Attempts were also made to couple trivalent azide (147) with alkyne derivative 
(105) by changing the copper source from CuSO4 to Cu(I) iodide and Cu(I) 
trifluoromethanesulfonate benzene complex. The use of a Cu(I) salt in CuAAC 
avoids the use of a reducing agent248 and, for the current work, the reactions 
could be carried out in DMSO only, thus avoiding a mixture of solvents. 
However on monitoring the reaction, the Cu(I) iodide-mediated click reaction 
did not show any new peaks on HPLC, while reactions with Cu(I) triflate 
benzene complex gave the Boc-protected dendrimer (148), but with lower 
yield. 
3.3 Biomolecules in PDT 
As discussed previously attachment of biomolecules to photosensitisers has 
become an area of interest for various researchers in recent years. In PDT, 
selectivity between a healthy cell and a tumour cell has always been a concern 
and attempts to deal with this include the attachment of targeting peptides, 
biomolecules and antibodies to the photosensitisers. An effective ALA 
prodrug-mediated PDT treatment requires that the drug should be effectively 
internalized inside the target cell through appropriate receptor and transport 
systems.249 Also, once inside the cell, ALA should be released from the 
prodrug and subsequently converted into protoporphyrin IX through an 
enzymatic pathway. Biomolecules which have been investigated to date with 
ALA include nucleosides such as adenosine and thymidine that target 
nucleoside receptors, sugars such as glucose, galactose and mannose, and 
vitamins such as vitamin E, vitamin D3 and biotin (discussed in chapter 1).  
3.3.1 Synthesis of vitamin E-ALA dendrons 
The synthesis of first-generation ALA dendrons targeted with vitamin E was 
attempted as shown in Schemes 34 and 35. In this work, racemic α-tocopherol 
(hereafter referred to as vitamin E) was used, as in the study by Vallinayagam 
et al.193 on ALA-vitamin conjugates. The p-hydroxybenzoic acid derivative 
azide core (142) was first esterified with vitamin E (152) using standard 
coupling conditions of EDC.HCl and DMAP (Scheme 34). After 36 h HPLC 




in good yield. The conjugate (153) was characterized by IR, 1H NMR, 13C NMR 
and mass spectrometry. 
 
Scheme 34. Conjugation of vitamin-E with azido spacer (153). Reagents and conditions: 
(142), vitamin E, EDC.HCl, DMAP, DCM, 32 °C, 36 h, 75%. 
The azido conjugate (153) was then coupled with both the alkyne derivatives 
(105) and (107) using Cu(I) trifluoromethanesulfonate benzene complex in 
DMSO. For these reactions, the previously established CuAAC conditions of 
CuSO4 and sodium ascorbate were not used, as the starting material (153) is 
highly lipophilic and insoluble in water. Both reactions were carried out for        
72 h and monitored by analytical HPLC (Figure 68). Disappearance of starting 
material (153) and formation of a new species as a broad single peak was 
seen at 14.6 min for (154) and 11.8 min for (155) respectively. The crude 
products were purified by semi-preparative HPLC and the conjugates (154) 
and (155) were both obtained as colourless oils in good yields (Scheme 35).  
 
Scheme 35. Synthesis of vitamin E-ALA dendrons (154) and (155) (Boc-protected). Reagents 
and conditions: (105) or (107), copper(I) trifluoromethanesulfonate benzene complex, DMSO,         






Figure 68. HPLC chromatograms for click coupling reaction of (154) and (155) after 72 h. 
A. Crude reaction mixture showing Boc-protected vitamin E ALA clicked prodrug (154). 
B. Crude reaction mixture showing Boc-protected vitamin E ALA clicked prodrug (155). 
Surprisingly, the Ext. Tris derivative (155) shows a somewhat shorter retention 










The Boc protecting groups of the protected dendrimers (154) and (155) were 
removed by treating the conjugates with 50% TFA in DCM for 30 min     
(Scheme 36). The reactions were monitored by analytical HPLC which showed 
disappearance of starting materials (154) and (155), and formation of new 
species at 4.6 min (156) and 4.5 min (157) respectively (Figure 69). The final 
conjugates were freeze-dried from H2O to obtain the bio-conjugates of ALA-
vitamin E (156) and (157) as TFA salts. 
 
Scheme 36. Synthesis of vitamin E-ALA dendrons (156) and (157) (TFA salts). Reagents and 
conditions: a. TFA: DCM (1:1, v/v), 30 min, ice-cold then RT, 97% (156), 96% (157).  
Figure 69 shows the overlay for HPLC chromatograms, each showing the ALA-
vitamin E bioconjugates (156) and (157) with the peaks for the starting 
materials (154) and (155) (Boc-protected derivative). Significantly, despite 
conjugation with the highly lipophilic vitamin E unit, both (156) and (157) were 
water-soluble and apparently have similar lipophilicities, based on HPLC 
retention times to the non-targeted conjugates (150) and (151) with 9 ALA 
units. 
Vallinayagam et al. have proposed that conjugation of ALA to vitamin E should 
lead to enhanced uptake due to increased lipophilicity of the resulting 
bioconjugate relative to ALA.193 Although this effect may not be relevant to 
(156) and (157), it has been reported by other authors that co-administration 
of vitamin E may lead to enhancement of PDT effects with ALA and other 
photosensitisers.250, 251 Therefore (156) and (157) may nonetheless offer an 







Figure 69. Overlay of HPLC chromatograms for clicked ALA dendrons (156) and (157). 
A. Overlay showing the product (156) and Boc-protected vitamin E ALA clicked prodrug (154). 









3.3.2 Synthesis of thymidine-ALA dendrimers 
Nucleoside derivatives have been in use clinically for the treatment of cancer 
and other disorders for over 50 years. They inhibit cellular division by 
incorporation into DNA and RNA and thus interfering with cellular 
metabolism.196 A thymidine-ALA bioconjugate has previously been reported 
and been shown to provide enhanced PpIX synthesis,197 therefore thymidine 
was chosen as the targeting unit for an ALA dendrimer in the current project. 
The synthesis of a dendrimeric ALA-thymidine conjugate was first attempted 
by the same strategy as for the vitamin E derivatives (156) and (157). 
Esterification of the 3’ and 5’ hydroxyl groups of thymidine with (142) was 
attempted using EDC.HCl and DMAP activation (Scheme 37). However, after 
monitoring the reaction for 36 h at RT, no new species was observed.  
 
Scheme 37. Bioconjugation of 2-thymidine with (142). Reagents and conditions: a. EDC.HCl, 
DMAP, dioxane, RT, 36 h. 
In view of this result, (142) was replaced with a simple aliphatic azido acid of 
comparable length, which it was reasoned would be more reactive towards the 
hydroxyls of the somewhat hindered thymidine core.    
When thymidine (158) was treated with 11-azidoundecanoic acid (160) using 
the same activation conditions, analytical HPLC after 48 h showed the 
formation of a single new species at 11.3 min (Scheme 38). Purification by 





Scheme 38. Bioconjugation of 2-thymidine (158) with 11-azido undecanoic acid (160). 
Reagents and conditions: a. EDC.HCl, DMAP, Dioxane, RT, 48 h, 73%. 
The thymidine-azido conjugate (161) was coupled with alkyne derivative (105) 
in DMSO using copper(I) trifluoromethanesulfonate benzene complex and the 
reaction was monitored by analytical HPLC for 24 h (Scheme 39). Formation 
of a new species (162) at 12.87 min was observed in addition to the unchanged 
starting material (161) (Figure 70). The crude material was purified by semi-
preparative HPLC to give (162) as white solid in 54% yield.  This demonstrates 
the feasibility of attaching more than one copy of an ALA dendron to a core 
targeting unit by CuAAC. 
 
Scheme 39. Synthesis of thymidine ALA dendrimer (162) (Boc-protected derivative). 
Reagents and conditions: a. (105), copper(I) trifluoromethanesulfonate benzene complex, 





Figure 70. HPLC chromatogram for crude reaction mixture for (162). 
The Boc protecting groups of the dendrimer (162) were removed by treating 
the conjugate with 50% TFA in DCM for 30 min. The reaction was monitored 
by analytical HPLC (Scheme 40), which again showed the disappearance of 
the starting material (162) and formation of a single new species at 5.97 min      
(163) (Figure 71).  
 
Scheme 40. Synthesis of thymidine ALA dendrimer (162) (TFA salt). Reagents and conditions: 
a. TFA: DCM (1:1), ice-cold then RT, 30 min, 93%. 
The product was freeze-dried from H2O to give the novel thymidine-ALA 
dendrimer (163) as the TFA salt. The structure was confirmed by mass 
spectrometry and 1H NMR which showed the expected integration of 2 x CH 







Figure 71. Overlay of HPLC chromatogram for thymidine conjugate (163) showing (162)      
(Boc-protected derivative) and (161) (azide). 
3.3.4 Synthesis of glycoside-ALA dendrimers 
The conjugation of carbohydrates with tetrapyrrolic structures has been 
studied by various researchers.249, 252 It is known that due to the increased 
metabolism and energy demand of cancer and proliferating endothelial cells, 
glycosylation pathways may undergo deregulation. This glycosylation also 
provides a possibility for interaction of specific conjugates with lectin-type 
receptors in certain cancer cell types and hence makes targeting such cells 
with the help of carbohydrates an attractive choice.249 
For the current study, 2,3,4,6-tetra-O-benzyl-D-gluco-pyranose (164, mixture 
of α and β anomers) was chosen as a precursor targeting unit. O-Benzyl 
groups served as protecting groups for the hydroxyl functional groups on (164), 
with the exception of the anomeric hydroxyl function which was required for 
attachment of the azido handle. The first step of the synthesis involved 
coupling of (142) with the anomeric hydroxyl group of (164) using EDC.HCl 
and DMAP (Scheme 41). Formation of a new species was observed by 
analytical HPLC, which was isolated by semi-preparative HPLC to give the 







mixture of predominantly the β anomer (20:1, β:α). The presence of the major 
β-product was confirmed by the large coupling constant (8.0 Hz) observed for 
the anomeric proton at δ 5.86, compared to that of α-anomer (δ 6.58, J = 4.0). 
The preferential formation of the β-anomer of (165) upon acylation of (164) 
with EDC.HCl is consistent with the report of Vallinayagam et al. who observed 
a distinct change in the proportion of α vs β-linked products when (164) was 
acylated using DCC compared to EDC.HCl as coupling agent.249 
 
Scheme 41. Bioconjugation of (142) with 2,3,4,6-tetra-O-benzyl-D-gluco-pyranose (164). 
Reagents and conditions: a. (142), EDC.HCl, DMAP, DCM, ice-cold then RT, 36 h, 70%. 
The azido conjugate (165) thus obtained was coupled with the alkyne 
derivative (105) using the previous CuAAC conditions, and after 36 h analytical 
HPLC indicated complete disappearance of starting material (165), and 
appearance of a new peak was observed at 12.53 min (Scheme 42). The crude 
material was purified by semi-preparative HPLC and freeze-dried from H2O to 
give the expected bioconjugate (166) in 54% yield. 1H NMR once again 
confirmed (166) to be predominantly the β anomer (7:1, β:α). 
 
Scheme 42. Click coupling of ALA dendron (105) with (165). Reagents and conditions: a. 
(105), copper(I) trifluoromethanesulfonate benzene complex, DMSO, RT, 36 h, 54%. 
The next step of the synthesis required removal of the O-benzyl protecting 
groups from sugar (166). This was first attempted according to the method of 




gas (Scheme 43). The triazole unit was expected to resist reduction, as     
Castro et al. have described the successful O-debenzylation of a similar 
carbohydrate-triazole derivative under such conditions.253 
 
Scheme 43. Attempt to cleave Z group from (166). Reagents and conditions: a. Pd/C, H2, 
DCM/EtOH (2:1), 16 h; b. Pd/C, H2, MeOH, 16 h; c. Pd(OH)2, H2, MeOH, 16 h. 
The reaction was monitored by analytical HPLC, however after stirring for         
16 h, no change was observed. This procedure (Scheme 43) has been 
reported to be effective for the complete debenzylation of ALA conjugates of 
(82)-(84) where ALA is attached to the anomeric hydroxyl group.245 Neither 
changing the solvent to MeOH nor replacing the catalyst with the more active 
Pd(OH)2 was effective. Presumably in this case the presence of the bulky 
dendrimeric group in (166) significantly hinders the deprotection compared to 
simpler related ALA conjugates.249 
3.4 Summary 
A successful synthetic route was developed to conjugate first-generation ALA 
dendrons (Chapter 2) to azido core units (142) and (147) via CuAAC. The 
clicked dendrons thus synthesised had 3 or 9 copies of ALA attached to the 
dendron and were obtained in good yields.  
The building blocks (142) and (147) were also used for the preparation of 
biomolecule-targeted ALA prodrugs. Vitamin E was conjugated with azido core 
unit (142) followed by coupling with ALA dendrons (105) and (107) via CuAAC 
to yield (156) and (157) in moderate yields. A similar strategy was also 
attempted for conjugation of thymidine with (142), however no successful 




aromatic core-azide (142) with an aliphatic-azido spacer unit (160), which gave 
the expected azido-thymidine conjugate (161). Click coupling with ALA 
dendron (105) gave the final thymidine-ALA dendrimer (163) having 6 copies 
of ALA. Lastly, the conjugation of ALA dendron (105) to 2,3,4,6-tetra-O-benzyl-
D-gluco-pyranose (164) was also studied. However, attempts to remove the 
Bn protecting groups from conjugate (166) using catalytic hydrogenolysis in 

















CHAPTER 4:  RESULTS AND DISCUSSION (Targeted ALA 
dendrons) 
4.1 Introduction to targeted photodynamic therapy 
Photodynamic therapy, in comparison to other conventional forms of cancer 
treatments, is a minimally invasive technique (Chapter 1). However PDT faces 
a challenge of tumour selectivity and, at times, it becomes difficult to irradiate 
only the tumour cells due to their close proximity to normal cells.254, 255  In the 
past few years, much work has been carried out on targeted photodynamic 
therapy with the aim of enhancing the accumulation of photosensitisers inside 
tumour cells by active or passive targeting.256 Passive targeting relies on the 
morphological and physiological differences between normal and tumour cells 
to deliver and accumulate nanostructures containing photosensitisers 
selectively within the cells.257 These nanostructures can be either 
biodegradable (made of natural or synthetic compounds) or non-
biodegradable (polyacrylamide, silica-based or metallic particles). 
Photosensitisers encapsulated within the biodegradable nanostructures are 
released for the production of singlet oxygen, whereas non-biodegradable 
nanostructures relies on the diffusion of singlet oxygen through these 
structures to biological targets (Figure 72). An example of a biodegradable 
nanostructure was reported by Pierre et al. in 2001 which involved 
encapsulation of ALA into liposomes made from ceramide, palmitic acid, 
cholesterol and cholesterol sulfate, which therefore resembled the lipid 
composition of the stratum corneum.258 The liposome formulation was found 
to successfully deliver ALA to the target skin layer. Non-biodegradable 
nanostructures are stable to pH and temperature fluctuations, which also 
allows control over the size, shape and porosity of these nanostructures during 
their preparation. Tang et al. in 2008 reported the preparation of 
polyacrylamide-based nanostructures encapsulating methylene blue, which 
undergoes rapid enzymatic inactivation when used clinically.259                           
The encapsulated methylene blue was stable to reduction by diaphorase 






Figure 72. Representation of singlet oxygen production by biodegradable and non-
biodegradable nanostructures inside tumour cells (adapted from Shirasu et al.).256 
4.1.1 EGFR-targeted photodynamic therapy 
The epidermal growth factor receptor (EGFR) is a cell-surface receptor and 
belongs to the ErbB family of tyrosine kinases. Overexpression of this receptor 
has been identified in various types of cancer including ovarian, breast, 
prostate, bladder, pancreatic and colorectal cancers.260 This has led to the 
development of various therapeutic agents such as monoclonal antibodies 
(mAbs), tyrosine kinase inhibitors (TKIs), antisense oligonucleotides, antibody-
based immunoconjugates and other agents like FR-18, peptides, affibodies 
and nanobodies.261 Photodynamic therapy targeted towards the EGFR 
receptor is a promising new therapeutic strategy for cancer treatment.        
Kadish et al. in 2010 reported experiments on benzoporphyrin derivative (BPD) 
conjugates in the EGFR overexpressing cell line A431 and EGFR-negative 
NR6 cells, and found the conjugates to be highly selective towards A431 cells 
with a 90% decrease in cell viability.262 Selective targeting of prodrug 




specific peptides that recognise the overexpression of the EGFR receptor in 
certain cancer cell lines. Master et al. in 2012 reported a study on A431 cells 
using the phthalocyanine PC4 photosensitiser conjugated with peptide ligands, 
which was found to have better tumour-selective accumulation and PDT 
effects as compared to that seen in MCF-7 cells.263 Ongarora et al. in 2012 
reported the synthesis of phthalocyanine-peptide conjugates (168a-b) which 
were designed to target the epidermal growth factor receptor and evaluated 
them in human carcinoma A431 and Hep2, human colorectal HT-29, and 
kidney vero (negative control) cells (Figure 73).264 The two peptide sequences 
(LARLLT and YHWYGYTPQNVI) were selected based on their reported EGFR 
targeting properties and ease of conjugation to various molecules. The 
phthalocyanine conjugate linked to the LARLLT peptide via a PEG spacer was 
found to be efficiently internalized by EGFR-positive cell lines and was found 
to be non-toxic to the cells. 
 











Building on the tools developed in the previous chapters for the synthesis of 
ALA dendrons (Chapter 2) and their ligation to biomolecules (Chapter 3), the 
aim of this part of the project was to generate a structure in which ALA dendron 
units were attached to a core unit displaying a specific targeting peptide. 
(Figure 74).  
 
Figure 74. Model for peptide-targeted ALA dendron system. Multiple ALA units are attached 
to a peptide-targeted core unit via CuAAC chemistry. 
4.2 Synthesis of targeting unit       
For this work, the targeting peptide LARLLT described by Ongaro was 
selected. The advantages of using short peptide ligands are their easy 
synthesis and their low immunogenicity. LARLLT was identified from 
computational screening of a virtual peptide library and had been shown to 
target EGFR both in vitro and in vivo.265 The peptide was synthesized on           
2-chlorotrityl resin on a 0.65 mmol scale by Fmoc SPPS. 2-Chlorotrityl resin is 
a commonly used resin in solid-phase peptide synthesis for the synthesis of     
C-terminal peptide acids, particularly for the generation of protected peptide 
fragments.266 Coupling of the first amino acid (Fmoc-Thr(tBu)-OH) (169) was 
carried out manually using DIEA as base. The resin was then transferred to an 
Activotec automated peptide synthesiser for the coupling of the remaining 
amino acids using PyBOP activation. The success of the final step of the 
synthesis, the removal of the Fmoc group from the terminal amino acid, was 
confirmed by the Kaiser test to yield the resin-bound peptide (171)             





Scheme 44. Synthesis of the targeting peptide (172). Reagents and conditions: a. Fmoc-
Thr(tBu)-OH, DIEA, DMF, RT, 1 h; b. Piperidine/DMF (1:4 v/v), 5 + 10 min; c. PyBOP, DIEA, 
DMF; d. TFA/TIS/H2O (95:2.5:2.5, v/v/v), 3 h, 85%. 
Cleavage from the resin and full side-chain deprotection was achieved using 
TFA/TIS/H2O (95:2.5:2.5, v/v/v) to give (172) in 85% yield. (172) was 
characterised by mass spectrometry and the purity was confirmed by analytical 
HPLC which showed a single peak (Rt = 5.5 min). Having confirmed the 
success of the solid-phase synthesis of the targeting peptide, the resin-bound 







4.3 Coupling of ALA dendrons to the targeting unit 
The next step of the synthesis involved coupling of the EGFR targeting peptide 
(172) with ALA dendrons (105) and (107). Scheme 45 summarises the 
different strategies that were explored to prepare these targeted ALA 
conjugates. 
 




4.2.1 Amide coupling of dendrimer to partially protected peptide in 
solution (A) 
In order to investigate the coupling of the targeting peptide to the click products 
(148) and (149), a partially protected peptide derivative (173) was required. 
This was obtained by treatment of (171) with 1% TFA in DCM (Scheme 46). 
This cleavage solution is mild enough to cleave the peptide from the resin 
leaving the Arg and Thr side-chain protecting groups still intact. The coupling 
of the partially deprotected peptide (173) to the clicked dendron was then first 
attempted using standard conditions of EDC.HCl/HOBt activation and DIEA as 
a base (Scheme 46). The reaction was monitored by analytical HPLC for 36 h. 
However the HPLC profile did not show any change in the peaks for the 
starting materials, nor appearance of new product peaks. Repeating the 
reaction using 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b] 
pyridinium 3-oxid hexafluorophosphate (HATU) as coupling agent  also did not 
change the outcome. 
 
Scheme 46. Synthesis of targeted dendrimer (174). Reagents and conditions: a. 1% TFA in 
DCM, 10% pyridine in MeOH, 69%; b. (148), EDC.HCl, HOBt.hydrate, DIEA, DCM, 36 h, RT 





4.2.2 Amide coupling of dendrimer to resin-bound peptide (B) 
As the initial attempt to conjugate the partially protected targeting peptide with 
the clicked ALA dendrimer (148) in solution did not give the desired results, an 
alternative strategy was attempted by conjugating the clicked dendrimer (148) 
directly to the peptide on resin (171) (Scheme 47). The coupling reaction was 
carried out in DMF at RT for 16 h with HATU and DIEA. This was then followed 
by the cleavage of the peptide and the side-chain protecting groups from the 
resin with TFA/TIS/H2O (95:2.5:2.5 v/v/v). Analytical HPLC showed the 
absence of non-acylated LARLLT (172) and the appearance of a new peak at 
6.09 min. Mass spectrometry confirmed the successful coupling of the 
targeting peptide and ALA dendrimer (148), although the final recovery of (181) 
was very low due to problems during HPLC purification (overloading column).  
 
Scheme 47. Coupling of the peptide (171) with Boc-protected ALA dendrimer (148) on resin. 
Reagents and conditions a. (148), HATU, DIEA, 16 h, RT b. TFA/TIS/H2O (95:2.5:2.5 v/v/v),  
3 h, 5%. 
4.2.3 On-resin click coupling (C) 
Although the previous approach was successful, there are number of 
limitations for the above strategy (section 4.2.2) which includes the need for a 
large scale synthesis and HPLC purification of a purified sample of ALA 
dendrimer (148) or (149) for each experiment. The synthetic strategy was 
therefore modified, so as to carry out the click coupling of the effector units to 




the azido spacer units (142) and (147) (readily available) were coupled with 
the EGFR peptide (171) on resin. The acylated intermediates (176) and (178) 
could then be subjected to on-resin coupling with an alkyne derivative (105).      
A sample of each resin-bound peptide (176) and (178) was treated with 
TFA/TIS/H2O (95:2.5:2.5 v/v/v) to generate the fully deprotected azido 
peptides (177) and (179). The purity was confirmed by analytical HPLC     
(Figure 75) and the intermediates were subsequently used in approaches D 
and E.  
 
Scheme 48. Coupling of the azido units (142) and (147) to the resin-bound peptide (171). 
Reagents and conditions: a. (142) (2 eq) or (147) (2 eq), HATU (2 eq), DIEA, DMF, RT, 24 h; 







Figure 75. HPLC chromatograms for peptide-azido core unit (177) and (179). 
A. Crude reaction mixture showing peptide-azido core unit (177). 
B. Crude reaction mixture showing peptide-azido core unit (179). 
A CuAAC click coupling was then attempted between the azide-containing 
resin-bound peptide (178) and alkyne unit (105). The different reaction 








Table 2. Different coupling conditions for on-resin click coupling of the targeted dendrimer 
(181). 
-N3  Coupling conditions Solvent Outcome 
(179) (105) CuSO4, sodium ascorbate DMSO/H2O/t-BuOH  
(179) (105) CuI DMSO  
(179) (105) CuI, DIEA 20% piperidine in DMF  
(179) (105) CuI, DIEA DMF/2,6-lutidine (7:3)  
(179) (105) (CF3SO3Cu)2.C6H6 DMSO  
(179) (107) (CF3SO3Cu)2.C6H6 DMSO  
In each experiment, a solution of 6 eq (105) and 6 eq (CF3SO3Cu)2.C6H6 in DMSO was 
agitated with 1 eq resin-bound azido-peptide (179) in a SPPS vessel for 5 days. The resin was 
then treated with TFA/TIS/H2O for 3 h and the product was analysed by HPLC. 
:   No reaction observed by analytical HPLC 
: Presence of new species observed by analytical HPLC and confirmed by mass           
spectrometry 
Initially standard conditions of CuAAC were applied as discussed in the 
previous chapter (CuSO4, sodium ascorbate, DMSO/H2O/t-BuOH). However 
after 3 days, HPLC did not show any progress. This could be attributed to the 
shrinking of the polystyrene resin in H2O which was the part of the solvent 
mixture (DMSO/H2O/t-BuOH). Alternative Cu sources were then investigated 
that have been previously used for on-resin peptide coupling. Zhang et al. 
(2006) reported a range of coupling conditions using different Cu species to 
carry out the solid phase synthesis of peptidotriazoles.248 This included Cu(I) 
iodide and 20% piperidine in DMF. It has been shown that Cu species which 
get deposited on the resin are dissolved by 20% piperidine in DMF and thus 
can be washed away at the end of the reaction.248 Using Cu(I) salts in click 
coupling avoids the use of reducing agents, although its recommended to add 
a catalytic amount of ascorbic acid to protect Cu(I) from oxidation. The peptide 
derivative with the azido spacer (176) was coupled with (105) in the presence 




48 h (Scheme 49). The final conjugate was cleaved from the resin along with 
removal of side-chain protecting groups using TFA:TIS:H2O (95:2.5:2.5 v/v/v). 
Analytical HPLC showed several peaks, however mass spectrometry did show 
the presence of the expected final conjugate (180). 
 
Scheme 49. On-resin click coupling of (176) and (105). Reagents and conditions: a. 2 eq 
(105), Cu(I)I, ascorbic acid, DIEA, 20% piperidine in DMF, 48 h b. TFA/TIS/H2O (95:2.5:2.5 
v/v/v), 3 h, multiple peaks. 
Optimum reaction conditions were achieved when (178) was coupled with 
alkyne derivatives (105) and (107) in the presence of copper(I) 
trifluoromethanesulfonate benzene complex in DMSO for 5 days. The final 
product was obtained by cleavage from the resin along with side chain 
deprotection by treating the resin with TFA/TIS/H2O (95:2.5:2.5 v/v/v)        
(Figure 76). Purification by semi-preparative HPLC gave the expected 
products (181) and (182) in 30% and 25% yields respectively (Scheme 50).  
 
Scheme 50. On-resin click coupling of peptide derivative (178) with alkyne derivatives (105) 
and (107). Reagents and conditions: a. Copper(I) trifluoromethanesulfonate benzene complex, 


















Figure 76. HPLC chromatograms for peptide-ALA dendron (181) and (182). 
A. Crude reaction mixture showing (181). 
B. Overlay for the final product (181) and starting azido-peptide (179). 
C. Crude reaction mixture showing (182). 
D. Overlay for the final product (182) and starting azido-peptide (179). 
The optimised conditions from above were also applied to the resin-bound 
peptide derivative functionalised with the hydroxybenzoic core (176). (176) 
was coupled with alkyne derivatives (105) and (107) (Scheme 51). The 
expected products (175) and (180) were isolated by semi-preparative HPLC 
and obtained in moderate yields. 
 
Scheme 51. On-resin click coupling of peptide derivative (176) with alkyne derivatives (105) 
and (107). Reagents and conditions: a. 2 eq (105) or (107), copper(I) 
trifluoromethanesulfonate benzene complex, DMSO, 5 d, RT; b. TFA/TIS/H2O (95:2.5:2.5 







Figure 77 shows the HPLC chromatograms of the crude reaction mixtures for 
















Figure 77. HPLC chromatograms for peptide-ALA dendron (175) and (180). 
A. Crude reaction mixture showing (175). 
B. Overlay for the final product (175) and starting material (177). 
C. Crude reaction mixture showing (180). 
D. Overlay for the final product (180) and starting material (177). 
4.2.4 Click coupling in solution (D) 
Loading of the core units (142) and (147) on the peptide-resin followed by           
on-resin click coupling proved to be a successful strategy for synthesizing 
targeted ALA dendrons. However the yields of the reactions were modest and 
the reaction could not be monitored (on-resin coupling). A modification was 
therefore made to the above strategy and the peptide-gallic acid core 
derivative (178) was first cleaved from the resin to obtain (179) (see section 
4.2.3) so that click coupling with the alkyne derivative (105) could be carried 








Scheme 52. Solution click coupling of peptide conjugate (179) with alkyne derivative (105). 
Reagents and conditions a. 6 eq (105), copper(I) trifluoromethanesulfonate benzene complex, 
DMSO, 36 h, RT, 69% b. TFA:DCM (1:1 v/v), 30 min, 94%.  
This allowed the progress of the CuAAC to be easily followed by analytical 
HPLC, and complete disappearance of the starting material (179) and 
formation of a new peak at 9.94 min (183) was observed at the end of 36 h 
(Figure 78). The product was obtained as the Boc protected derivative, which 










Figure 78. HPLC chromatograms for peptide-ALA dendron (181). 
A. Crude reaction mixture showing (181). 










4.2.5 Click coupling via microwave irradiation (E) 
The above strategies helped to identify the right Cu source and optimum 
conditions that allowed the progress of the reaction to be monitored. A final 
attempt to further reduce the duration of reaction was made by following the 
strategy in 4.2.4, but carrying out the reaction under microwave irradiation. 
Various successful examples of solid-phase peptide synthesis and the 
preparation of peptidomimetics via CuAAC under microwave irradiations have 
been reported with high yields.267, 268  
A reaction vial containing the alkyne derivative (105), targeting core (179) and 
copper(I) trifluoromethanesulfonate benzene complex in DMSO was irradiated 
at 10-15 W at a predetermined temperature and for a fixed time (Scheme 53).  
 
Scheme 53. Click coupling of peptide conjugate (179) with alkyne derivative (105) via 
microwave irradiation. Reagents and conditions: a. 6 eq (105), copper(I) 
trifluoromethanesulfonate benzene complex, DMSO, 10 min, 70 °C, microwave irradiation     
(10-15 W), 75%; b. TFA:DCM (1:1 v/v), 30 min, 95%.   
The results from these experiments are summarised in Table 4. When the 
reaction was carried out at 70 °C for 5 min, no disappearance of starting 
material or appearance of new species was observed by HPLC. However 
repeating the same reaction for 10 and 15 min showed a single product peak 











70 5 DMSO No reaction 
70 10 DMSO Clean conversion to product 
70 15 DMSO Clean conversion to product 
80 5 DMSO Additional peaks observed 
80 10 DMSO Additional peaks observed 
80 15 DMSO Additional peaks observed 
100 5 DMSO Additional peaks observed 
100 10 DMSO Additional peaks observed 
100 15 DMSO Additional peaks observed 
In each experiment, a solution of 6 eq (105) and 6 eq (CF3SO3Cu)2.C6H6 in DMSO was treated 
with 1 eq azido peptide (179) in a MW vessel followed by microwave irradiation (10-15 W) at 
different temperature and time conditions. The reaction mixture was then analysed by HPLC 
Reactions carried out at 80 °C and 100 °C showed additional peaks at a higher 
retention time in addition to the product peak, suggesting a possible 











Figure 79. HPLC chromatograms for (183) post-microwave irradiation at two different 















70 °C for 10 min 














80 °C for 10 min 
(183) 




Following the reaction at 70 °C for 10 min (Scheme 52), the product was 
isolated by semi-preparative HPLC and Boc protecting groups were removed 
with TFA to obtain (181) in 95% yield asin Scheme 53.  
Table 4 summarises the outcome of different synthetic strategies adopted for 
synthesizing the targeted ALA dendrimer (181) (Figure 80) 
 
Figure 80. Chemical structure of the targeted ALA dendrimer (181). 
Table 4. Summary of different synthetic strategies adopted to synthesize EGFR-targeted ALA 
dendrimers. 
Mode of synthesis Reaction time Yield (%)a 
Solution coupling  NA 
On resin coupling 16 h 5b 
On resin click coupling 5 d 30b 
Solution click coupling 36 h 69c 
Microwave irradiation           
(in solution) 
10 min 75c 
 
:   No reaction observed by analytical HPLC 
aIsolated yields after semi-preparative HPLC. 
bFully deprotected derivative (181). 







4.3 Biological experiments 
4.3.1 Background 
Time-course fluorescence studies 
The purpose of these studies was to measure the evolution of PpIX 
fluorescence from the prodrugs over time. In this case, the cells were 
incubated with ALA for a fixed period of time and PpIX fluorescence was 
measured using a CLARIOstar high performance microplate reader (410 nm 
excitation and 635 nm emission). 
Photocytotoxicity/PDT activity 
In order to investigate the PDT effect of the synthesized conjugates, 
phototoxicity studies were carried out by irradiating the cells incubated with 
prodrugs for a fixed time period corresponding to a specific light dose for short 
duration of time. The cytotoxicity was then assessed by MTT assay.  
MTT assay 
In order to determine the cytotoxicity of the synthesized prodrugs with or 
without irradiation an MTT assay was carried out.270 The principle of this assay 
is based on the fact that mitochondrial activity is linearly correlated with the 
number of viable cells. The assay uses 3-[4,5-dimethylthiazol-2-yl]-2,5 
diphenyl tetrazolium bromide (MTT) which is reduced by cellular 
dehydrogenases to form the water-insoluble purple-blue formazan dye 
(Scheme 54).  
 




The formazan is dissolved in DMSO and the absorbance is determined 
colorimetrically, which gives a measure of metabolic activity and hence the 
number of viable cells.   
4.3.2 Time-course fluorescence studies 
The build-up of PpIX fluorescence induced by the ALA dendrimers (145)         
(3-ALA units), (150) (9-ALA units), and (181) (EGFR targeting with 9 ALA units) 
was investigated in MDA-MB-231 cells (EGFR-overexpressing breast cancer 
cell line). The cells were incubated with freshly prepared solutions of ALA and 
ALA containing dendrimers (145), (150) and (181) for 24 h. Serum-free 
medium was used in order to avoid loss of PpIX from cells, thus leading to loss 
of fluorescence signal.168, 206 Phenol red-free DMEM was also used during 
those fluorescence measurements. Phenol red was found to produce 
significant autofluorescence during the initial experiments which interfered with 
the PpIX detection (Figure 81).  
 
Figure 81. ALA-induced PpIX fluorescence in phenol red and phenol red-free DMEM. 
MDA-MB-231 cells were seeded in a 96 well plate at two different densities (3000 and 6000). 
ALA at a concentration of 1 mM was incubated with the cells for 4 h and fluorescence 
measurements were performed with CLARIOstar high performance microplate reader 
(CLARIOstar® BMG LABTECH, United Kingdom). The results were expressed as mean ± SD 
(n = 3). 
It was observed that wells containing phenol red DMEM showed higher 




with ones in phenol red-free medium at the same concentration. Hence it was 
concluded that phenol red-free DMEM was the right medium for all the 
fluorescence measurements. The concentration selected for ALA was 1.0 mM 
which was below the limit at which any toxic effects should be observed.206 
Equimolar concentrations of ALA dendrimers (adjusted for number of ALA 
units) were used along with two or three higher doses to investigate any 
possible dark toxicity. The PpIX fluorescence was measured at the end of 4, 8 







Figure 82 (A-C). ALA-induced PpIX generation from (145), (150) and (181) in MDA-MB-231 
cells. 
A. MDA-MB-231 cells were treated with (145) (0.11 mM) and were incubated at 37 °C in the 
dark. Fluorescence readings taken at 4, 8 and 24 h intervals and the results were compared 
with an equimolar concentration of ALA (1.0 mM). Additional experiments with a higher 
concentration of ALA prodrug (145) (0.33 mM) were also included in this current study (n = 3).  
B. MDA-MB-231 cells were treated with ALA dendrimer (150) (0.11 mM) and the same protocol 
was followed as for A. above. Higher concentrations of (150) (0.33, 0.66 and 1.0 mM) were 
also included in this study. 
C. MDA-MB-231 cells were treated with EGFR targeted ALA-dendrimer (181) (0.33 mM) and 
the same protocol was followed as for A. above. A higher concentration of (181) (0.66 mM) 
was also included in this study. 
Results are expressed as mean ± SD (n = 3) 
* :   p<0.05 significantly different from the ALA treated cells. 
Φ:  p<0.05 significantly different from ALA prodrug treated cells (145), (150) and (181) at 
different doses. 
From the results, it can be deduced that the synthesized ALA dendrimers show 
a sustained release of PpIX in comparison to equimolar concentrations of ALA, 
which shows a sharp decline at the end of 24 h. A similar release pattern was 
also observed with higher concentrations of the ALA dendrimers. These results 




sustained release of ALA-induced PpIX from an 18-ALA dendron over 24 h, 
and where basal values were not reached until 48 h.207 ALA-induced PpIX 
fluorescence was initially investigated with (145) and (150) (Figure 82 A-B). 
The cells incubated with these two conjugates showed a lower release of PpIX 
(0.33 and 0.66 mM for (145) and 0.11, 0.33 and 0.66 mM for (150)) at the end 
of 4 and 8 h in comparison to free ALA (1.0 mM). (145) showed almost 50% of 
PpIX fluorescence compared to ALA at the end of 4 h, while it showed only 
25% at the end of 8 h. However (150) produced a similar PpIX fluorescence to 
ALA at the end of 4 h, while it was 60% at the end of 8 h. When (145) and 
(150) at a concentration of 1.0 mM (3 times or 9 times the concentration of 
ALA) were incubated with cells, a decrease in porphyrin levels was observed 
at all time points (4, 8 and 24 h) indicating possible dark toxicity.  
PpIX fluorescence was then investigated with the EGFR-targeted dendrimer 
(181) at two different concentrations (0.11 and 0.33 mM) (Figure 82 C). The 
level of ALA-induced PpIX fluorescence from the dendrimers was higher in 
comparison to equimolar doses of ALA. The release of PpIX was also higher 
in comparison to (145) and (150) consistent with the desired enhanced and 




4.3.3 Cytotoxicity and MTT assay 
Having established that non-toxic concentrations of the synthesized ALA 
dendrimers produced PpIX in MDA-MB-231 cells, the effectiveness of (145), 
(150) and (181) for PDT was investigated. In order to establish appropriate 
experimental conditions, ALA was initially incubated with the cells and 
irradiated with light for different time intervals. Irradiation was performed from 
above the plates (see section 7.3.7) using a broad spectrum UVA lamp whose 
emission overlapped with the Soret band absorption of PpIX (405 nm). Cell 
viability was assessed by MTT assay as previously and the results are shown 
in Figure 83.  
 
Figure 83. PDT effect of ALA on MDA-MB-231 cells at different time intervals. 
MDA-MB-231 cells were treated with ALA (1.0 mM) and were incubated for 4 h at 37 °C in the 
dark. Cells were illuminated with UVA lamp for 0.5, 1.0, 1.5, 2.0 and 2.5 min. MTT analysis 
was carried out 24 h after light illumination, and the results were expressed as mean ± SD        
(n = 3) and plotted as percentage normalised cell viability. 
*: p<0.05 significantly different from non-irradiated cells (dark) 
It could be deduced from the results that light doses of 0.5, 1.0 and 1.5 min 
should be suitable for the study. 
Phototoxicity studies were now carried out in MDA-MB-231 cells by incubating 




at a range of concentrations for 4 h at 37 °C, and irradiating them with UVA 
light for different time intervals up to 1.5 min. Control cells were treated 
identically except that they were either not treated with ALA dendrimers (145), 
(150) and (181) (or free ALA), or not irradiated. Statistical analysis was done 
at the end of study by plotting the percentage of enzymatic activity of the 
investigated compounds with respected to control cells (without any 








Figure 84 (A-C). PDT effect of (145), (150) and (181) on MDA-MB-231 cells after incubation 
for 4 h. 
A. MDA-MB-231 cells were treated with ALA dendrimer (145) (0.33 mM) and were incubated 
for 4 h at 37 °C in the dark. Cells were illuminated with UVA lamp for 0.5, 1.0 and 1.5 min. 
MTT analysis was carried out 24 h after light illumination and the results were compared with 
equimolar doses of ALA (1.0 mM). Higher concentrations of (145) (0.66 and 1.0 mM) were 
also included in this study.  
B. MDA-MB-231 cells were treated with ALA dendrimer (150) (0.11 mM) and the same protocol 
was followed as for A. above. Higher concentrations of (150) (0.33, 0.66 and 1.0 mM) were 
also included in this study. 
C. MDA-MB-231 cells were treated with EGFR targeted ALA-dendrimer (181) (0.11 mM) and 
the same protocol was followed as for A. above. Higher dose of (181) (0.33 mM) was also 
included in this study. 
Results were expressed as mean ± SD (n = 3) and plotted as percentage normalised cell 
viability.  







The results (Figure 84 A-C) show a difference in percentage of cell viability for 
ALA prodrugs (145) (3-ALA units), (150) (9-ALA units) and (181) (targeted 9-
ALA units) in comparison to free ALA. (145) (with 3-ALA units attached) was 
found to be the least active conjugate of all the three ALA derivatives 
investigated in comparison to free ALA. At a dose of 0.33 and 0.66 mM and 
irradiation times of 0.5 and 1.0 min, the prodrug (145) showed almost the same 
cell viability in comparison to cells which were treated with the same 
concentration but not irradiated (dark). These results were slightly improved 
when the exposure time for the above two doses were increased to 1.5 min 
(cell viability was 66% for 0.33 mM and 62% for 0.66 mM), however it was still 
lower than that observed with free ALA (48% at 1.0 mM concentration).  
The 9-ALA conjugate (150) showed better results in comparison to (145). The 
cell viability at a concentration of 0.33 mM and 0.66 mM, showed a decrease 
across all three exposure times. With 0.5 min light exposure, cell viability was 
69% (0.33 mM) and 57% (0.66 mM). These results are consistent with an 
improvement in PDT activity with increasing dendrimer (more ALA units 
leading to increased PpIX production). 
(181) which is an EGFR targeting dendrimer with 9-ALA units showed cell 
viability of 35% at 0.11 mM and around 25% at 0.33 mM thus indicating better 
uptake and release of ALA inside the cell from the dendrimer. The dark toxicity 
(cytotoxicity without irradiation) for the ALA and its dendrimers were also 
assessed. It can be noted from the data above that the dendrimers did not 
show any dark toxicity at equimolar doses. However (145) and (150) showed 
dark toxicity at dose of 1 mM which was three or nine times the concentration 









In summary, different synthetic strategies were attempted to conjugate EGFR 
targeting peptide to ALA dendrons. Amide coupling of peptide to an ALA 
dendron in solution gave no result, whereas attachment of the dendron to the 
peptide on resin gave the desired product, although isolated in low yield. 
Changing the synthetic strategy by attaching initially the core azido unit to the 
peptide on resin, followed by coupling of ALA dendrons (105) and (107) via 
copper catalysed azide-alkyne cycloaddition gave the expected products (181) 
and (182) with moderate yields (30% and 25% respectively). The reaction time 
could be significantly reduced and the recovery of the clicked product was 
significantly improved when the CuAAC reaction was carried out in solution 
with a fully deprotected azido-peptide.  Tthe reaction time could be further 
decreased significantly when coupling in solution was carried out under 
microwave conditions.  
Biological evaluation in the EGFR-overexpressing cell line MDA-MB-231 
showed sustained release of PpIX from the synthesized ALA dendrimers 
(145), (150) and (181) in comparison to equimolar doses of ALA. ALA 
dendrimer (145) was found to show the least PpIX production in comparision 
to free ALA and similar results were also found in PDT experiments where it 
was the least active of all the conjugates tested at different doses. ALA 
dendrimer (150) with 9 copies of ALA attached showed a PpIX release which 
was better than (145) but still less than free ALA at all time points. The peptide 
targeted ALA dendrimer (181) was found to be the most efficient of all the 
conjugates in terms of having higher PpIX production as well as enhanced 






CHAPTER 5: RESULTS AND DISCUSSION (Peptide-porphyrin 
conjugates) 
5.1 Background 
Porphyrins and their analogues as discussed previously constitute a major 
group of photosensitisers in PDT (Chapter 1). Considerable effort in recent 
years has been given to the development of peptide-targeted photosensitisers 
to improve the pharmacokinetic properties and tissue-specificity of otherwise 
hydrophobic derivatives and Chapter 1 discusses some examples of this 
approach. In general, peptide-porphyrin conjugates can be synthesized by 
either covalently linking a peptide to the photosensitisers, or alternatively 
multiple units of peptide and photosensitiser units can be attached to a core 
structure.271 Another approach that has been explored is to modify the surface 
of liposomes encapsulating porphyrin photosensitisers by peptide units    
(Figure 85). 
 
Figure 85. Different strategies explored for developing peptide-porphyrin conjugates a. direct 




5.2 Strain promoted azide-alkyne cycloaddition (SPAAC) 
Copper-catalysed azide-alkyne cycloaddition, as discussed previously, leads 
to the formation of a triazole and has been used for the assembly of various 
multifunctional molecules (Chapter 3). However, it has been reported that the 
presence of copper as a catalyst in CuAAC may lead to toxicity in bacterial as 
well as mammalian cells and thus limits its applications for the preparation of 
therapeutic agents.272, 273 Recently bioorthogonal ligation chemistry has 
yielded a range of novel reactions related to the original triazole approach in 
which the use of a strained alkyne component replaces the need for copper      
catalysis.237, 274  Wittig et al. (1961) were the first to report a reaction between 
cyclooctyne and phenyl azide which proceeded rapidly to give a triazole 
product. Forty years later Bertozzi et al.236 repeated the same reaction under 
physiological conditions and noted that a strained cyclooctyne requires much 
less activation energy for triazole formation compared to a simple terminal 
alkyne (Scheme 55). The requirement for an exogenous catalyst is thus 
avoided, although a mixture of triazole regioisomers may be formed, 
depending on the cyclooctyne structure.275  
 
Scheme 55. Reaction mechanism for strain-promoted azide-alkyne cycloaddition (SPAAC). 
However, cyclooctynes typically suffer from poor water solubility, which limits 
their applications in biological environment and, over the years, chemical 
modifications on the cyclooctyne ring have been carried out to overcome the 
solubility issue as well as improve the second-order rate constant of the click 
reaction (Figure 86). Bertozzi et al. investigated some of the modifications on 
the cyclooctyne ring and found (185) and (186) to be highly reactive, whereas 
Boons et al.276 fused two benzene rings to the cyclooctyne which provided 




cyclooctyne (188) to be approximately three times higher than the simple 
cyclooctyne (184). van Delft et al. reported a further increase in the reactivity 
of (188) by synthesizing aza-dibenzocyclooctyne (189) which had the 
favourable kinetics of (188) as well as the increased hydrophilicity of (186).277 
Symmetrical cyclooctynes such as (187) have the advantage that they can 
only generate a single triazole product.278  
 
Figure 86. Structures of cyclooctyne (184) and its modified derivatives (185)-(189). 
5.3 Synthesis of peptide porphyrin conjugates 
Applying the tools developed previously (chapter 4) for the synthesis of EGFR-
targeted ALA derivatives, the aim of this chapter was to prepare alternative 
EGFR-targeted photosensitisers using strain-promoted azide-alkyne 
cycloaddition (SPAAC) and assess their biological efficacy in selected cell 
lines (Figure 87). Strain promoted azide-alkyne cycloaddition was favoured 
over CuAAC for the current work as previous studies on porphyrin-related 
compounds have shown incorporation of copper into the macrocycle under 






Figure 87. Structure of an EGFR-targeted porphyrin photosensitiser synthesized via SPAAC. 
For the current work, a dibenzocyclooctyne (DBCO) derivative was chosen as 
the strained alkyne as these are widely available and have been used in a 
variety of applications.277 Three different tetrapyrrole derivatives were selected 
for the synthesis of targeted peptide-porphyrin conjugates: 5-(4-aminophenyl)-
10,15,20-triphenylporphyrin (190), chlorin e6 derivative (191) and verteporfin 
(13) (Figure 88).  
 





5-(4-Aminophenyl)-10,15,20-triphenylporphyrin (190) is a porphyrin-type 
macrocycle and is largely water insoluble and highly hydrophobic. The 
clinically used chlorin e6 is a derivative of chlorophyll a and it possesses three 
chemically distinct carboxylic acid functions that have been previously 
functionalized with biomolecules such as peptides, sugars, lipoproteins, 
polyethylene glycols, and polyamines.279-286 Chlorin e6 also has a superior 
absorption in the red region of the visible spectrum along with one order of 
magnitude higher extinction coefficient than the corresponding porphyrin.287 
VISUDYNE® (verteporfin), a benzoporphyrin derivative is a 1:1 mixture of two 
equally active regioisomeric esters (Verteporfin I and II, Figure 89) and is used 
as a photosensitiser in photodynamic therapy for the treatment of the wet form 
of macular degeneration.288 
 
Figure 89. Structures of the two regioisomers of verteporfin (I and II) (13). 
Preparing specific peptide-targeted conjugates of the above three 
photosensitisers (190), (191) and (13) would potentially enhance their uptake 
in EGFR-overexpressing cancer cell line. In the case of 5-(4-aminophenyl)-
10,15,20-triphenylporphyrin (190), it should also increase its water solubility as 
well as balance the hydrophobicity of the photosensitiser with a hydrophilic 
peptide. A DBCO-functionalised derivative of (192) was synthesised as shown 
in Scheme 56. TPP (6) was nitrated and reduced to (190) by a modification of 
the method of Luguya et al.289 The amino group of porphyrin (190) was then 
acylated with DBCO-acid (small excess) using EDC.HCl/HOBt activation and 




HPLC (Figure 91). The product (192) was isolated in good yield and was 
characterized by NMR and mass spectrometry.                 
 
Scheme 56. Scheme of synthesis for the preparation of DBCO conjugate of (190). Reagents 
and conditions: a. NaNO2, TFA, 3 min; b. 5% Pd/C, NaBH4, MeOH/DCM (1:4 v/v), 30 min, 
31%; c. DBCO-acid, EDC.HCl, HOBt. Hydrate, DIEA, DCM, RT, overnight, 76%.  
A selectively derivatised chlorin e6 derivative (191) was prepared starting from 
pheophorbide a (prepared by Dr R. Dondi from Pheophytin-a from Spirulina 
spp).290 Pheophorbide a (30) was treated with 1,2-diaminoethane according to 
the method of Smith et al.290 and the product (191) was acylated with DBCO-
acid as for (192) (Scheme 57). Purification by column chromatography gave 





Scheme 57. Scheme of synthesis for the preparation of Ce6-DBCO conjugate (193). 
Reagents and conditions: a. 1,2-diaminoethane, anhydrous THF, overnight, quant; b. DBCO, 
EDC.HCl, HOBt. hydrate, DIEA, DCM, RT, overnight, 57%. 
The required verteporfin-DBCO derivative (194) was synthesised by Dr R. 
Dondi from commercial verteporfin (mixture of esters) and the corresponding 
DBCO-NH2 derivative (Figure 90).  
 




With the three DBCO derivatives (192)-(194) in hand, SPAAC to produce 
EGFR-targeted conjugates (See Figure 87) could be investigated. Reaction of 
2 eq of the DBCO-photosensitiser conjugates (192)-(194) with the azido-
functionalised EGFR peptide (177) proceeded smoothly in DMSO to give the 
expected conjugates (195)-(197) in good yields. The final conjugates were 
obtained as an inseparable mixture of triazole regioisomers as expected due 
to the unsymmetrical structure of the DBCO unit (Scheme 58).  
 
Scheme 58. Synthesis of peptide-targeted porphyrins (195)-(197). Reagents and conditions: 
a. (192)-(194), DMSO, RT, 8 h, 68% (195), 66% (196), 73% (197). 
It should be noted that conjugates (195) and (196) were mixture of two 
regioisomers while (197) was a mixture of four regioisomers, since verteporfin 












































Figure 91. HPLC chromatograms for peptide-photosensitiser conjugates (195)-(197).  
A. Crude reaction mixture showing (195) and (192). 
B. Overlay for the final product (195) and starting materials (177) and (192). 
C. Crude reaction mixture showing (196). 
D. Overlay for the final product (196) and starting materials (177) and (193). 
E. Crude reaction mixture showing (197) and (194). 
















5.4 Biological evaluation 
PART 1: Biological studies involving (195) including the cell viability by MTT 
and cellular uptake studies by fluorescence microscopy were performed in Prof 
A. J. MacRobert’s laboratory by Z. Mazhari and Dr E. Yaghini at University 
College London, London.  
5.4.1 PDT activity and MTT assay for (195) 
Two different cell lines were used to assess the phototoxic effects of the 
synthesized targeted porphyrin (195): MDA-MB-231 (EGFR-overexpressing 
breast cancer cell line) and MCF-7 (non-EGFR-overexpressing breast cancer 
cell line). The cells were incubated with a range of concentrations of drug in 
96 well plate format for 24 h, before illumination (blue light) from the bottom of 
the plate at two different time intervals (7 and 10 min). This incubation period 
is required for internalisation of the porphyrin within the cells before the light 
treatments are conducted on the plates. The blue light source used for the 
above experiments has an emission at 420 nm which overlaps with the 
absorption of the porphyrin Soret band. MTT assays were conducted 48 h after 
light treatment and the results are shown in Figure 92 (A and B).  
From the results (Figure 92 A-B), it can be can deduced that, while similar 
concentrations and illumination periods were used for both cell lines, 
significant cytotoxic effects were only observed in MDA-MB-231 cells. Figure 
91 A shows that as the concentration and light illumination time increases, the 
corresponding cytotoxicity also increases in MDA-MB-231 cells. When the 
MTT was conducted 48 h post light illumination, a concentration and time-
dependent cell killing was observed with approximately 32% cell viability in 
MDA-MB cells as compared to 91% in MCF-7 cells at a similar concentration 









Figure 92 (A-B). Phototoxicity of EGFR-targeted porphyrin (195). 
A. MDA-MB-231 cells (EGFR overexpressing cell line) were incubated with various 
concentrations of (195) for 24 h. Cells were illuminated with a blue lamp for 7 or 10 min. MTT 
analysis was performed 48 h after light illumination.  
B. Similar treatments were done for MCF-7 cells (non-EGFR overexpressing cell line).  
The control samples were treated identically except that they were either not irradiated but 
incubated with various concentration of (195) (dark) or not treated with (195) (control). The 
results were expressed as mean ± standard deviation (n = 6). 




These results clearly show that the targeted porphyrin derivative (195) 
destroys the cancer cells which are overexpressing the EGFR receptor but, in 
the case of MCF-7 cells which show lower EGFR expression, a lower PDT 
effect was seen throughout the range of concentrations. These results are in 
agreement with the previous work reported on EGFR-targeted PDT with other 
photosensitisers which has shown higher degrees of selective toxicity towards 

















5.4.2 Cellular uptake of porphyrin conjugates 
In order to confirm the selective cellular uptake of the targeted porphyrin (195), 
MDA-MB-231 cells were incubated with 10 µM (195) for 24 h and the 
fluorescence of the samples was detected with an Olympus IMT-2 microscope 
(Figure 93).  
  
Figure 93. Cellular uptake of EGFR-targeted porphyrin (195) A. Control B. Fluorescence 
image of (195) C. Phase contrast D. Merged (B & C). 
The results showed that there was a clear uptake of the peptide-porphyrin 
conjugate (195) after 24 h in the cells as compared to the control sample which 
did not show any fluorescence signal. These findings were therefore consistent 








PART 2: Biological studies involving (196) and (197) were performed at 
University of Bath.  
5.4.3 Preliminary studies  
Phototoxic effects of the targeted photosensitisers (196) (Ce6 conjugate) and 
(197) (Verteporfin conjugate) were assessed in MDA-MB-231 cells. The cells 
were incubated with a range of concentrations of (196) for 24 h before light 
illumination for 1.0 min. As in section 5.4.1, this incubation period was required 
for internalisation of the photosensitisers within the cells before the light 
treatment was conducted on the plates. Illumination here was from above with 
a broad-spectrum UVA lamp whose emission overlapped with the Soret bands 
of (196) and (197). MTT assay was conducted 48 h after the light treatment 
and initial results for (196) are shown in Figure 94. 
 
Figure 94. PDT effect of (196) on MDA-MB-231 cells at various concentrations. 
MDA-MB-231 cells were treated with (196) at different concentrations (200-2000 nM) and were 
incubated for 24 h at 37 °C in the dark. Cells were irradiated with UVA lamp for 1.0 min. MTT 
analysis was carried out 48 h after light illumination and the results were expressed as mean 
± SD (n = 3) and plotted as percentage normalised cell viability.  
* :  p<0.05 significantly different from the control (dark). 
These initial results showed that a similar PDT effect was occuring across 




that leakage of light (cross-talk) was occurring between different wells 
containing cells incubated with different concentrations of (196). Different 
types of 96 well plates were therefore investigated with the aim of reducing this 
possible cross talk effect.  
Three types of 96 well plates were chosen for this study: clear, black wall with 
clear base, and complete black plate. Cells were grown in each of these plates 
followed by incubation of (196) with the cells at three different concentrations 
(200, 1000 and 2000 nM). The plates were then illuminated with light at 
different time intervals (0.5, 1.0, 1.5 and 2.0 min) and MTT assays were 
performed 48 h after the light illumination. The results are summarised in                    











Figure 95 (A-C). The PDT effect of EGFR-targeted photosensitiser (196) on MDA-MB-231 
cells in different types of 96 well plates.  
A: MDA-MB-231 cells were treated with different doses of EGFR-targeted photosensitiser 
(196) in a clear 96 well plate and were incubated for 24 h at 37 °C in the dark. Cells were 
illuminated with UVA lamp for 0.5, 1.0 and 1.5 min and MTT analysis was carried out 48 h 
after light illumination. The results were expressed as mean ± SD (n = 3) and plotted as 
percentage normalised cell viability.   
B: Same treatment was followed as for A. above in a 96 well plate with black walls and 
clear base. 
C: Same treatment was followed as for A. above in a completely black 96 well plate. 
* :  p<0.05 significantly different from the control. 
Φ: p<0.05 significantly different EGFR-targeted porphyrin (196) illuminated with UVA light for 
0.5 1.0 or 1.5 min. 
The results above demonstrate the effect of the properties of different types of 
96 well plates on the cell viability when illuminated from above. In the case of 
clear plates, a similar cell death was seen across the three concentrations 
chosen, indicating cross talk between wells as observed above. However, in 
the case of black plates and plates having black walls with a clear base, 
concentration and time-dependent cell death was observed, indicating 
effective blocking of cross talk between different wells. The data also 




studies. This is because in the case of plates having a black wall with clear 
base, the normalised cell viabilities were consistently lower than the ones 
observed in completely black plates. This again suggests some possible cross 
talk between the wells from the clear bottom side. Another important 
observation made from the above study was the choice of different time 
intervals for light illumination. It was noted that light intervals of 0.5, 1.0 and 
1.5 min produced concentration and light dependent cell death. Exposure of 
cells for 2.0 min caused significant cytotoxicity irrespective of the 
concentration, and so this condition was omitted from further studies.  
5.4.4 PDT activity and MTT assay for (196) and (197) 
PDT studies for (196) (LARLLT-Ce6) and (197) (LARLLT-verteporfin) were 
carried out on MDA-MB-231 cells using the optimized conditions from above        
(Section 5.4.3). It had previously been observed that the peptide-porphyrin 
conjugate (196) showed enhanced cell killing in EGFR-overexpressing cells 
(MDA-MB-231) as compared to MCF-7 cells (breast cancer cell line which 
does not overexpress EGFR). MDA-MB-231 cells were incubated with a range 
of concentrations of drug for 18 h before light illumination (UVA lamp) at 
different time intervals (0.5, 1.0 and 1.5 min). MTT assay was conducted 48 h 






Figure 96 (A-B). The PDT effect of EGFR-targeted photosensitisers (196) and (197) on MDA-
MB-231 cells. 
A: MDA-MB-231 cells were treated with different doses of EGFR-targeted photosensitiser 
(196) in a completely black 96 well plate and were incubated for 24 h at 37 °C in the dark. 
Cells were illuminated with a UVA lamp for 0.5, 1.0 and 1.5 min and MTT analysis was carried 
out 48 h after light illumination. The results were expressed as mean ± SD (n = 4) and plotted 
as percentage normalised cell viability.   
B: Same treatment was followed as for A. above with EGFR-targeted photosensitiser (197). 
* :  p<0.05 significantly different from the dark conditions. 
Φ: p<0.05 significantly different from EGFR-targeted photosensitiser (196) or (197) illuminated 
with UVA light for 0.5, 1.0 or 1.5 min. 
The same concentration and illumination periods were used for both the 
compounds (196) (LARLLT-Ce6) and (197) (LARLLT-verteporfin). MTT results 
for cells treated with (196) showed concentration and time-dependent cell 
killing across all the concentrations (Figure 96 A). A 33% cell viability was 
observed at 800 nM and irradiation for 1.0 min, while only 17% cell viability 
was observed at 2000 nM for the same light exposure. The results also showed 
that control cells (without drug treatment) and dark conditions (cells treated 
with (196) but without light illumination) did not show any reduction in cell 




the absence of light.  
MTT assay on cells treated with (197) (Verteporfin conjugate) also showed 
time-dependent cell killing across all concentrations (Figure 96 B). A 50% cell 
viability was observed at a concentration of 800 nM and irradiation for 1.0 min, 
whereas approximately 42% cell viability was observed at a concentration of 
2000 nM for the same light exposure. 
Comparison of the data obtained for both the conjugates (196) and (197) 
showed enhanced cell killing for the chlorin e6-peptide conjugate as compared 
to verteporfin-peptide conjugate at a given dose of light and drug 
concentration. For example, a 16% cell viability was observed for (196) at a 
concentration of 1600 nM and 1.0 min light exposure as compared to 39% cell 
viability observed for (197) at the sames dose of light and drug. 
Overall, the results are consistent with the findings obtained with (195) 
(LARLLT-TPP). (196) and (197) both show concentration and time-dependent 
phototoxicity consistent with enhanced uptake in the EGFR-overexpressing 
cell line. Although a few anti-EGFR immunoconjugates with chlorin e6 have 
been described,291, 292 these appear to be the first examples of the targeting of 
these photosensitisers with a short EGFR-selective peptide.  
5.5 Summary 
New EGFR-targeted photosensitisers based on 5-(4-aminophenyl)-10,15,20-
triphenylporphyrin (190), chlorin e6 derivative (191) and verteporfin (13) were 
synthesized via SPAAC with an unprotected targeting azido-peptide (177). The 
syntheses were straightforward and the expected products (195)-(197) were 
obtained in good yields.  
Biological studies involving conjugate (195) were done at University College 
London and showed selective phototoxicity in the EGFR-overexpressing cell 
line MDA-MB-231, compared to MCF-7 (non-EGFR-overexpressing cell line).   
Biological studies involving targeted conjugates (196) and (197) were done at 
University of Bath and showed effective PDT activity for Ce6 conjugate (196) 




CHAPTER 6: RESULTS AND DISCUSSION (CPP-porphyrin 
and CPP-ALA conjugates) 
6.1 Introduction to cell penetrating peptides 
Cell-penetrating peptides (CPPs) in general are short sequences, typically 8-
30 amino acids, that are able to cross cell membranes and also deliver a range 
of bioactive cargo either covalently or non-covalently attached, which 
otherwise would be poorly internalised.293, 294 Some of the main characteristics 
of CPPs are low toxicity, ability to carry cargo of varying size, and their ability 
to cross the membranes of various cell types. They thus having a great 
potential for targeted drug delivery.295-297 Some of the most commonly studied 
CPPs are summarised in Table 5. 
Table 5. Sequences of common CPP293, 294 
Peptide Sequence Origin 
Tat (48-60) GRKKRRQRRRPPQ Protein-derived 
Penetratin RQIKIWFQNRRMKWKK Protein-derived 
pVEC LLIILRRRIRKQAHAHSK Protein-derived 
Pep-1 KETWWETWWTEWSQPKKKRKV Chimeric 
MAP KLALKLALKALKAALKLA Synthetic 
Transportan GWTLNSAGYLLGKINLKALAALAKKIL Chimeric 
VP22 NAKTRRHERRRKLAIER Protein-derived 
Oligoarginine Rn (n = 6-12) Designed 
 
6.2 Applications of CPPs in photodynamic therapy 
CPPs have been intensely explored as biocompatible carriers and found to 
have great potential for targeted drug delivery.293, 294 In recent years, there 
have been several investigations into the conjugation of CPP with various 
photosensitisers to improve their pharmacokinetic properties, solubility and 




applications302, 303. Some of the reported CPP-porphyrin conjugates that have 
been synthesized and evaluated are shown in Figure 97. Sibrian-Vazquez et 
al. (2006) reported the synthesis and in vitro evaluation of porphyrin-peptide 
conjugates bearing the nuclear-localizing sequence SV40 or a fusogenic 
peptide (HIV-1 Tat 40-60 or octaarginine) connected to the photosensitiser by 
a low molecular weight poly(ethylene glycol) spacer (Figure 97).298 Conjugates 
(198a-c) were based on a hydrophobic porphyrin, whereas (198d-e) were 
based on carboxylic acid-functionalized porphyrin. In vitro studies in human 
HEp2 cell line revealed enhanced cellular uptake for conjugates bearing the 
fusogenic peptide sequences (198b), (198c) and (198e) in comparison to 
(198a) and (198d) bearing the nuclear-localizing sequence, SV40. However, 
the subcellular localization of these conjugates was dependent on the nature 
of substituents on the porphyrin. The hydrophobic porphyrin conjugates    
(198a-c) localized preferentially in the endoplasmic reticulum whereas 
carboxylic acid functionalized porphyrin (198d) and (198e) localized in the 
lysosomes. Dixon et al. (2007) reported the conjugation of ALA with a 
penetratin analogue (71) and biological studies confirmed the effective uptake 
of the conjugate by PAM212 cells and successful conversion to the PpIX.189 
Bourrè et al. (2010) reported the photoinactivation properties of a HIV-1Tat 
peptide-porphyrin conjugate (199) against gram-positive and gram-negative 
bacterial strains.302 Wang et al. (2012) also reported further photophysical and 
photobiological studies on the same peptide. It was found that  the conjugation 
of the hydrophobic tetraphenyl porphyrin unit to the C-terminus of the cationic 
Tat peptide gave  a water soluble bioconjugate.304 Cellular uptake studies were 
carried out in HN5 human head and neck squamous cell carcinoma and the 
conjugate (199) was found to localise in endo/lysosomal membranes, a 










The main aim of this chapter was to build upon the chemistry developed in 
chapter 3 to attach ALA dendrons to selected cell-penetrating peptides via 
copper-catalyzed azide-alkyne cycloaddition (Scheme 59). 
 
Scheme 59. Proposed route of synthesis for CPP-ALA conjugates. 
Four cell-penetrating peptide sequences were chosen (200)-(203) and 
modified to include an amino acid side chain suitable for CuAAC. Peptide (200) 
is a C-terminal heptapeptide (RRMKWKK) derived from the third helix of the 
Antennapedia transcription factor,293, 305 wherein the peptide was extended at 
the C-terminus by glycine and the amino acid lysine next to the C-terminal 
glycine was replaced by azidolysine (Scheme 60). 
 
Scheme 60. Design of ligatable cell penetrating peptide (200) derived from penetratin. 
Peptide (201) is derived from a HIV-1 Tat (48–57) analogue, wherein the 
peptide was extended at the C-terminus by the tetrapeptide amide             




(GYKC) was replaced by azidolysine for ligation with effector units (ALA 
dendron) via CuAAC, and cysteine was replaced by glycine to facilitate loading 
of the Rink amide resin (Scheme 61).  
 
Scheme 61. Design of ligatable cell penetrating peptide Tat-(48-57)-GYKG, (201). 
Peptide (202) is an extension of cell penetrating peptide (201) at the N-
terminus by LGASWHRPDKG, which is derived from residues 1-21 of the           
N-terminus of human herpes virus 8-encoded protein, vMIP-II 
(LGASWHRPDKCCLGYQKRPLP). This peptide has previously displayed a 
significant binding affinity for the chemokine coreceptor CXCR4.306 The 
CXCR4 receptor is overexpressed in many forms of cancer (prostate, breast, 
cervical, brain, ovarian etc), so peptide (202), would be expected to provide 
enhanced delivery to tumour cells compared to Tat peptide (201) (Scheme 62) 
 
Scheme 62. Design of ligatable cell penetrating peptide (202). 
Finally, pVEC (203) is a CPP derived from murine vascular endothelial-
cadherin protein and for the current work, the C-terminal lysine was again 





Scheme 63. Design of ligatable cell penetrating peptide (203) (pVEC-N3) 
6.2 Synthesis of CPPs 
An azidolysine derivative suitable for Fmoc SPPS was prepared according to 
the method of Chapman et al. (2010), using the Stick diazo transfer reagent 
(imidazole-1-sulfonyl azide hydrochloride) (Scheme 64).308 The final product 
(205) was obtained as a solid in good yield, and the structure was confirmed 
by IR which showed the disappearance of amino group peaks and the 
presence of the expected band at 2100 cm-1 due to the azido function. 
 
Scheme 64. Synthesis of azidolysine (205) using imidazole-1-sulfonyl azide hydrochloride. 
Reagents and conditions: a. Imidazole-1-sulfonyl azide hydrochloride, NaHCO3, CuSO4.5H2O, 
H2O, 16 h, RT, 68%. 
Peptides (200)-(203) were synthesised by Fmoc peptide synthesis on Rink 
amide MBHA resin, using PyBOP activation. Scheme 65 shows the 
preparation of the C-terminally ligatable azido-cell penetrating peptide (200). 
The first step of the synthesis was to remove the Fmoc protection from the 
Rink amide MBHA resin using piperidine in DMF (1:4, v/v) which was 




amino acid, Fmoc-Gly-OH using DIC/DIEA pre-activation (Scheme 65). 
Capping of the resin was performed using acetylation (Ac2O/DIEA/DMF, 1:1:8 
v/v/v) to block any unreacted amino groups on the resin. The peptide chain 
was then assembled using PyBOP/DIEA activation followed by cleavage from 
the resin including side-chain deprotection with TFA/TIS/H2O (95:2.5:2.5 
v/v/v). This gave the final azido-containing CPP (200) in 65% yield. The peptide 
was analysed by analytical HPLC (Figure 98) and the identity was confirmed 
by mass spectrometry. 
 
Scheme 65. Preparation of azido penetratin (200). Reagents and conditions: a. 
Piperidine/DMF (1:4, v/v), 20 min; b. Fmoc-Gly-OH, DIC, DIEA, DMF, RT, 30 min; c. Fmoc 
SPPS, PyBOP, DIEA, DMF, 60 °C; d. TFA/TIS/H2O (95:2.5:2.5 v/v/v), 3 h, RT, 65%. 
The remaining peptides (201)-(203) were synthesized on a similar scale as 
(200) and cleavage of a sample of the resin in each case gave the peptides           





Scheme 66. Preparation of azido CPPs (201)-(203). Reagents and conditions: a. 
TFA/TIS/H2O (95/2/5/2/5,v/v/v), 3 h, RT, 67% (201), 47% (202), 59% (203). 






















Figure 98. HPLC chromatograms for the crude isolated azido CPPs (200)-(203). 
A. (200), penetratin derived CPP. 
B. (201), Tat-(48-57) derived CPP. 
C. (202), v-MIP-II derived CPP. 










 6.3 Synthesis of CPP-ALA derivatives  
Having verified the successful synthesis of the cell-penetrating peptides (200)-
(203), the next step involved the conjugation of ALA dendrons to the CPPs on 
resin via CuAAC.  
The resin-bound azido CPP (206) was reacted with the ALA dendron (206) by 
CuAAC using copper(I) trifluoromethanesulfonate benzene complex       
(Scheme 67). The reaction was carried out for 5 days on-resin, followed by 
cleavage from the resin and side chain deprotection using TFA/TIS/H2O 
(95:2.5:2.5 v/v/v). Analysis of the crude product by HPLC showed the absence 
of (200) at 5.06 min and formation of a new species at 4.36 min. The product 
was purified by semi-preparative HPLC to give the final CPP-ALA conjugate 
(210) in 43% yield, whose identity was confirmed by mass spectrometry.  
 
Scheme 67. Synthesis of CPP-ALA conjugate (210) based on penetratin. Reagents and 
conditions: a. (105), copper (I) trifluoromethanesulfonate benzene complex, DMSO, RT, 5 d; 
b. TFA/TIS/H2O (95/2/5/2/5,v/v/v), 3 h, RT, 43%. 
The other resin-bound azido CPPs (207) and (208) were subjected to CuAAC 
with alkyne (105) under the same conditions as for (210) (Figure 99). The 
conjugation with ALA effector units proceeded efficiently to give the respective 
CPP-ALA derivatives in 31-46% yield. pVEC peptide on resin (209) was 
conjugated with the alkyne (105) and (107) under the same conditions, giving 
the expected products (213) and (214) in 31% and 39% yield respectively           
(Figure 99). The yields of the pVEC-ALA conjugates (213) and (214) were 




(210)-(212). This could be due to the postion of azidolysine which is attached 
directly to the resin therefore making it slightly less accessible to the alkyne 
unit for CuAAC in comparision to other CPP-ALA conjugates (210)-(212) 
where the azidolysine residue is separated from the resin by a glycine residue. 
In the case of pVEC-ALA conjugate (213), the reaction was also carried out for 
3 days. However, cleavage from the resin showed the presence of azido-CPP 
(203) in addition to final CPP-ALA conjugate (213) on HPLC indicating 
incomplete coupling. An attempt was also made to conjugate azido-CPP (203) 
to alkyne (105) in solution, however monitoring the reaction by HPLC showed 
no change in the chromatogram. This could be possibly due to folding of the 
peptide on deprotection and hence making the azido function inaccessible for 
the effector units, although further studies are required to verify this issue. 
Figure 100 shows the HPLC chromatograms of the crude isolated CPP-ALA 
conjugates (210)-(214). In all cases, the desired conjugate is present as the 
major component upon cleavage from the resin following 120 h reaction. 
 




















Figure 100. HPLC chromatograms for crude CPP-ALA derivatives (210)-(214). 
A. (210), penetratin derived CPP-ALA conjugate. 
B. (211), Tat-(48-57) derived CPP-ALA conjugate. 
C. (212), v-MIP-II derived CPP-ALA conjugate. 
D. (213), pVEC derived CPP-ALA conjugate. 










6.4 Synthesis of CPP-porphyrin derivative 
The functionalised cell-penetrating peptide (203) synthesised previously was 
also conjugated in solution with a two-fold excess of dibenzocyclooctyne 
derivative of 5-(4-Aminophenyl)-10,15,20-triphenylporphyrin (192) via strain 
promoted azide-alkyne cycloaddition (Scheme 68). The reaction was carried 
out in DMSO at room temperature and monitored by analytical HPLC (Figure 
101). Unlike the previously attempted CuAAC reaction, the reaction proceeded 
smoothly to give the expected product (215) in 69% yield as an inseparable 
mixture of triazole regioisomers. The final conjugate was purified by semi-
preparative HPLC and confirmed by analytical HPLC and mass spectrometry. 
 
Scheme 68. Synthesis of cell-penetrating peptide-porphyrin conjugate (215) via SPAAC. 







Figure 101. HPLC chromatograms for the CPP-porphyrin conjugate (215). 
A. Crude reaction mixture showing (215) and excess unchanged starting material (192).  
















6.5 Biological evaluation 
Biological studies involving (215) including the cell viability by MTT were 
carried out in Prof A. J. MacRobert’s laboratory by Z. Mazhari and Dr E. 
Yaghini at UCL, London. 
6.5.1 PDT activity and MTT assay 
The phototoxicity of the CPP-porphyrin conjugate (215) was assessed on both 
MDA-MB-231 and MCF-7 breast cancer cell lines as for (195) (EGFR-targeted 
porphyrin) by incubating (215) at various concentrations for 24 h followed by 
illumination with a blue lamp at three time intervals (3, 5 and 7 min). MTT assay 
was carried out 48 h after light illumination and the results are summarised in 






Figure 102 (A-B). The PDT effect of CPP-porphyrin conjugate (215) on MDA-MB-231 and 
MCF-7 cells. 
A: MDA-MB-231 cells were treated with different concentrations of CPP-porphyrin conjugate 
(215) and were incubated for 24 h at 37 °C in the dark. Cells were illuminated with a blue lamp 
for 3.0, 5.0 and 7.0 min and MTT analysis was carried out 48 h after light illumination. The 
results were expressed as mean ± SD (n = 6) and plotted as percentage normalised cell 
viability.   
B: Same treatment was followed as for A. above in MCF-7 cells. 
* :  p<0.05 significantly different from the dark conditions. 
Φ: p<0.05 significantly different from CPP-porphyrin conjugate (215) illuminated for 3.0, 5.0 
and 7.0 min. 
The results above show significant PDT effects for both the cell lines incubated 
with the CPP- porphyrin conjugate (215). At a concentration of 1120 nM and 
illumination for 7 min, both MDA-MB-231 cells and MCF-7 cells showed only 
23% cell viability. These results were in agreement with the enhanced 
photosensitiser delivery and phototoxicity that has been previously observed 
with such CPP conjugates,298 regardless of the receptor selectivity in both cell 
lines. Control experiments in the dark for CPP-porphyrin conjugate (215) 




the cell viability was due to light and not due to any membrane-disrupting 
effects due to the CPP moiety. 
6.6 Summary 
Four cell-penetrating peptides (200)-(203) were synthesised, each containing 
a functionalised amino acid with a reactive group (azido), which could later 
take part in CuAAC with the ALA dendrons (105) or (107). The azido-CPPs 
were coupled on resin with (105) or (107) via CuAAC to give the expected 
CPP-ALA conjugates (210)-(214) in good yields.  
Conjugation of functionalised CPP (203) with dibenzocyclooctyne derivative 
(192) via SPAAC was also attempted. This gave the expected product (215) 
in 69% yield. Biological evaluation in EGFR-positive and -negative cell lines 
(MDA-MB-231 and MCF-7) showed significant PDT effects across a range of 













CHAPTER 7: EXPERIMENTAL 
7.1 General 
Chemical reagents were purchased from Sigma, Aldrich, Fluka, Acros and 
Novabiochem. Anhydrous DCM was obtained by distillation over calcium 
hydride. Peptide grade DMF was purchased from Rathburn Chemicals.  All 
other solvents were purchased from Fisher Scientific. Analytical TLC was 
performed using silica gel 60 F254 pre-coated on aluminium sheets (0.25 mm 
thickness) and reverse-phase analytical TLC was performed with RP-18 F254s 
pre-coated on aluminium sheets (0.27 mm thickness). Column 
chromatography was performed on silica gel 60 (35-70 micron) from Fisher 
Scientific. Melting points were recorded on an Electrothermal IA9200 melting 
point apparatus in open capillaries, and are quoted uncorrected. UV spectra 
were recorded on a Perkin-Elmer Lambda 19 uv/vis spectrophotometer. 
Fluorescence spectra were recorded on a Cary Eclipse fluorimeter. IR spectra 
were recorded on a Perkin-Elmer 782 infra-red spectrometer and values are 
given in cm-1. 1H and 13C NMR spectra were recorded using a Bruker Advance 
DPX 500MHz FT and Varian Mercury VX 400MHz spectrometers. J values are 
given in Hz. Mass spectrometry was performed using a microTOF instrument 
from Bruker Daltonics (Bremen, Germany). Microwave irradiations were 
carried out using a Biotage® Initiator microwave synthesiser. Time-course 
fluorescence studies were carried out on a CLARIOstar high performance 
multimode microplate reader (CLARIOstar®, BMG LABTECH, United 
Kingdom). Analytical RP-HPLC was performed on a Dionex Ultimate 3000 
system (Dionex, UK), with a VWD-3400 variable wavelength detector. 
Analyses were performed at 35 ± 0.1 °C on a Gemini 5 μm C18 110A column, 
(150 x 4.6 mm - Phenomenex, UK), equipped with a SecurityGuard C18 (ODS) 
4 x 3.0 mm ID guard column (Phenomenex, UK), at a flow rate of 1 mL/min. 
Semi-preparative RP-HPLC was performed on a Dionex HPLC system 
equipped with a Phenomenex Gemini 5 µm C-18 (250 x 10 mm) column with 
a flow rate of 2.5 mL min-1. Mobile phase A was 0.1% TFA in water and mobile 





Gradient 1 was T = 0 min, B = 5%; T = 10 min, B = 95%; T = 15 min, B = 95%; 
T = 15.1 min, B = 5%; T = 18.1 min, B = 5%.  
Gradient 2 was T = 0 min, B = 5%; T = 25 min, B = 95%; T = 35 min, B = 95%; 
T = 35.1min, B = 5%. 
Gradient 3 was T = 0 min, B = 50%; T = 10 min, B = 95%; T = 15 min, B = 
95%; T = 15.1 min, B = 5%; T = 18.1 min, B = 5%. 
Gradient 4 was T = 0 min, B = 50%; T = 25 min, B = 95%; T = 35 min, B = 
95%; T = 35.1min, B = 5%. 
The completeness of solid phase acylations or deprotection reactions was 
confirmed by the Kaiser test.309 A few beads of the resin were placed in an 
Eppendorf tube and 2-3 drops of the following solutions were added: 100 mM 
ninhydrin in EtOH, 2.1 M phenol in EtOH and 0.02 mM KCN in pyridine.  The 
tube was heated and the presence of free/unacylated amino function was 
indicated by a dark blue colouration of the beads. 
For estimating the loading of resin derivatised with Fmoc groups, an Fmoc 
loading test was performed at the end of the synthesis.310 Fmoc-protected-
resin (10 mg) in a graduated flask (10 mL) was treated with 2% DBU in DMF 
(2 mL) and agitated gently for 30 min. The solution was then diluted to 10 mL 
with MeCN and 2 mL of this solution was further diluted to 25 mL with MeCN 
(test sample). A similar treatment was performed for the reference sample but 
without the resin. Measurement of the test sample against the reference 
sample was done using a Unicam Helios UV/Vis spectrophotometer, and the 
absorbance was recorded at 304 nm. An estimate of the loading of the resin 
was then calculated using the equation:  





7.2 Synthesis of compounds 
5-(tert-Butoxycarbonylamino)-4-oxopentanoic acid (99)203  
 
A stirred solution of ALA.HCl (1.68 g, 10.0 mmol) in dry THF (120 mL) was 
treated with di-tert butyl dicarbonate (4.66 g, 21.4 mmol). The mixture was 
cooled in an ice bath under N2 and was then treated with a solution of DIEA 
(1.7 mL, 10.0 mmol) in dry THF (30 mL) added dropwise over 3 h. The mixture 
was then stirred overnight at RT, then the solvent was evaporated and the 
residue obtained was taken up in DCM (40 mL) and washed with aq. citric acid     
(2 x 40 mL). The organic phase was dried over MgSO4, filtered, and the solvent 
evaporated to give the crude product which was purified by column 
chromatography on silica gel eluting with 10% MeOH in DCM + 0.05% AcOH. 
Removal of solvent gave (99) as a yellow oil (1.70 g, 78%); Rf = 0.59               
(10% MeOH in DCM); IR (film) 3373 (NH), 2976 (CH), 1713 (CO), 1685 (CO);             
1H NMR (CD3OD, 400MHz) δ 1.46 (9H, s, (CH3)3C), 2.59 (2H, t, J = 6.6, 
COCH2CH2), 2.74 (3H, t, J = 6.4, COCH2CH2), 3.93 (2H, s, NHCH2CO), 4.88 
(1H, br, NH); 13C NMR (CD3OD, 100 MHz) δ 28.50 (COCH2CH2), 28.68 
((CH3)3C), 35.03 (COCH2CH2), 50.79 (NHCH2CO), 80.58 ((CH3)3C), 158.40 
(CO), 176.17 (CO), 207.49 (CO). 
N-Z-tris(hydroxymethyl)aminomethane (100)224 
 
A stirred biphasic suspension of NaHCO3 (4.4 g, 53 mmol) and tris-
(hydroxymethyl) aminomethane, Tris (97) (5.0 g, 42 mmol) in H2O and EtOAc        




dropwise keeping the temperature around 20 °C. The mixture was stirred at 
RT for 5 h, then the suspended solid was filtered off and the two phases were 
left to separate. The aqueous phase was extracted with EtOAc (3 x 20 mL) 
and the combined organic extracts were then washed with H2O (80 mL). The 
organic extracts were dried over MgSO4, filtered, and the solvent evaporated 
to give the crude product as a white solid. Recrystallization from 
EtOAc/petroleum ether gave (100) as white solid (4.96 g, 47%);                           
Mp = 100-102 °C (lit. 101-103 °C)224; 1H NMR ((CD3)2SO, 400 MHz) δ 3.56 
(6H, d, J = 5.6, 3 x CH2OH), 4.47 (3H, t, J = 6.0, 3 x OH), 4.97 (2H, s, OCH2Ph), 




A solution of (99) (0.2 g, 0.9 mmol) in DCM (5 mL) was treated with dendron 
(100) (0.06 g, 0.23 mmol) in DCM (20 mL) and DMAP (0.01 g, 0.09 mmol). 
The reaction mixture was cooled in an ice-bath for 10 min and EDC.HCl          
(0.19 g, 1.01 mmol) was added. The reaction mixture was stirred under N2 for 
96 h at 30 °C, then it was partitioned with H2O (30 mL) and the organic phase 
was washed with 10% aq. NaHCO3 (2 x 30 mL), brine (2 x 30 mL) and dried 
over MgSO4. The organic extract was filtered and solvent was evaporated to 
give the crude product as a yellow oil. Purification by column chromatography 
on silica gel eluting with 1-3% MeOH in DCM gave (90) as a yellow oil (0.08 g, 
43%); 1H NMR (CDCl3, 400 MHz) δ 1.41 (27H, s, 3 x (CH3)3C), 2.57-2.63 (6H, 
m, 3 x CH2CH2CO), 2.66-2.72 (6H, m, 3 x CH2CH2CO), 3.95-4.02 (3 x 
COCH2NH), 4.32 (3 x CCH2O), 5.06 (3H, br, 3 x NH), 5.28 (1H, br, NH), 7.28-





2-Amino-2-(5-(tert-butoxycarbonyl) amino)-4-oxopentanoyl) oxy) methyl) 
propane-1,3-diyl bis(5-((tert-butoxycarbonyl) amino)-4-oxopentanoate) 
acetate salt (92) 
 
Method A 
A solution of (90) (0.2 g, 0.8 mmol) in MeOH (25 mL) was treated with 
ammonium formate (0.2 g, 3.7 mmol) and the reaction flask was degassed with 
N2. 10% Pd/C (40 mg) was added to the reaction mixture which was stirred for 
1.5 h at RT, and the reaction was monitored by TLC (10% MeOH in DCM). No 
change was observed. 
Method B 
Method A was repeated omitting ammonium formate and stirring under an 
atmosphere of H2. 
Method C 
Method B was repeated with the addition of 2M HCl in dioxane (60 µL) to the 
reaction mixture. 
Method D 
A solution of Z-protected amine (90) (0.1 g, 0.1 mmol) in MeOH: AcOH (8 mL, 
3:1) was treated with 10% Pd/C (80 mg) and the pH of the solution was 
checked (acidic, pH 2.0). The mixture was stirred under an atmosphere of H2 
for 20 min at RT. The reaction mixture was filtered through celite, which was 
washed with MeOH. The solvents were evaporated and the residue was dried 
under vacuum to give (92) as a white solid (98 mg, 90%) which was used 
without further purification. 1H NMR (CD3OD, 400 MHz) δ 1.51 (27H, s, 3 x 
(CH3)3C), 2.70 (6H, t, J = 6.4, 3 x COCH2CH2), 2.82- 2.91 (6H, m, 3 x 




2,5-Dioxopyrrolidin-1-yl pent-4-ynoate (106)311, 312 
 
A solution of (104) (0.5 g, 5.1 mmol) and N-hydroxysuccinimide (0.59 g, 5.1 
mmol) in DMF (12 mL) was stirred in an ice-bath and was treated with EDC.HCl 
(0.97 g, 5.1 mmol). The resulting mixture was stirred at RT for 16 h and the 
solvent was evaporated under vacuum. The residue was dissolved in EtOAc 
(10 mL) and was extracted with 5% aq. NaHCO3 (2 x 10 mL), H2O (10 mL) and 
brine (2 x 10 mL). The organic extracts were dried over MgSO4, filtered, and 
the solvent evaporated to give the crude product (0.75 g). Recrystallization 
from CH2Cl2/petroleum ether gave (106) as white solid (0.53 g, 71%); Mp = 
79.0-79.5 °C (lit. 79.9-80.5 °C)312; 1H NMR (CDCl3, 400 MHz) δ 2.02 (1H, t,        
J = 2.6, HC≡CCH2CH2), 2.55-2.60 (2H, m, HC≡CCH2CH2), 2.77-2.86 (6H, m, 
HC≡CCH2CH2, CH2CH2CO-N). 
Benzyl (1,7-dihydroxy-4-(3-hydroxypropyl)heptan-4-yl) carbamate (101)  
 
A solution of Z-OSu (0.55 g, 2.20 mmol) in THF (15 mL) was cooled to 0°C 
and the mixture was stirred under N2. 4-Amino-4-(3-hydroxypropyl) heptane-
1,7-diol (0.5 g, 2.4 mmol) and TEA (0.46 mL, 3.30 mmol) were added to the 
reaction mixture and it was allowed to stir at RT for 16 h, then the solvent was 
evaporated to give the crude product as a colourless oil. Purification by column 
chromatography on silica gel eluting with 0-20% MeOH in EtOAc gave (101) 
as a colourless oil (0.62 g). The product on dissolving in the minimum volume 
of cold water precipitated out as a white solid (0.3 g, 42%); Mp = 85-87 °C 




δ 1.47-1.62 (6H, m, 3 x CH2CH2CH2OH), 1.66-1.82 (6H, m, 3 x 
CH2CH2CH2OH), 3.59 (6H, t, J = 8.0, 3 x CH2CH2CH2OH), 5.07 (2H, s, 
OCH2Ph), 6.6 (1H, s, NH), 7.34-7.40 (5H, m, Ph); 13C NMR (CD3OD,                       
100 MHz) δ 27.49 (CCH2CH2CH2OH), 32.47 (CCH2CH2CH2OH), 58.31 
(CCH2CH2CH2OH), 63.37 (CCH2CH2CH2OH), 66.71 (OCH2Ph), 128.65 (Ph), 
128.90 (Ph), 129.50 (Ph), 138.73 (Ph), 156.73 (CO); [Found (ESI+) 340.2118 
[M+H]+, C18H30N1O5 requires 340.2123]. 
4-(((Benzyloxy) carbonyl) amino)-4-(3-((5-((tert-butoxycarbonyl) amino)-
4-oxopentanoyl) oxy) propyl) heptane-1,7-diyl bis(5-((tert-
butoxycarbonyl) amino)-4-oxopentanoate) (102) 
 
A solution of (99) (0.77 g, 3.54 mmol) in DCM (5 mL) was treated with dendron 
(101) (0.3 g, 0.88 mmol) in DCM (20 mL) and DMAP (0.04 g, 0.35 mmol). The 
reaction mixture was cooled in an ice-bath for 10 min and EDC.HCl (1.13 g, 
3.89 mmol) was added. The reaction mixture was stirred under N2 for 96 h at 
30 °C, then it was partitioned with H2O (30 mL) and the organic phase was 
washed with 10% aq. NaHCO3 (2 x 30 mL), brine (2 x 30 mL) and dried over 
MgSO4. The organic extract was filtered and solvent was evaporated to give 
the crude product as a yellow oil. Purification by column chromatography on 
silica gel eluting with 1-3% MeOH in DCM gave (102) as a yellow oil (0.3 g, 
40%); Rf = 0.42 (5% MeOH in DCM); 1H NMR (CDCl3, 400 MHz) δ 1.41 (27H, 
s, 3 x (CH3)3C), 1.48-1.58 (6H, m, 3 x CH2CH2CH2O), 1.60-1.70 (6H, m, 3 x 
CH2CH2CH2O) 2.57-2.63 (6H, m, 3 x CH2CH2CO), 2.68-2.74 (6H, m, 3 x 
CH2CH2CO), 4.01-4.04 (12H, 3 x CH2CH2CH2O, 3 x COCH2NH) 4.67 (1H, s, 
OCONHC), 5.01 (2H, s, CH2Ph), 5.32 (3H, s, COCH2NH) 7.28-7.33 (5H, m, 
Ph); 13C NMR (CDCl3, 100 MHz) δ 22.45 (CCH2CH2CH2O), 27.65 




50.17 (COCH2NH), 56.87 (CCH2CH2CH2O), 64.59 (CCH2CH2CH2O), 66.09 
(OCH2Ph), 79.76 ((CH3)3C), 127.87 (Ph), 128.05 (Ph), 128.47 (Ph), 154.12 
(CO), 155.62 (CO), 172.35 (CO), 204.50 (CO); [Found (ESI+) 979.5135 
[M+H]+, C48H75N4O17 requires 979.5127].  
4-Amino-4-(3-((5-((tert-butoxycarbonyl) amino)-4-oxopentanoyl) oxy) 
propyl) heptane-1,7-diyl bis(5-((tert-butoxycarbonyl) amino)-4-
oxopentanoate) acetate salt (103)203 
 
A solution of (102) (0.27 g, 0.28 mmol) in MeOH: AcOH (8 mL, 3:1) was treated 
with Pd/C (50 mg) and the pH of the solution was checked (acidic, pH 2.0). 
The mixture was stirred under an atmosphere of H2 for 20 min at RT. The 
reaction mixture was filtered through celite, which was washed with MeOH. 
The solvents were evaporated and the residue was dried under vacuum to give 
(103) as a white solid (0.25 g, 96%) which was used without further purification. 
1H NMR (CDCl3, 400 MHz) δ 1.40 (27H, s, 3 x (CH3)3C), 1.50-1.80 (12H, m,    
3 x CH2CH2CH2O, 3 x CH2CH2CH2O), 2.60-2.62 (6H, m, 3 x CH2CH2CO), 2.72-
2.80 (6H, m, 3 x CH2CH2CO), 4.02-4.07 (12H, m, 3 x CH2CH2CH2O,                             
3 x COCH2NH) 5.46 (2H, s, OCH2Ph); 13C NMR (CDCl3, 100 MHz) δ 22.34 
(CH2CH2CH2O), 27.67 (CH2CH2CO), 28.25 (CH3)3C), 33.80 (CH2CH2CO), 
34.25 (CH2CH2CH2O), 50.15 (COCH2NH), 64.64 (CH2CH2CH2O), 79.78 
((CH3)3C), 155.74 (CO), 172.40 (CO), 204.76 (CO); [Found (ESI+) 845.4857 











A solution of Trishydroxylmethylaminomethane (97) (0.5 g, 4.1 mmol) in DMF 
(40 mL) was treated with imidazole (1.40 g, 20.6 mmol) and triisopropylsilyl 
chloride, TIPS-Cl (4.0 mL, 21 mmol). The reaction mixture was then heated at 
50 °C while stirring under N2 for 60 h. The mixture was cooled down to RT and 
DMF was removed under reduced pressure, then the resulting crude mixture 
was dissolved in a mixture of EtOAc and H2O (60 mL, 1:1). The organic phase 
was washed with 10% aq. NaHCO3 (30 mL), brine (3 x 30 mL), dried over 
MgSO4, filtered and the solvent was evaporated to give (110) as a colourless 
oil (2.4 g, quant) which was used without further purification. IR (film) 3380 
(NH), 2943 (CH), 2867 (CH); 1H NMR (CDCl3, 400 MHz) δ 1.02-1.05 (63H, m, 
9 x (OSiCH(CH3)2, OSiCH(CH3)2), 3.65 (6H, s, 3 x CH2O); 13C NMR (CDCl3, 
100 MHz) δ 12.04 (OSiCH(CH3)2), 18.16 (OSiCH(CH3)2),  58.23 (C(CH2)3), 





A solution of 4-pentynoic acid (104) (0.26 g, 2.70 mmol) in DMF (35 mL) was 
treated with EDC.HCl (0.6 g, 3.2 mmol) and HOBt. hydrate (0.7 g, 4.6 mmol) 
and the mixture was cooled to 0 °C for 40 min. DIEA (0.6 mL, 3.2 mmol) was 
then added to the reaction mixture and the pH checked (basic). The mixture 
was then treated with (110) (1.6 g, 2.7 mmol) and was stirred at RT under N2 
for 25 h. DMF was then removed under reduced pressure and the residue was 




washed with 5% aq. citric acid (40 mL), 10% aq. NaHCO3 (40 mL), brine           
(40 mL), dried over MgSO4, filtered and the solvent was evaporated to give the 
crude product as a colourless oil (1.57 g). Purification by column 
chromatography on silica gel eluting with 0-5% EtOAc in petroleum ether gave 
(112) as a colourless oil (1.47 g, 82%); Rf = 0.42 (5% EtOAc in petroleum 
ether); IR (film) 3423 (NH), 3315 (≡-H), 2943 (CH), 2867 (CH), 2100 (C≡C), 
1669 (CO); 1H NMR (CDCl3, 400 MHz) δ 1.02-1.06 (63H, m, 9 x (OSiCH(CH3)2, 
OSiCH(CH3)2), 1.92-1.93 (1H, t, J = 2.6, HC≡CCH2CH2), 2.30-2.34 (2H, m, 
HC≡CCH2CH2), 2.43-2.46 (2H, m, HC≡CCH2CH2), 4.03 (6H, s, 3 x CCH2O), 
5.79 (1H, s, CH2CONH);     13C NMR (CDCl3, 100 MHz) δ 12.06 (OSiCH(CH3)2), 
14.87 (HC≡CCH2CH2), 18.12 (OSiCH(CH3)2), 36.27 (HC≡CCH2CH2), 61.31 
(CCH2O), 62.47 (CCH2O), 68.92 (HC≡CCH2CH2), 83.39 (CHCCH2CH2), 




A solution of (112) (0.5 g, 0.8 mmol) in THF (20 mL) was treated with 
TBAF.H2O (1.1 g, 3.4 mmol) and AcOH (0.13 mL) was added to the reaction 
mixture (pH- neutral). The reaction mixture was stirred under N2 for 3 h at RT 
and the solvent was removed under reduced pressure. The residue was then 
dissolved in MeOH (10 mL) and Dowex (50WX8, hydrogen form, 200-400 
mesh) (2.35 g) and CaCO3 (0.78 g) were added to the above solution. The 
mixture was stirred for 3 h, and then it was filtered through celite, which was 
washed with MeOH. The solvents were evaporated to give the crude product. 
Purification by column chromatography on silica gel eluting with 0-50% EtOAc 
in petroleum ether and then with 0-20% MeOH in EtOAc gave (108) as a white 
solid (0.11 g, 70%); Mp = 182-184 °C (Uncorrected); Rf = 0.48 (10% MeOH in 
EtOAc); IR (KBr disc) 3420-3230 (OH), 2931 (CH), 2118 (C≡C), 1627 (CO); 




(4H, m, CH2CH2CONH), 3.79 (6H, s, 3 x CCH2OH); 13C NMR (CD3OD, 100 
MHz) δ 15.62 (HC≡CCH2CH2), 36.4 (HC≡CCH2CH2), 62.49 (CCH2OH, 63.68 
(CCH2OH), 70.28 (HC≡CCH2CH2), 83.56 (HC≡CCH2CH2), 175.01 
(CH2CH2CONH); [Found (ESI+) 224.0893 [M+Na]+, C9H15NNaO4 requires 
224.0872]. 
3-({5-[(tert-Butoxycarbonyl) amino]-4-oxopentanoyl} oxy)-2-[({5-[(tert-
butoxycarbonyl) amino]-4-oxopentanoyl} oxy) methyl]-2-(pent-4-




A solution of 4-pentynoic acid (104) (0.03 g, 0.23 mmol) in DMF (2 mL) was 
treated with EDC.HCl (0.06 g, 0.23 mmol) and HOBt hydrate (0.05 g, 0.38 
mmol). The reaction mixture was cooled in an ice bath for 40 min and (92) 
(0.11 g, 0.13 mmol) was added. The reaction mixture was treated with DIEA 
(22 µL, 0.16 mmol) added over 1 h and stirred under N2 for 48 h. The solvent 
was evaporated and the residue was dissolved in a mixture of EtOAc/H2O       
(20 mL, 1:1). The organic layer was washed with 5% aq. citric acid (10 mL), 
10% aq. NaHCO3 (10 mL), brine (10 mL) and dried over MgSO4. The organic 
extract was filtered, and the solvent was evaporated to give the crude product 
as a yellowish oil (0.03 g). Purification by column chromatography on silica gel 
eluting with 0-20% EtOAc in petroleum ether gave (105) as a yellowish oil   
(0.01 g, 11%); Rf = 0.32 (20% EtOAc in petroleum ether). 
Method B 
A solution of (92) (0.10 g, 0.12 mmol) in DMF (2 mL) was treated with (106) 
(0.05 g, 0.24mmol). The reaction mixture was treated with DIEA (18 µL, 0.15 




evaporated and the residue was dissolved in a mixture of EtOAc/H2O (20 mL, 
1:1) and the organic layer was washed with 5% aq. citric acid (10 mL), 10% 
aq. NaHCO3 (10 mL), brine (10 mL) and dried over MgSO4. The organic extract 
was filtered, and the solvent was evaporated to give the crude product as a 
yellowish oil (0.05 g). Purification by column chromatography on silica gel 
eluting with 0-20% EtOAc in petroleum ether gave (105) as a yellowish oil          
(7 mg, 7%); Rf = 0.36 (20% EtOAc in petroleum ether). 
Method C 
A solution of (108) (0.05 g, 0.23 mmol) in DCM (15 mL) was treated with (99)    
(0.20 g, 0.93 mmol) and DMAP (0.01 g, 0.09 mmol). The reaction mixture was 
cooled in an ice bath for 10 min and EDC.HCl (0.20 g, 1.03 mmol) was added. 
The reaction mixture was stirred under N2 for 48 h at 30 °C, then the solvent 
was evaporated and the residue was dissolved in a mixture of EtOAc/H2O       
(80 mL, 1:1). The organic layer was washed with 5% aq. citric acid (1 x 40 mL), 
10% aq. NaHCO3 (40 mL), brine (40 mL) and dried over MgSO4. The organic 
extract was filtered, and the solvent was evaporated to give the crude product 
as a yellowish oil (0.20 g). Purification by column chromatography on silica gel 
eluting with 70-100% acetone in DCM gave (105) as a yellowish oil (0.18 g, 
89%); Rf = 0.70 (30% acetone in DCM); IR (film) 3373 (NH), 2979 (CH), 2931 
(CH) 2129 (C≡C); 1H NMR (CDCl3, 400 MHz) δ 1.40 (27H, s, 3 x (CH3)3C), 
2.01 (1H, t, J = 2.6, HC≡CCH2CH2), 2.36-2.39 (2H, m, HC≡CCH2CH2), 2.42-
2.46 (2H, m, HC≡CCH2CH2), 2.58-2.61 (6H, m, 3 x COCH2CH2) 2.68-2.72 (6H, 
m, 3 x COCH2CH2), 3.98-4.00 (6H, m, 3 x COCH2NH), 4.36 (6H, s, 3 x 
CCH2O), 5.33 (3H, s, COCH2NH), 6.33 (1H, s, CONHC); 13C NMR (CDCl3, 100 
MHz) δ 14.66 (NHCOCH2CH2), 27.63 (COCH2CH2), 28.30 (CH3)3C), 33.80 
(COCH2CH2), 34.23 (HC≡CCH2CH2), 35.52 (CCH2O), 50.16 (NHCH2CO), 
58.26 (CH2)3C), 62.46 (CH2)3C), 69.32 (CH≡CCH2CH2), 79.94 ((CH3)3C), 
82.98 (CH≡CCH2CH2), 155.78 (CO), 171.53 (CO), 171.87 (CO), 204.51 (CO); 









A solution of (98) (0.5 g, 2.4 mmol) in DMF (20 mL) was treated with imidazole 
(0.99 g, 14.6 mmol) and TIPS-Cl (2.87 mL, 14.6 mmol) was added. The 
reaction mixture was then heated at 50 °C while stirring under N2 for 48 h. The 
mixture was cooled down to RT and DMF was removed under reduced 
pressure and the resulting crude mixture was dissolved in a mixture of EtOAc 
and H2O (60 mL, 1:1). The organic phase was washed with 10% aq. NaHCO3      
(30 mL), brine (3 x 30 mL) and dried over MgSO4. The organic extract was 
filtered, and the solvent was evaporated to give (111) as a colourless oil       
(1.54 g, 94%) which was used without further purification. IR 3466 (NH), 2942 
(CH), 2866 (CH); 1H NMR (CDCl3, 400 MHz) δ 1.02-1.06 (63H, m,                           
9 x (OSiCH(CH3)2, OSiCH(CH3)2), 1.35-1.39 (6H, m, 3 x CH2CH2CH2O), 1.48-
1.53 (6H, m, 3 x CH2CH2CH2O), 3.65 (6H, t, J = 6.3, 3 x CH2CH2CH2O);            
13C NMR (CDCl3, 100 MHz) δ 12.42 (OSiCH(CH3)2), 18.18 (OSiCH(CH3)2), 
27.33 (CCH2CH2CH2O), 36.47 (CCH2CH2CH2O), 52.80 (CCH2CH2CH2O), 
64.09 (CCH2CH2CH2O); [Found (ESI+) 696.5608 [M+Na]+, C37H83N1NaO3Si3 
requires 696.5578]. 
N-(3,3,13,13-Tetraisopropyl-2,14-dimethyl-8-(3-((triisopropylsilyl)oxy) 
propyl)-4,12-dioxa-3,13-disilapentadecan-8-yl) pent-4-ynamide (113) 
 




EDC.HCl (0.52 g, 2.71 mmol) and HOBt. hydrate (0.59 g, 3.85 mmol) and the 
mixture was cooled to 0 °C for 40 min. DIEA (0.47 mL, 2.71 mmol) was then 
added to the reaction mixture and the pH checked (basic). The mixture was 
then treated with (111) (1.58 g, 2.26 mmol) and was stirred at RT under N2 for 
25 h. DMF was then removed under reduced pressure and the residue was 
dissolved in a mixture of EtOAc/H2O (80 mL, 1:1). The organic layer was 
washed with 5% aq. citric acid (40 mL), 10% aq. NaHCO3 (40 mL), brine           
(40 mL) and dried over MgSO4. The organic extract was filtered, and the 
solvent was evaporated to give the crude product as a colourless oil (1.72 g). 
Purification by column chromatography on silica gel eluting with 0-5% EtOAc 
in petroleum ether gave (113) as a colourless oil (1.39 g, 81%); Rf = 0.35 (5% 
EtOAc in petroleum ether); IR (film) 3325 (NH), 2944 (CH), 2866 (CH), 2115 
(C≡C), 1660 (CO); 1H NMR (CDCl3, 400 MHz) δ 1.02-1.06 (63H, m, 9 x 
(OSiCH(CH3)2, OSiCH(CH3)2), 1.46-1.51(6H, m, 3 x CH2CH2CH2O), 1.71-1.75 
(6H, m, 3 x CH2CH2CH2O), 1.96 (1H, t, J = 2.6, HC≡CCH2CH2CO), 2.28-2.31 
(2H, m, HC≡CCH2CH2CO), 2.44-2.48 (2H, m, HC≡CCH2CH2CO), 3.64 (6H, t, 
J= 6.5, 3 x CH2CH2CH2O), 5.28 (1H, s, NH); 13C NMR (CDCl3, 100 MHz)              
δ 12.10 (OSiCH(CH3)2), 15.19 (HC≡CCH2CH2), 18.17 (OSiCH(CH3)2), 27.04 
(CH2CH2CH2O) 31.47 (HC≡CCH2CH2CO), 36.47 (CH2CH2CH2O), 58.75 
(CCH2CH2CH2O), 63.66 (CH2CH2CH2OH), 69.41 (HC≡CCH2CH2CO), 83.36 
(HC≡CCH2CH2CO), 169.93 (CO); [Found (ESI+) 754.6087 [M+H]+, 
C42H88N1O4Si3 requires 754.6021]. 
N-[1,7-Dihydroxy-4-(3-hydroxypropyl)heptan-4-yl]pent-4-ynamide (114) 
 
A solution of (113) (1.38 g, 1.83 mmol) in THF (35 mL) was treated with 
TBAF.H2O (2.59 g, 8.23 mmol) and AcOH (0.36 mL) was added to the reaction 
mixture (pH- neutral). The reaction mixture was stirred under N2 for 16 h at RT 
and the solvent was removed under reduced pressure. The residue was then 




mesh) (5.74 g) and CaCO3 (1.90 g) were added to the above solution. The 
mixture was stirred for 3 h, and then it was filtered through celite, which was 
washed with MeOH. The solvents were evaporated to give the crude product 
(0.71 g). Purification by column chromatography on silica gel eluting with           
0-50% EtOAc in petroleum ether and then with 0 to 20% MeOH in EtOAc gave 
(114) as a white solid (0.34 g, 65%); Mp = 118-120 °C; Rf = 0.40 (5% MeOH 
in EtOAc); IR (KBr disc) 3400-3315 (OH), 2943 (CH), 2869 (CH), 2118 (C≡C), 
1683 (CO); 1H NMR (CD3OD, 400 MHz) δ 1.52-1.59 (6H, m, 3 x 
CCH2CH2CH2OH), 1.78-1.82 (6H, m, 3 x CCH2CH2CH2OH), 2.34 (1H, t, J = 
2.6, HC≡CCH2CH2CO), 2.40-2.44 (2H, m, HC≡CCH2CH2CO), 2.48-2.52 (2H, 
m, HC≡CCH2CH2CO), 3.59 (6H, t, J = 6.6, CCH2CH2CH2O); 13C NMR 
(CD3OD, 100 MHz) δ 15.87 (HC≡CCH2CH2CO), 27.41 (CCH2CH2CH2OH), 
32.13 (CCH2CH2CH2OH), 36.68 (HC≡CCH2CH2CO), 59.61 
(CCH2CH2CH2OH), 63.32 (CCH2CH2CH2OH), 70.37 (HC≡CCH2CH2CO), 
83.78 (HC≡CCH2CH2CO), 173.25 (CO); [Found (ESI+) 286.2003 [M+H]+, 
C15H28N1O4 requires 286.2012]. 
7-({5-[(tert-Butoxycarbonyl) amino]-4-oxopentanoyl} oxy)-4-[3-({5-[(tert-





A solution of (103) (0.24 g, 0.27 mmol) in DMF (10 mL) was treated with (106) 
(0.10 g, 0.53mmol). The reaction mixture was treated with DIEA (55 µL, 0.32 
mmol) added over 1 h and stirred under N2 for 48 h. The solvent was 
evaporated and the residue was dissolved in a mixture of EtOAc/H2O (20 mL, 




aq. NaHCO3 (10 mL), brine (10 mL) and dried over MgSO4. The organic extract 
was filtered, and the solvent was evaporated to give the crude product as a 
yellowish oil (0.18 g). Purification by column chromatography on silica gel 
eluting with 70-100% acetone in DCM gave (107) as a yellowish oil (0.10 g, 
40%). 
Method B 
A solution of (114) (0.24 g, 0.84 mmol) in dry DCM (40 mL) was treated with 
(99) (0.73 g, 3.36 mmol) and DMAP (0.04 g, 0.34 mmol). The reaction mixture 
was cooled in an ice bath for 10 min and EDC.HCl (0.71 g, 3.70 mmol) was 
added. The reaction mixture was stirred under N2 for 32 h at 30 °C, then the 
solvent was evaporated and the residue was dissolved in a mixture of 
EtOAc/H2O (40 mL, 1:1) and the organic layer was washed with 5% aq. citric 
acid (20 mL), 10% aq. NaHCO3 (20 mL), brine (20 mL) and dried over MgSO4. 
The organic extract was filtered, and solvent was evaporated to give the crude 
product as a yellowish oil (0.78 g). Purification by column chromatography on 
silica gel eluting with 70-100% acetone in DCM gave (107) as a yellowish oil 
(0.60 g, 77%); Rf = 0.68 (10% acetone in DCM); IR (film) 3383 (NH), 3005 
(CH), 2917 (CH), 2099 (C≡C), 1717 (CO); 1H NMR (CDCl3, 400 MHz) δ 1.33 
(27H, s, 3 x (CH3)3C), 1.41-1.48 (6H, m, 3 x CCH2CH2CH2O), 1.59-1.63 (3 x 
CCH2CH2CH2O), 1.95 (1H, t, J = 2.6, HC≡CCH2CH2), 2.23-2.26 (2H, m, 
HC≡CCH2CH2), 2.36-2.40 (2H, m, HC≡CCH2CH2), 2.49-2.52 (6H, m, 3 x 
COCH2CH2), 2.62-2.66 (6H, s, 3 x COCH2CH2), 3.91-3.96 (12H, m, 3 x 
CCH2CH2CH2O, 3 x COCH2NH), 5.39-5.46 (3H, m, COCH2NH), 5.60 
(CONHC); 13C NMR (CDCl3, 100 MHz) δ 14.90 (HC≡CCH2CH2CO), 22.44 
(CCH2CH2CH2O), 27.67 (COCH2CH2), 28.22 ((CH3)3C), 30.87 (COCH2CH2), 
34.15 (CCH2CH2CH2O), 35.80 (HC≡CCH2CH2CO), 50.09 (COCH2NH), 57.99 
(CCH2CH2CH2O), 64.55 (CCH2CH2CH2O), 69.51 (HC≡CCH2CH2CO), 79.62 
((CH3)3C), 83.11 (HC≡CCH2CH2CO), 155.71 (CO), 170.39 (CO), 172.29 (CO), 






Di-tert-butyl 3,3'-((2-amino-2-((3-(tert-butoxy)-3-oxopropoxy) methyl) 
propane-1,3-diyl)bis(oxy))dipropanoate (117)228 
 
A solution of tris(hydroxylmethyl)methylamine (97) (1.21 g, 10.0 mmol) in dry 
DMSO (2.0 mL) was cooled to 15 °C under N2. 5.0 M aq. NaOH (0.2 mL) was 
then added to the reaction mixture while stirring, followed by dropwise addition 
of tert butyl propenoate (5.0 mL, 34 mmol). The reaction mixture was stirred at 
RT for 24 h, followed by removal of excess reagent and solvent under vacuum 
at RT. The crude product was purified by column chromatography on silica gel 
eluting with 67% EtOAc in petroleum ether + 0.01% NH4OH) to give (117) as 
a colourless oil (1.3 g, 26%); Rf = 0.6, EtOAc in petroleum ether (2:1 + 0.01% 
NH4OH); IR (film) 3448 (NH), 3382 (NH), 2978 (CH), 1731 (CO); 1H NMR 
(CDCl3, 400 MHz) δ 1.40 (27H, s, C(CH3)3), 2.40 (6H, t, J = 6.4, 3 x 
CH2CH2COO), 3.27 (6H, s, CCH2O), 3.60 (6H, t, J = 6.4, 3 x CH2CH2COO).  
Di-tert-Butyl 3,3'-((2-((3-(tert-butoxy)-3-oxopropoxy)methyl)- 2- (pent-4-
ynamido) propane-1,3-diyl)bis(oxy))dipropanoate (118) 
 
A solution of (104) (0.06 g, 0.63 mmol) was treated with EDC.HCl (0.15 g,     




to 0 °C for  40 min. DIEA (0.13 mL, 0.76 mmol) was then added to the reaction 
mixture and the pH checked (basic). The mixture was then treated with (117)     
(32 g, 0.63 mmol) and was stirred at RT under N2 for 36 h. DMF was then 
removed under reduced pressure and the residue was dissolved in a mixture 
of EtOAc/H2O (40 mL, 1:1). The organic layer was washed with 5% aq. citric 
acid (20 mL), 10% aq. NaHCO3 (20 mL), brine (20 mL) and dried MgSO4. The 
organic extract was filtered, and the solvent was evaporated to give the crude 
product as a colourless oil (0.37 g). Purification by column chromatography on 
silica gel eluting with 10-30% EtOAc in petroleum ether gave (118) as a 
colourless oil (0.23 g, 63%); IR (film) 3335 (NH), 3283 (≡-H), 2943 (CH), 2119 
(C≡C), 1709 (CO); 1H NMR (CDCl3, 400 MHz) δ 1.37  [27H, s, 3 x C(CH3)3], 1-
88-1.90 (1H, m, CH≡CCH2CH2CO), 2.32-2.41 (10H, m, HC≡CCH2CH2CO, 3 x 
CH2CH2CO), 3.56 (6H, t, J = 6.4, 3 x CH2CH2COO), 3.62 (6H, s, 3 x CCH2O), 
6.16 (1H, CONH); 13C NMR (CDCl3, 100 MHz) δ 14.82 (HC≡CCH2CH2CO), 
28.12 [C(CH3)3], 35.83 (HC≡CCH2CH2CO), 36.14 (CH2CH2CO), 59.85 
(CCH2O), 67.04 (CH2CH2CO), 68.90 (HC≡CCH2CH2CO), 69.14 (CCH2O), 
80.46 [C(CH3)3], 83.15 (HC≡CCH2CH2CO), 170.97 (CO), 171.14 (CO); [Found 
(ESI+) 586.3603 [M+H]+, C30H52N1O10 requires 586.3591]. 
3,3'-((2-((2-Carboxyethoxy)methyl)-2-(pent-4-ynamido)propane-1,3-
diyl)bis (oxy)) dipropanoic acid (119) 
 
A solution of (118) (1.9 g, 3.2 mmol) in DCM (10 mL) was cooled to 0 °C and 
TFA (5 mL) was added dropwise. The reaction mixture was stirred for 4 h at 
RT, then the solvent was evaporated under vacuum and the residue was co-
evaporated with Et2O (x 3) to remove excess TFA. The crude product was 
obtained as a yellowish oil and was dried under vacuum, then used without 




ether. IR (film) 3285 (≡-H), 3055-2610(OH broad), 2915 (CH), 2115 (C≡C), 
1705 (CO); 1H NMR (CD3OD, 400 MHz) δ 2.22-2.26 (1H, m, HC≡CCH2CH2), 
2.37-2.42 (4H, m, HC≡CCH2CH2), 2.50-2.58 (6H, m, 3 x CH2CH2COOH), 3.63-
3.71 (12H, m, 3 x CH2CH2COOH, 3 x CCH2O); 13C NMR (CD3OD, 100 MHz) 
δ 15.66 (HC≡CCH2CH2), 35.70 (CH2CH2COOH), 36.58 (HC≡CCH2CH2), 61.49 
(CCH2O), 68.11 (CH2CH2COOH), 69.94 (CCH2O), 70.20 (HC≡CCH2CH2), 
83.71 (HC≡CCH2CH2), 174.01 (CO), 175.45 (CO); [Found (ESI+) 440.1535 
[M+Na]+, C18H27N1NaO10 requires 440.1532]. 




A solution of Z-β-ALA-OH (120) (0.87 g, 3.91 mmol) in DMF (15 mL) was 
treated with EDC.HCl (0.89 g, 4.69 mmol) and HOBt. hydrate (1.06 g, 6.64 
mmol) and the mixture was cooled to 0 °C for 40 min. DIEA (0.82 mL, 4.69 
mmol) was then added to the reaction mixture and the pH checked (basic). 
The mixture was then treated with (110) (2.31 g, 3.91 mmol) and was stirred 
at RT under N2 for 36 h. DMF was then removed under reduced pressure and 
the residue was dissolved in a mixture of EtOAc/H2O (80 mL, 1:1). The organic 
layer was washed with 5% aq. citric acid (40 mL), 10% aq. NaHCO3 (40 mL), 
brine (40 mL) and dried over MgSO4. The organic extract was filtered, and the 
solvent was evaporated to give the crude product as a colourless oil (1.89 g). 
Purification by column chromatography on silica gel eluting with 0-5% EtOAc 
in petroleum ether gave (121) as a colourless oil (1.53 g, 49%);                               
1H NMR (CDCl3, 400 MHz)  δ 0.98-1.09 (63H, m, 9 x (OSiCH(CH3)2, 
OSiCH(CH3)2), 2.30-2.35 (2H, m, CONHCH2CH2CONH), 2.40-2.46 (2H, m, 
CONHCH2CH2CONH). 4.01 (6H, s, NHCCH2), 5.06 (2H, s, Ph-CH2), 7.27-7.33 
(5H, m, Ph); 13C NMR (CDCl3, 100 MHz) δ 11.53 (OSiCH(CH3)2), 17.89 




61.12 (NHCCH2), 62.27 (NHCCH2), 66.44 (Ph-CH2), 127.88 (Ph), 127.91 (Ph), 
128.36 (Ph), 136.62 (Ph), 156.33 (CO), 170.68 (CO); [Found (ESI+) 795.5607 
[M+H]+, C42H83N2O6Si3 requires 795.5558]. 
Benzyl (3-((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl) amino)-3-
oxopropyl) carbamate (122) 
 
A solution of (121) (1.50 g, 1.88 mmol) in THF (30 mL) was treated with 
TBAF.H2O (2.67 g, 8.49 mmol) and AcOH (0.37 mL) was added to the reaction 
mixture (pH-neutral). The reaction mixture was stirred under N2 for 3 h at RT 
and the solvent was removed under reduced pressure. The residue was then 
dissolved in MeOH (35 mL) and Dowex (50WX8, hydrogen form, 200-400 
mesh) (5.91 g) and CaCO3 (1.96 g) were added to the above solution. The 
mixture was stirred for 3 h, and then it was filtered through celite, which was 
washed with MeOH. The solvents were evaporated to give the crude product 
(0.61 g). Purification by column chromatography on silica gel eluting with           
0-100% EtOAc in petroleum ether and then with 5- 20% MeOH in EtOAc gave 
(122) as a white solid (0.45 g, 74%); Mp = 82.5-83.0 °C (Uncorrected); IR (KBr 
disc) 3443-3198 (OH), 2942 (CH), 1693 (CO); 1H NMR (CD3OD, 400 MHz)         
δ 2.50 (2H, t, J = 6.5, CONHCH2CH2CONH), 3.46 (2H, t, J = 6.5, 
CONHCH2CH2CONH), 3.78 (6H, s, NHCCH2), 5.13 (2H, s, Ph-CH2), 7.35-7.41 
(5H, m, Ph); 13C NMR (CD3OD, 100 MHz) δ 37.85 (CONHCH2CH2CONH), 
38.52 (CONHCH2CH2CONH), 62.37 (NHCCH2), 63.70 (CCH2), 67.46 (Ph-
CH2), 128.80 (Ph), 128.96 (Ph), 129.45 (Ph), 138.33 (Ph), 158.88 (CO), 174.89 







Z-NH-beta-alanine ALA-dendron (123) 
 
A solution of (99) (1.09 g, 5.03 mmol) in dry DCM (30 mL) was treated with 
(122) (0.41 g, 1.26 mmol) and DMAP (0.06 g, 0.05 mmol). The reaction mixture 
was cooled in an ice bath for 10 min and EDC.HCl (1.06 g, 5.53 mmol) was 
added. The reaction mixture was stirred under N2 for 36 h at 32 °C, then the 
solvent was evaporated and the residue was dissolved in a mixture of 
EtOAc/H2O (60 mL, 1:1). The organic layer was washed with 5% aq. citric acid 
(30 mL), 10% aq. NaHCO3 (30 mL), brine (30 mL) and dried over MgSO4. The 
organic extract was filtered, and the solvent was evaporated to give the crude 
product as a yellowish oil (1.18 g). Purification by column chromatography on 
silica gel eluting with 0-5% MeOH in DCM gave (123) as a yellowish oil          
(0.88 g, 72%); 1H NMR (CDCl3, 400 MHz) δ 1.43 (27H, s, 3 x (CH3)3C), 
2.43.244 (2H, m, NHCH2CH2CONH), 2.57-2.60 (6H, m, 3 x COCH2CH2), 2.67-
2.68 (6H, m, 3 x COCH2CH2), 3.44-3.48 (2H, m, NHCH2CH2CONH), 3.98-3.99 
(6H, m, 3 x COCH2NH), 4.40 (6H, s, 3 x CCH2O), 5.07 (2H, s, CH2), 5.29-5.34 
(3H, m, 3 x COCH2NH), 5.62 (1H, s, NH), 6.29 (1H, s, NH), 7.33-7.35 (5H, m, 











Attempted acylation of (119) and (124) 
 
Step 1. Cleavage of Z group from (123) 
 
A solution of Z-protected amine (123) (0.57 g, 0.59 mmol) in MeOH: AcOH          
(16 mL, 3:1) was treated with 10% Pd/C (113 mg) and the pH of the solution 
was checked (acidic, pH 2.0). The mixture was stirred under an atmosphere of 
H2 for 20 min at RT. The reaction mixture was filtered through celite, which 
was washed with MeOH. The solvents were evaporated and the residue was 
dried under vacuum to give (124) as a white solid (0.41, 79%) which was used 
without further purification. [Found (ESI+) 854.4036 [M+Na]+, C37H61N5NaO16 
requires 854.4011]. 
Step 2. Attachment of (119) 
 




HATU (18 mg, 47 µmol) for 3 min and added to a vial containing (124) (56 mg, 
62 µmol) in DMF (2 mL). The reaction was stirred at RT for 32 h and monitored 
by TLC. No disappearance of starting material (119) and (124) nor appearance 
of new species was observed.  
Diethyl 5-aminobenzene-1,3-dicarboxylate (128)313  
 
A solution of 5-aminoisophthalic acid (126) (3.0 g, 17 mmol) in EtOH (50 mL) 
was treated with conc. sulfuric acid (1.5 mL) and was heated under reflux for        
20 h. The reaction mixture was cooled down and the solvent was evaporated. 
The residue was diluted with EtOAc (50 mL) and extracted with 10% aq. 
NaHCO3 (2 x 50 mL) and brine (2 x 50 mL) and dried over MgSO4. The solvent 
was evaporated under reduced pressure to give the product (128) as a white 
solid (3.06 g, 77%) which was used without further purification. Mp = 118-119 
°C (lit. 117-118 °C)313; Rf = 0.50 (30% petroleum ether in EtOAc); IR (KBr disc) 
3456 (NH), 3362 (NH), 2998 (CH), 1695 (CO); 1H NMR (CDCl3, 400 MHz)          
δ 1.37 (6H, t, J = 7.2, COOCH2CH3), 3.96 (2H, br, NH2), 4.35 (4H, q, J = 6.8, 
COOCH2CH3), 7.51 (2H, d, J = 1.2, 2 x Ar-CH), 8.04 (1H, t, J = 1.6, Ar-CH). 
Diethyl 5-(pent-4-ynamido)benzene-1,3-dicarboxylate (129) 
 
A solution of (104) (0.62 g, 6.32 mmol) was treated with EDC.HCl (1.5 g, 7.6 
mmol) and HOBt. hydrate (1.64 g, 10.7 mmol) and the mixture was cooled to 
0 °C for  40 min. DIEA (4.4 mL, 25.3 mmol) was then added to the reaction 
mixture and the pH checked (basic). The mixture was then treated with (128) 




removed under reduced pressure and the residue was dissolved in a mixture 
of EtOAc/H2O (60 mL, 1:1) and the organic layer was washed with 5% aq. citric 
acid (30 mL), 10% aq. NaHCO3 (30 mL), brine (30 mL), and dried over MgSO4. 
The organic extract was filtered, and the solvent was evaporated to give the 
crude product as a colourless solid (2.05 g). Purification by column 
chromatography on silica gel eluting with 10-30% EtOAc in petroleum ether 
gave (129) as a colourless solid (1.94 g, 97%); Mp = 182-184 °C; Rf = 0.68 
(40% EtOAc in petroleum ether); IR (KBr disc) 3364 (NH), 3257 (≡-H), 2991 
(CH), 2113 (C≡C), 1706, 1608 (C=C); 1H NMR [(CD3)2CO, 400 MHz] δ 1.38 
(6H, t, J = 7.2, COOCH2CH3), 2.35-2.36 (1H, m, HC≡CCH2CH2CO), 2.55-2.59 
(2H, m, HC≡CCH2CH2CO), 2.66-2.70 (2H, m, HC≡CCH2CH2CO), 4.38 (4H, q, 
J = 7.2, COOCH2CH3), 8.28 (1H, t, J = 1.6, Ar-CH), 8.53 (2H, d, J = 1.6, 2 x 
Ar-CH); 13C NMR [(CD3)2CO, 100 MHz] δ 14.59 (COOCH2CH3), 14.88 
(HC≡CCH2CH2CO), 36.64 (HC≡CCH2CH2CO), 61.97 (COOCH2CH3), 70.36 
(HC≡CCH2CH2CO), 79.21 (HC≡CCH2CH2CO), 124.54 (Ar-CH), 124.63 (Ar-
CH), 125.49 (Ar-C), 132.46 (Ar-C), 140.85 (Ar-C), 165.87 (CO), 170.62 (CO); 

















((triisopropylsilyl) oxy) propyl)-4,12-dioxa-3,13-disilapentadecan-8-yl) 
isophthalamide (130) 
 
Step 1. Hydrolysis of diethyl 5-(pent-4-ynamido)isophthalate (129) 
 
A solution of (129) (1.0 g, 3.15 mmol) in MeOH (30 mL) was heated at 55 °C 
and NaOH (0.38 g, 9.45 mmol) was added. The mixture was stirred for 2 h and 
the reaction was monitored by TLC which showed disappearance of the 
starting material and appearance of new species. The reaction mixture was 
then neutralized with 1M aq. HCl (1.5 mL) and extracted with EtOAc/H2O (1:1,       
30 mL). The combined organic extracts were dried over MgSO4, filtered and 
the solvent was evaporated to give the crude product as a yellowish solid (127) 
(0.79 g, 96%) which was used in the next step without further purification.          
IR 3389 (NH), 3257 (≡-H), 3011-2588 (OH broad), 1702 (CO); [Found (ESI+) 






Step 2. Attachment of (111) 
 
A solution of (127) (0.1 g, 0.4 mmol) in DMF (10 mL) was treated with EDC.HCl 
(0.15 g, 0.76 mmol) and HOBt. hydrate (0.2 g, 1.3 mmol) and the mixture was 
cooled to 0 °C for 40 min. DIEA (0.26 mL, 1.52 mmol) was then added to the 
reaction mixture and the pH checked (basic). The mixture was then treated 
with (111) (1.02 g, 1.52 mmol) and was stirred at RT under N2 for 36 h. DMF 
was then removed under reduced pressure and the residue was dissolved in 
a mixture of EtOAc/H2O (20 mL, 1:1) and the organic layer was washed with 
5% aq. citric acid (10 mL), 10% aq. NaHCO3 (10 mL), brine (10 mL) and dried 
over MgSO4. The organic extract was filtered, and solvent was evaporated to 
obtain the crude product as a colourless oil (0.62 g). Purification by column 
chromatography on silica gel eluting with 0-20% EtOAc in petroleum ether 
gave (130) as a colourless oil (0.38 g, 64%); Rf = 0.45 (15% EtOAc in 
petroleum ether); 1H NMR (CDCl3, 400 MHz) δ 0.97-1.10 (126H, m, 18 x 
(OSiCH(CH3)2, 18 x OSiCH(CH3)2), 1.47-1.54 (12H, m, 6 x CCH2CH2CH2O), 
1.84-1.88 (12H, m, 6 x CCH2CH2CH2O), 2.051-2.057 (1H, m, 
CH≡CCH2CH2CO), 2.59-2.60 (CH≡CCH2CH2CO), 3.66 (12H, t, J = 6.4, 
CCH2CH2CH2O), 5.88 (2H, s, 2 x NH), 7.79 (1H, s, Ar-CH), 8.06-8.07 (2H, m, 
2 x Ar-CH); 13C NMR (CDCl3, 100 MHz) δ 12.05 (OSiCH(CH3)2), 14.53 
(CH≡CCH2CH2CO), 18.14 (OSiCH(CH3)2), 27.01 (CCH2CH2CH2O), 31.53 
(CCH2CH2CH2O), 36.33 (CH≡CCH2CH2CO), 59.47 (CCH2CH2CH2O), 63.60 
(CCH2CH2CH2O), 70.12 (CH≡CCH2CH2CO), 82.60 (CH≡CCH2CH2CO), 




169.90 (CO).  
Alkyne-Isophthalic-ALA-Boc (125) 
 
Step 1. Desilylation of (130) 
 
A solution of (130) (100 mg, 0.06mmol) in THF (5 mL) was treated with 
TBAF.H2O (241 mg, 0.762 mmol) and AcOH (50 µL) was added to the reaction 
mixture (pH- neutral). The reaction mixture was stirred under N2 for 4 h at RT 
and the solvent was removed under reduced pressure. The residue was then 
dissolved in MeOH (10 mL) and Dowex (50WX8, hydrogen form, 200-400 
mesh, 615 mg) and CaCO3 (204 mg) was added to the above solution. The 
mixture was stirred for 3 h, and then it was filtered through celite, which was 
washed with MeOH. The solvents were evaporated to give the crude product 
(75 mg) which was used in the next step without further purification. [Found 





Step 2. Attachment of Boc-ALA (99) 
 
A solution of (131) (7.5 mg, 0.01 mmol) in dry DCM (5 mL) was treated with 
(99) (22 mg, 0.10 mmol) and DMAP (1.50 mg, 0.02 mmol). The reaction 
mixture was cooled in an ice bath for 10 min and EDC.HCl (20 mg, 0.11 mmol) 
was added. The reaction mixture was stirred under N2 for 48 h at 30 °C, then 
the solvent was evaporated and the residue was dissolved in a mixture of 
EtOAc/H2O (10 mL, 1:1) and the organic layer was washed with 5% aq. citric 
acid (5 mL), 10% aq. NaHCO3 (5 mL), brine (5 mL), dried over MgSO4 and 
concentrated to give the crude product as a yellowish oil (71 mg). Purification 
by semi-preparative HPLC gave (125) as a yellowish oil; Rf = 0.68 (10% 
acetone in DCM); [Found (ESI+) 979.9798 [M+2Na]2+, C93H143N9Na2O33 
requires 979.9786]. 
2-[2-(2-azidoethoxy) ethoxy] ethanol (134)230 
 
A solution of 2-[2-(2-chloroethoxy) ethoxy] ethanol (1.53 g, 9.07 mmol) in H2O 
(5 mL) was treated with sodium azide (1.18 g, 18.1 mmol) and the reaction 
mixture was heated at 75 °C while stirring for 48 h. The reaction mixture was 
then cooled down to RT and H2O was evaporated under reduced pressure. 
The resulting residue was suspended in diethyl ether (10 mL) and filtered 
through a sintered funnel. The solvent was evaporated to obtain (134) as a 
colourless liquid (1.58 g, 99%) which was used without further purification. IR 




(2H, m, CH2N3), 3.50-3.80 (10H, m, 5 x OCH2).  
1-azido-2-[2-(2-chloroethoxy) ethoxy] ethane (135)230  
 
A mixture of (134) (1.30 g, 7.37 mmol) and benzyltriethylammonium chloride 
(BTEAC) (5.00 mg, 0.02 mmol) was heated at 65 °C in a three-necked round 
bottom flask under Ar. The reaction mixture was treated with SOCl2 (4.30 mL, 
59.2 mmol) added dropwise via an addition funnel, and the reaction was stirred 
for 3 h. After cooling at RT, excess SOCl2 was removed under reduced 
pressure and the resulting crude product was suspended in phosphate buffer 
(50 mM, pH 7.0, 20 mL) and extracted with a mixture of EtOAc/petroleum ether 
(40 mL, 1:1). The organic layer was washed with phosphate buffer (20 mL) 
and dried over MgSO4. The organic extract was filtered, and solvent was 
evaporated to give (135) as a pale yellow liquid (1.05 g, 74%) which was used 
without further purification. IR (film) 2892 (CH), 2109 (N3); 1H NMR (CDCl3, 
400 MHz) δ 3.33-3.40 (2H, m, CH2N3), 3.58-3.77 (10H, m, 5 x OCH2).  
Methyl- 4-hydroxy benzoate (137)314 
 
A solution of 4-hydroxybenzoic acid (136) (5.00 g, 36.2 mmol) in MeOH           
(36 mL) was treated with conc. sulfuric acid (0.72 mL) and was heated under 
reflux for 20 h. The reaction mixture was concentrated down to half the original 
volume under reduced pressure and was extracted with EtOAc/H2O (40 mL, 
1:1). The organic layer was washed with 1M aq. NaOH (20 mL), H2O (20 mL), 
brine (20 mL) and dried over MgSO4. The organic extract was filtered and 
evaporated to give the crude product as a white solid (2.3 g). Purification by 
column chromatography on silica gel eluting with 30-70 % EtOAc in petroleum 
ether gave (137) as a white solid (2.21 g, 40.0%); Mp = 125-127 °C                        
(lit. 122-124 °C)314; Rf = 0.78 (30% petroleum ether in EtOAc; IR (film) 3299 




(2H, d, J = 9.0, Ar-CH), 7.76 (2H, d, J = 9.0, Ar-CH). 
Methyl (4-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)benzoate (138)315 
 
A stirred solution of (135) (0.4 g, 2 mmol) in DMF (18 mL) was treated with 
(137) (0.29 g, 1.90 mmol), dry K2CO3   (0.88 g, 6.3 mmol) and 18-crown-6      
(0.02 g, 0.06 mmol). The mixture was heated at 80 °C for 36 h under N2, and 
was partitioned between EtOAc and H2O (30 mL, 1:1). The aqueous phase 
was extracted with EtOAc (15 mL) and the combined organic extracts were 
washed with brine (2 x 30 mL) and dried over MgSO4. The organic extract was 
filtered and evaporated to give the crude product as a colourless oil. 
Purification by column chromatography on silica gel eluting with 
EtOAc/petroleum (2:1) gave (138) as a colourless oil (0.41 g, 75%); Rf = 0.35 
(EtOAc: petroleum ether, 3:7); IR (film) 2951 (CH), 2879 (CH), 2106 (N3), 1714 
(CO), 1607 (C=C); 1H NMR (CDCl3, 500 MHz) δ 3.30 (2H, t, J = 5.0, CH2N3), 
3.59-3.62 (4H, m, 2 x OCH2), 3.65-3.69 (2H, m, OCH2), 3.80-3.82 (5H, m, 
OCH3, OCH2), 4.11 (2H, t, J = 5.0, OCH2), 6.85 (2H, d, J = 8.5, Ar-CH) 7.90 
(2H, d, J = 8.5, Ar-CH); 13C NMR (CDCl3, 100 MHz) δ 50.72 (CH2N3), 51.93 
(OCH3), 67.61 (OCH2), 67.61 (OCH2), 69.70 (OCH2) 70.17 (OCH2) 70.80 
(OCH2) 70.98 (OCH2), 114.24 (Ar-CH), 122.77 (Ar-C), 131.61 (Ar-CH), 162.60 
(CO), 166.89 (Ar-C); [Found (ESI+) 310.1425 [M+H]+, C14H20N3O5 requires 
310.1402].  
4-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)benzoic acid (142)315  
 
A solution of (138) (0.1 g, 0.3 mmol) in THF (3 mL) was treated with KOH         
(0.02 g, 0.40 mmol) in H2O (0.5 mL) and the reaction was stirred at 50 °C for 
24 h. The reaction mixture was then neutralized with 1M aq. HCl (0.3 mL) and 




MgSO4. The organic extract was filtered and evaporated to give the crude 
product as white solid (99 mg). Purification by column chromatography on 
silica gel eluting with 0-40 % EtOAc in petroleum ether gave (142) as a white 
solid (83 mg, 87%); Mp = 75-77 °C (Uncorrected); Rf = 0.2 (EtOAc: Petroleum 
ether, 2:8); IR (film) 3005-2665 (OH broad), 2908 (CH), 2111 (N3), 1705 (CO); 
Analytical HPLC (Gradient 1) Rt = 7.89 min; 1H NMR (CDCl3, 400 MHz) δ 3.38 
(2H, t, J = 5.0, CH2N3), 3.66-3.70 (4H, m, 2 x OCH2), 3.73-3.77 (2H, m, OCH2), 
3.88-3.92 (2H, m, OCH2), 4.18-4.22 (2H, m, OCH2), 6.95 (2H. d, J = 9.2,           
Ar-CH), 8.04 (2H, d, J = 8.8, Ar-CH); 13C NMR (CDCl3, 100 MHz) δ 50.77 
(CH2N3), 67.71 (OCH2), 69.73 (OCH2), 70.25 (OCH2), 70.86 (OCH2), 71.04 
(OCH2), 114.41 (Ar-CH), 121.89 (Ar-C), 132.43 (Ar-CH), 163.36 (CO), 171.85 
(Ar-C); [Found (ESI+) 318.1065 [M+Na]+, C13H17N3NaO5 requires 318.1065].  
Methyl 3,4,5-tris(2-(2-(2-azidoethoxy)ethoxy)ethoxy)benzoate (140)230 
 
A solution of (135) (2.80 g, 14.5 mmol) in DMF (40 mL) was treated with methyl 
gallate (139) (0.84 g, 4.59 mmol), dry K2CO3 (6.48 g, 46.8 mmol) and                
18-crown-6 (0.10 g, 0.40 mmol) and the resulting suspension was heated at 
80 °C under N2 for 36 h. After cooling down to RT, the solvent was evaporated 
and the residue was extracted with EtOAc and H2O (80 mL, 1:1). The aqueous 
phase was extracted with EtOAc (40 mL) and the combined organic phases 
were washed with brine (2 x 40 mL) and dried over MgSO4. The organic extract 
was filtered, and solvent was evaporated to obtain the crude product (2.85 g). 
Purification by column chromatography on silica gel eluting with EtOAc gave 
(140) as a dark yellow oil (2.16 g, 72%); Rf = 0.42 (EtOAc);  IR (film) 2902 (CH), 
2112 (N3), 1718 (CO); 1H NMR (CDCl3, 400 MHz) δ 3.37-3.42 (6H, m, 3 x 




7.26 (2H, s, Ar-CH).  
3,4,5-Tris(2-(2-(2-azidoethoxy)ethoxy)ethoxy)benzoic acid (147) 
 
A solution of (140) (0.55 g, 0.84 mmol) in THF (6 mL) was treated with KOH 
(0.06 g, 1.05 mmol) in H2O (1 mL) and the reaction was stirred at 50 °C for    
24 h. The reaction mixture was then neutralized with 1M aq. HCl (0.5 mL) and 
extracted with EtOAc/H2O (1:1, 40 mL) and combined organics were dried over 
MgSO4. The organic extract was filtered and evaporated under reduced 
pressure to give (147) as yellowish oil (0.5 g, 94%) which was used in next 
step without further purification. Rf = 0.3 (EtOAc: Petroleum ether, 2:8); IR 
(film) 3025-2776 (OH broad), 2908 (CH), 2111 (N3), 1705 (CO); 1H NMR 
(CDCl3, 400 MHz) δ 3.36-3.40 (6H, m, 3 x OCH2), 3.64-3.90 (24H, m, 12 x 
OCH2), 4.20-4.27 (6H, m, 3 x OCH2), 7.36 (2H, s, Ar-CH). 
Dend-(Tris-ALA-Boc) (143) 
 
A solution of (138) (5.40 mg, 18.3 µmol) and (105) (20.0 mg, 23.7 µmol) in 
DMSO (4.25 mL) was treated with 1M aq. CuSO4 (25.0 µL, 23.7 µmol), a 
solution of sodium ascorbate (90.5 mg, 0.46 mmol) in H2O (250 µL) and                
t-BuOH (450 µL). The reaction mixture was left stirring for 12 h and monitored 
by analytical HPLC (Gradient 1) which showed complete disappearance of 
(138) and formation of new species at 9.43 min. The crude product was purified 




53%); Analytical HPLC (Gradient 1) Rt = 9.43 min; 1H NMR (CDCl3, 400 MHz) 
δ 1.43 (27H, s, 3 x C(CH3)3), 2.58-2.61 (6H, m, 3 x CH2CH2CO), 2.67-2.73 (8H, 
m, 3 x CH2CH2CO + CH2CH2CONH), 2.99-3.05 (2H, m, CH2CH2CONH), 3.64-
3.69 (4H, m, 2 x OCH2), 3.84-3.88 (4H, m, 2 x OCH2), 4.02 (6H, s, 3 x 
COCH2NH), 4.20-4.22 (2H, m, OCH2), 4.31 (6H, s, 3 x CCH2), 4.54-4.57 (2H, 
m, OCH2), 5.48 (3H, s, 3 x COCH2NH), 5.96 (1H, s, CH2CH2CONH), 6.93-6.95 
(2H, m, Ar-CH), 7.78 (1H, s, triazole CH), 8.00-8.02 (2H, m, Ar-CH); 13C NMR 
(CDCl3, 100 MHz) 20.32 (CH2CH2CONH), 27.78 (CH2CH2CO), 28.44 
(C(CH3)3), 34.39 (CH2CH2CO), 35.19 (CH2CH2CONH), 50.27 (COCH2NH), 
51.69 (OCH2), 58.29 (CCH2O), 62.37 (CCH2O), 67.77 (OCH2), 68.89 (OCH2), 
69.73 (OCH2), 70.70 (OCH2), 70.83 (OCH2), 80.21 (C(CH3)3), 114.48 (Ar-CH), 
125.26 (triazole-CH), 132.37 (Ar-CH), 156.22 (CO), 163.12 (Ar-C), 169.85 
(CO), 172.02 (CO), 172.64 (CO), 204.88 (CO); [Found (ESI+) 1136.5245 
[M+H]+, C52H78N7O21 requires 1136.5226]. 
Dend-(Tris-ALA) .3TFA (145) 
 
A solution of (143) (20.0 mg, 17.6 µmol) in DCM (4 mL) was treated with TFA     
(4 mL) at 0 °C and the reaction mixture was stirred for 30 min and monitored 
by HPLC which showed complete disappearance of starting material. The 
solvent was evaporated under vacuum and the residue was co-evaporated 
with Et2O (x 3) to remove excess TFA. This material was freeze-dried from 
H2O to give (145) as a off-white solid (18 mg, 92%); Analytical HPLC         
(Gradient 1) Rt = 4.80 min); 1H NMR (CD3OD, 400 MHz) 2.58 (2H, t, J = 7.6, 
CH2CH2CONH), 2.64-2.70 (6H, m, 3 x CH2CH2CO), 2.81-2.89 (6H, m, 3 x 
CH2CH2CO), 2.91-2.94 (2H, m, CH2CH2CONH), 3.61-3.64 (2H, m, OCH2), 
3.66-3.69 (2H, m, NHCOCH2CH2), 3.79-3.85 (2H, m, OCH2), 3.87 (2H, t, J = 
5.0, OCH2), 4.05 (6H, s, 3 x NH2CH2CO), 4.16-4.21 (2H, m, OCH2), 4.39 (6H, 
s, 3 x CCH2O), 4.54 (2H, t, J = 5.0, OCH2), 6.96-7.02 (2H, m, Ar-CH), 7.80 (1H, 




(CH2CH2CONH) 28.27 (CH2CH2CO), 35.29 (CH2CH2CO), 36.41 
(CH2CH2CONH), 48.14 (COCH2NH2), 51.44 (OCH2), 63.29 (CCH2O), 68.83 
(OCH2), 70.35(OCH2), 70.59 (OCH2), 71.41 (OCH2), 71.64 (OCH2), 115.30 
(Ar-CH), 124.23 (triazole CH), 132.86 (Ar-CH), 147 (CO), 164.16 (Ar-C), 
169.70 (CO), 173.51 (CO), 174.98 (CO), 203.18 (CO); [Found (ESI+) 836.3694 
[M+H]+, C37H54N7O15 requires 836.3677]. 
Dend-(Ext.Tris-ALA-Boc) (144) 
 
A solution of alkyne (107) (85.0 mg, 0.10 mmol) and azide (138) (15 mg, 0.05 
mmol) in DMSO/ H2O (9:1, 1.5 mL) was treated with 1M aq CuSO4 (50.0 µL, 
0.05 mmol) and sodium ascorbate (149 mg, 0.75 mmol). The reaction was 
stirred for 12 h and monitored by analytical HPLC (Gradient 1) which showed 
complete disappearance of (138) and formation of a new species at 9.62 min. 
The reaction mixture was purified by semi-preparative HPLC (Gradient 2) to 
give (144) as white solid (26.7 mg, 44%); Analytical HPLC (Gradient 1)               
Rt = 9.62 min); 1H NMR (CDCl3, 400 MHz) 1.37-1.46 (33H, m, 3 x C(CH3)3, 3 x 
CCH2CH2CH2), 1.62-1.66 (6H, m, 3 x CCH2CH2CH2), 2.59-2.62 (6H, m, 3 x 
CH2CH2CO), 2.70-2.73 (8H, m, 3 x CH2CH2CO, CH2CH2CONH), 3.09 (2H, t, 
J = 7.2, CH2CH2CONH), 3.63-3.68 (4H, m, 2 x OCH2), 3.82-3.84 (2H, m, 
OCH2), 3.87-3.89 (2H, m, OCH2), 3.98-4.04 (12H, m, 3 x COCH2NH, 3 x 
CCH2CH2CH2), 4.18-4.20 (2H, m, OCH2), 4.53-4.56 (2H, m OCH2), 5.51 (3H, 
s, 3 x COCH2NH), 6.32 (1H, s, CH2CH2CONH), 6.68 (1H, s, NHCOCH2CH2), 
6.92-6.94 (2H, m, Ar-CH), 7.77 (1H, s, triazole CH), 7.99-8.01 (2H, m, Ar-CH); 
13C NMR (CDCl3, 100 MHz) 21.22 (CH2CH2CONH), 22.63 (CCH2CH2CH2), 
27.95 (CH2CH2CO), 28.46 (C(CH3)3), 31.24 (CCH2CH2CH2), 34.47 
(CH2CH2CO), 35.88 (CH2CH2CONH), 50.37 (COCH2NH), 51.33 (OCH2), 
58.34 (CCH2CH2CH2O), 64.81 (CCH2CH2CH2), 67.77 (OCH2), 69.11 (OCH2), 




122.48 (triazole-CH), 132.32 (Ar-CH), 156.04 (CO), 163.03 (Ar-C), 169.46 
(CO), 171.86 (CO), 172.54 (CO), 204.87 (CO); [Found (ESI+) 1218.6053       
[M-H]+, C58H88N7O21 requires 1218.6039]. 
Dend-(Ext.Tris-ALA) .3TFA (146) 
 
A solution of (145) (25 mg, 20 µmol) in DCM (5 mL) was treated with TFA           
(5 mL) at 0 °C and reaction mixture was stirred for 30 min and monitored by 
HPLC (Gradient 1) which showed complete disappearance of (145) and 
formation of new species at 4.98 min. The solvent was evaporated under 
vacuum and residue was co-evaporated with Et2O (x 3) to remove excess TFA. 
This material was freeze-dried from H2O to give (146) as a off-white solid      
(23.8 mg, 94%); Analytical HPLC (Gradient 1) Rt = 4.98 min; 1H NMR (CD3OD,          
400 MHz)  δ 1.43-53 (6H, m, 3 x CCH2CH2CH2), 1.64-1.72 (6H, m, 3 x 
CCH2CH2CH2), 2.53 (2H, t, J = 7.6, CH2CH2CONH), 2.63-2.70 (6H, m, 
CH2CH2CO), 2.79-2.87 (6H, m, CH2CH2CO), 2.93 (2H, t, J = 7.2, 
CH2CH2CONH), 3.61-3.65 (2H, m, OCH2), 3.67-3.71 (2H, m, OCH2), 3.80-3.84 
(2H, m, OCH2), 3.85-3.91 (2H, m, OCH2), 4.00-4.07 (12H, m, 3 x COCH2NH, 
3 x CCH2CH2CH2 ), 4.17-4.21 (2H, m, OCH2), 4.51-4.56 (2H, m, OCH2), 6.97-
7.02 (2H, m, Ar-CH), 7.81 (1H, s, triazole CH), 7.94-7.99 (2H, m, Ar-CH);          
13C NMR (CD3OD, 100 MHz) 22.64 (CH2CH2CONH), 23.60 (CH2CH2CO), 
28.52 (CCH2CH2CH2O), 31.77 (CH2CH2CONH), 35.30 (CCH2CH2CH2O), 
36.82 (CH2CH2CO), 48.15 (COCH2NH2), 51.41 (OCH2), 59.10 
(CCH2CH2CH2O), 66.03 (CCH2CH2CH2O), 68.87 (OCH2), 70.42 (OCH2), 
70.64 (OCH2), 71.45 (OCH2), 71.69 (OCH2), 115.32 (Ar-CH), 124.30 (triazole-
CH), 132.89 (Ar-CH), 164.18 (Ar-C), 169.67 (CO), 174.10 (CO), 203.12 (CO); 






A solution of (147) (10.0 mg, 15.5 µmol) and (105) (78.6 mg, 93.5 µmol) in 
DMSO/ H2O (9:1, 2 mL) was treated with 1M aq. CuSO4 (0.14 mL, 0.14 mmol) 
and sodium ascorbate (108 mg, 0.55 mmol) were added. The reaction was 
stirred for 72 h and monitored by analytical HPLC (Gradient 1) which showed 
complete disappearance of (147) and formation of new species at 10.53 min. 
The reaction mixture was purified by semi-preparative HPLC (Gradient 2) to 
obtain (148) as a white solid (24.5 mg, 50%); Analytical HPLC (Gradient 1)                
Rt = 10.53 min; 1H NMR (CD3OD, 500 MHz) δ 1.43-1.49 (81H, s, 9 x C(CH3)3), 
2.57-2.65 (24H, m, 9 x CH2CH2CO, 3 x CH2CH2CONH), 2.74-2.82 (18H, m,    
9 x CH2CH2CO), 2.92-2.99 (6H, m, 3 x CH2CH2CONH), 3.60-3.72 (12H, m,      
6 x OCH2), 3.75-3.79 (2H, m, OCH2), 3.83-3.97 (28H, m, 5 x OCH2,                         
9 x COCH2NH), 4.20-4.25 (6H, m, 3 x OCH2), 4.35-4.42 (18 H, s, 9 x CCH2O), 
4.55-4.60 (6H, m, 3 x OCH2), 7.38 (2H, s, Ar-CH), 7.83-7.88 (3H, m, triazole 
CH); 13C NMR (CD3OD, 125 MHz) 24.21 (CH2CH2CONH), 28.59 (CH2CH2CO), 
28.77 (C(CH3)3), 35.01 (CH2CH2CO), 36.30 (CH2CH2CONH), 50.75 
(COCH2NH), 51.60 (OCH2), 59.17 (CCH2O), 63.18 (CCH2O), 70.11 (OCH2), 
70.39 (OCH2), 70.81 (OCH2), 71.53 (OCH2), 73.68 (OCH2), 80.61 (C(CH3)3), 
110.10 (Ar-CH), 124.83 (triazole CH), 127.01 (Ar-C), 143.56 (Ar-C), 158.41 
(CO), 169.17 (CO), 173.64 (CO), 174.76 (CO), 207.40 (CO); [Found (ESI+) 






Dend-(Tris-ALA)3 .9TFA (150) 
 
A solution of (148) (20 mg, 6.32 µmol) in DCM (5 mL) was treated with TFA          
(5 mL) at 0 °C and the reaction mixture was stirred for 30 min and monitored 
by HPLC (Gradient 1) which showed complete disappearance of starting 
material (148). The solvent was evaporated under vacuum and the residue 
was co-evaporated with Et2O (x 3) to remove excess TFA. This material was 
freeze-dried from H2O to give (150) as a off-white solid (17.5 mg, 88.0%); 
Analytical HPLC (Gradient 1) Rt = 4.35 min; 1H NMR (CD3OD, 400 MHz) δ 2.59 
(6H, t, J = 7.4, 3 x CH2CH2CONH), 2.65-2.69 (18H, m, 9 x CH2CH2CO), 2.84-
2.87 (18H, m, 9 x CH2CH2CO), 2.92 (6H, t, J = 7.4, 3 x CH2CH2CONH), 3.60-
3.68 (12H, m, 6 x OCH2), 3.73-3.76 (2H, m, OCH2), 3.82-3.89 (10H, m, 5 x 
OCH2), 4.05 (18H, s, 9 x COCH2NH2), 4.19-4.22 (6H, m , 3 x OCH2), 4.39 
(18H, s, 9 x CCH2O), 4.52-4.54 (6H, m, 3 x OCH2), 7.37 (2H, s, Ar-CH), 7.78-
7.79 (3H, m, triazole CH); 13C NMR (CD3OD, 125 MHz) 22.22 (CH2CH2CONH), 
28.28 (CH2CH2CO), 35.27 (CH2CH2CO), 36.45 (CH2CH2CONH), 48.10 
(COCH2NH2), 51.29 (OCH2), 51.37 (OCH2), 59.12 (CCH2O), 63.32 (CCH2O), 
69.98 (OCH2), 70.44 (OCH2), 70.76 (OCH2), 71.29 (OCH2), 71.47 (OCH2), 
71.59 (OCH2), 71.70 (OCH2), 73.64 (OCH2), 110.04 (Ar-CH), 124.38 (triazole 
CH), 127.31 (Ar-C), 143.13 (Ar-C), 147.57 (triazole-C), 153.60 (Ar-C), 169.20 
(CO), 173.55 (CO), 175.05 (CO), 203.24 (CO); [Found (ESI+) 1132.0125 
[M+2H]2+, C97H149N21O41 requires 1132.0104].        








A solution of (147) (5.8 mg, 9.0 µmol) and (107) (50 mg, 54 µmol) in DMSO/ 
H2O (9: 1, 2 mL) was treated with 1M aq. CuSO4 (80 µL, 80 µmol) and sodium 
ascorbate (44.6 mg, 0.23 mmol). The reaction was stirred for 72 h and 
monitored by analytical HPLC (Gradient 1) which showed complete 
disappearance of (147) and formation of a new species at 11.03 min. The 
reaction mixture was purified by semi-preparative HPLC (Gradient 2) to give 
(149) as a white solid (16 mg, 52%); Analytical HPLC (Gradient 1) Rt = 11.03 
min; 1H NMR (CD3OD, 500 MHz) δ 1.40-1.52 (99H, m, 9 x C(CH3)3, 9 x 
CH2CH2CO), 1.64-1.73 (18H, m, 9 x CCH2CH2CH2O), 2.52-2.59 (24H, m, 9 x 
CH2CH2CO, 3 x CH2CH2CONH), 2.71-2.78 (18H, m, 9 x CH2CH2CO), 2.90-
2.98 (6H, m, 3 x CH2CH2CONH), 3.57-3.67 (12H, m, 6 x OCH2), 3.72-3.76 (2H, 
m, OCH2), 3.80-3.94 (28H, m, 9 x COCH2NH2, 5 x OCH2), 3.98-4.05 (18H, m, 
9 x CCH2CH2CH2O), 4.18-4.22 (6H, m, 3 x OCH2), 4.51-4.54 (6H, m, 3 x 
OCH2), 7.36 (2H, s, Ar-CH), 7.81 (3H, s, triazole CH); 13C NMR (CD3OD, 125 
MHz) 22.57 (CH2CH2CONH), 23.62 (CCH2CH2CH2O), 28.57 (CH2CH2CO), 
28.75 (C(CH3)3), 31.78 (CCH2CH2CH2O), 35.03 (CH2CH2CO), 36.79 
(CH2CH2CONH), 50.80 (COCH2NH), 51.42 (OCH2) 51.93 (OCH2), 59.12 
(CCH2CH2CH2O), 65.91 (CCH2CH2CH2O), 70.13 (OCH2), 70.45 (OCH2),   
70.82 (OCH2), 73.69 (OCH2), 80.56 (C(CH3)3), 110.15 (Ar-CH), 124.48 
(triazole CH), 127.05 (Ar-C), 143.61 (Ar-C), 153.70 (Ar-C), 158.35 (CO), 
169.10 (CO), 174.34 (CO), 207.43 (CO); [Found (ESI+) 1708.3880 [M+2H]2+, 





Dend-(Ext.Tris-ALA)3 .9TFA (151) 
 
A solution of (149) (15.5 mg, 4.53 µmol) in DCM (6 mL) was treated with TFA     
(6 mL) at 0 °C and the reaction mixture was stirred for 30 min and monitored 
by HPLC (Gradient 1) which showed complete disappearance of starting 
material (149). The solvent was evaporated under vacuum and the residue 
was co-evaporated with Et2O (x 3) to remove excess TFA. This material was 
freeze-dried from H2O to give (151) as a off-white solid (13.8 mg, 90%); 
Analytical HPLC (Gradient 1) Rt = 4.63 min; 1H NMR (CD3OD, 500 MHz)             
δ 1.43-53 (18H, m, 9 x CCH2CH2CH2), 1.64-1.74 (18H, m, 9 x CCH2CH2CH2), 
2.51-2.58 (6H, m, 3 x CH2CH2CONH), 2.63-2.69 (18H, m, 9 x CH2CH2CO), 
2.80-2.89 (18H, m, 9 x CH2CH2CO), 2.92-2.97 (6H, m, 3 x CH2CH2CONH), 
3.60-3.68 (12H, m, 6 x OCH2), 3.72-3.75 (2H, m, OCH2), 3.80-3.85 (4H, m,        
2 x OCH2), 3.86-3.91 (6H, m, 3 x OCH2), 4.02-4.08 (36H, m,  9 x COCH2NH2, 
9 x CCH2CH2CH2), 4.17-4.21 (6H, m, 3 x OCH2), 4.52-4.55 (6H, m, 3 x OCH2), 
7.37 (2H, m, Ar-CH), 7.82 (3H, s, triazole-CH); 13C NMR (CD3OD, 125 MHz)     
δ 22.66 (CH2CH2CONH), 23.60 (CH2CH2CO), 28.52 (CCH2CH2CH2O), 31.76 
(CH2CH2CONH), 35.33 (CCH2CH2CH2O), 36.80 (CH2CH2CO), 48.15 
(COCH2NH2), 51.35 (OCH2), 59.11 (CCH2CH2CH2O), 66.04 (CCH2CH2CH2O), 
70.00 (OCH2), 70.45 (OCH2), 70.77 (OCH2), 71.33 (OCH2), 71.48 (OCH2), 
71.61 (OCH2), 71.71 (OCH2), 73.64 (OCH2), 110.05 (Ar-CH), 124.34 (triazole 
CH), 127.31 (Ar-C), 143.17 (triazole-C), 153.62 (CO), 161.58 (Ar-C), 169.15 
(CO), 174.11 (CO), 203.19 (CO); [Found (ESI+) 839.1056 [M+3H]3+, 







A solution of (142) (0.15 g, 0.5 mmol) in dry DCM (15 mL) was treated with 
(152) (0.2 g, 0.46 mmol) and DMAP (5 mg, 46 µmol). The reaction mixture was 
cooled in an ice bath for 10 min and EDC.HCl (0.11 g, 0.55 mmol) was added. 
The reaction was stirred at 32 °C for 36 h under N2, then the solvent was 
evaporated and the residue was dissolved in a mixture of EtOAc/H2O (30 mL, 
1:1). The organic layer was washed with 5% aq. citric acid (15 mL), 10% aq. 
NaHCO3 (15 mL), brine (15 mL), dried over MgSO4 and concentrated to give 
the crude product as a colourless oil (0.34 g). The crude product was purified 
by semi-preparative HPLC (Gradient 4) to give (153) as colourless oil (0.24 g, 
75%); Analytical HPLC (Gradient 3) Rt = 10.1 min; 1H NMR (CDCl3, 400 MHz) 
δ 0.84-0.89 (12H, m, 4 x CH3), 1.01-1.57 (24H, m, 9 x CH2, 3 x CH, CH3), 1.73-
1.88 (2H, m, CH2), 2.00 (3H, s, CH3), 2.04 (3H, s, CH3), 2.11 (3H, s, CH3), 2.61    
(2H, t, J = 6.6, CH2), 3.39 (2H, t, J = 5.2, OCH2), 3.68-3.71 (4H, m, 2 x OCH2), 
3.75-3.79 (2H, m, OCH2), 3.90-3.95 (2H, m, OCH2), 4.21-4.26 (2H, m OCH2), 
7.00-7.04 (2H, m, Ar-CH), 8.17-8.21 (2H, m, Ar-CH); 13C NMR (CDCl3, 100 
MHz) 11.98 (CH3), 12.33 (CH3), 13.18 (CH3), 19.73 (CH3), 19.82 (CH3), 19.89 
(CH3), 20.76 (CH2), 21.18 (CH2), 22.76 (CH3), 22.85 (CH3), 23.84 (CH3), 24.33 
(CH3), 24.58 (CH2), 24.95 (CH2), 28.11 (CH), 32.91 (CH2), 37.42 (CH2), 37.52 
(CH2), 37.59 (CH2), 37.67 (CH2), 39.50 (CH2), 50.82 (OCH2), 67.78 (OCH2), 
69.78 (OCH2), 70.27 (OCH2), 70.90 (OCH2), 71.09 (OCH2), 114.53 (Ar-CH), 
117.55 (Ar-C), 122.28 (Ar-C), 123.18 (Ar-C), 125.35 (Ar-C), 127.14 (Ar-C), 
132.33 (Ar-CH), 140.77 (Ar-C), 149.50 (Ar-C), 163.09 (Ar-C), 165.01 (CO); 








A solution of (153) (50 mg, 71 µmol) and (105) (118 mg, 141 µmol) in DMSO 
(2 mL) was treated with copper(I) trifluoromethanesulfonate benzene complex 
(17.7 mg, 70.6 µmol). The reaction was stirred for 72 h and monitored by 
analytical HPLC (Gradient 3) which showed complete disappearance of (153) 
and formation of new species at 14.66 min. The reaction mixture was purified 
by semi-preparative HPLC (Gradient 4) to give (154) as a white solid (59 mg, 
54%); Analytical HPLC (Gradient 3) Rt = 14.66 min; 1H NMR ((CD3)2SO,            
500 MHz) δ 0.86-0.90 (12H, m, 4 x CH3), 1.11-1.65 (51H, 9 x CH2, 3 x CH, 
CH3, 3 x C(CH3)3), 1.77-1.85 (2H, m, CH2), 1.96 (3H, s, CH3), 1.98 (3H, s, 
CH3), 2.08 (3H, s, CH3), 2.51-2.55 (8H, m, 3 x CH2CH2CO, CH2), 2.60-2.64 
(2H, m, CH2CH2CONH), 2.69-2.74 (6H, m, 3 x CH2CH2CO), 2.81-2.88 (2H, m, 
CH2CH2CONH), 3.58-3.72 (4H, m, 2 x OCH2), 3.79-3.83 (8H, m, 3 x 
COCH2NH, OCH2), 3.84-3.87 (2H, m, OCH2), 4.23-4.27 (2H, m, OCH2), 4.31-
4.35 (6H, m, 3 x CCH2O), 4.45-4.49 (2H, m, OCH2), 6.49-6.58 (3H, br, 3 x 
COCH2NH), 7.13 (2H, d, J = 8.5, Ar-CH), 7.35-7.38 (1H, m, CH2CH2CONH), 
7.69-7.72 (1H, m, triazole CH), 8.10 (2H, d, J = 8.5, Ar-CH); 13C NMR 
((CD3)2SO, 125 MHz)  δ 11.55 (CH3), 11.86 (CH3), 12.70 (CH3), 19.52 (CH3), 
19.58 (CH3), 19.90 (CH2), 21.05 (CH2), 22.42 (CH3), 22.50 (CH3), 23.66 (CH2), 
24.10 (CH2), 26.87 (CH2CH2CO), 27.12 (CH), 27.34 (CH), 27.80 (CH), 28.10 
(C(CH3)3), 31.97 (CH), 32.01 (CH), 33.57 (CH2CH2CO), 34.11 (CH2), 35.06 
(CH2), 36.54 (CH2), 36.66 (CH2), 38.72 (CH2), 46.67 (CH2), 49.19 (OCH2), 
49.40 (COCH2NH), 56.91 (CCH2O), 61.69 (CCH2O), 67.56 (OCH2), 68.64 
(OCH2), 68.80 (OCH2), 69.53 (OCH2), 69.74 (OCH2), 114.77 (Ar-CH), 117.38 
(Ar-C), 120.91 (Ar-C), 121.82 (Ar-C), 122.20 (triazole-CH), 125.00 (Ar-C), 
126.41 (Ar-C), 131.79 (Ar-CH), 140.35 (Ar-C or triazole C), 148.61 (Ar-C or 
triazole C), 164.01 (CO), 171.68 (CO), 172.07 (CO), 205.92 (CO); [Found 




Dend-(Tris-ALA)1-Vit-E. 3TFA (156) 
 
A solution of (154) (25 mg, 16 µmol) in DCM (2 mL) was treated with TFA          
(2 mL) at 0 °C and the reaction mixture was stirred for 30 min and monitored 
by HPLC (Gradient 3) which complete disappearance of starting material 
(154). The solvent was evaporated under vacuum and the residue was co-
evaporated with Et2O (x 3) to remove excess TFA. This material was freeze-
dried from H2O to give (156) as a off-white solid (19 mg, 97%); Analytical HPLC 
(Gradient 3) Rt = 4.63 min; 1H NMR (CD3OD, 500 MHz) δ 0.86-0.91 (12H, m, 
4 x CH3), 1.10-1.63 (24H, m, 9 x CH2, 3 x CH, CH3), 1.79-1.84 (2H, m, CH2), 
1.98 (3H, s, CH3), 2.01 (3H, s, CH3), 2.11 (3H, s, CH3), 2.59 (2H, t, J = 7.5, 
CH2CH2CONH), 2.64-2.69 (8H, m, 3 x CH2CH2CO, CH2), 2.81-2.87 (6H, m, 3 
x CH2CH2CO), 2.93 (2H, t, J = 6, CH2CH2CONH), 3.63-3.67 (2H, m, OCH2), 
3.68-3.72 (2H, m, OCH2), 3.85-3.91 (4H, m, 2 x OCH2), 4.03 (6H, s, 
COCH2NH2), 4.23-4.27 (2H, m, OCH2), 4.39 (6H, s, 3 x CCH2O), 4.53-4.57 
(2H, m, OCH2), 7.10 (2H, d, J = 8.5, Ar-CH), 7.80 (1H, s, triazole-CH), 8.16 
(2H, d, J = 9.0, Ar-CH); 13C NMR (CD3OD, 125 MHz) δ 12.08 (CH3), 12.28 
(CH3), 13.16 (CH3), 20.14 (CH3), 20.19 (CH3), 21.56 (CH2), 22.21 
(CH2CH2CONH), 23.00 (CH3), 23.09 (CH3), 25.42 (CH2), 25.90 (CH2), 28.26 
(CH2CH2CO), 29.14 (CH), 33.92 (CH), 35.28 (CH2CH2CO), 36.49 
(CH2CH2CONH), 38.38 (CH2), 40.53 (CH2), 48.08 (COCH2NH2), 51.41 
(OCH2), 59.13 (CCH2O), 63.29 (CCH2O), 68.99 (OCH2), 70.44 (OCH2), 70.62 
(OCH2), 71.46 (OCH2), 71.72 (OCH2), 115.70 (Ar-CH), 118.94 (Ar-C), 122.92 
(Ar-C), 124.47 (triazole-CH), 126.44 (Ar-C), 127.99      (Ar-C), 133.25 (Ar-CH), 
150.57 (Ar-C), 164.88 (CO), 166.77 (Ar-C), 173.53 (CO), 175.03 (CO), 203.17 






Dend-(Ext. Tris-ALA-Boc)-Vit-E (155) 
 
A solution of (153) (25 mg, 35 µmol) and (107) (65 mg, 70 µmol) in DMSO (2 
mL) was treated with copper(I) trifluoromethanesulfonate benzene complex              
(18 mg, 35 µmol). The reaction was stirred for 72 h and monitored by analytical 
HPLC (Gradient 3) which showed complete disappearance of starting material 
(153) and formation of new species at 11.80 min. The reaction mixture was 
purified by semi-preparative HPLC (Gradient 4) to give (155) as a colourless 
oil (34 mg, 59%); Analytical HPLC (Gradient 3) Rt = 11.80 min;                               
1H NMR ((CD3)2SO, 500 MHz) δ 0.80-0.86 (12H, m, 4 x CH3), 1.05-1.68 (63H, 
m, 9 x CH2, 3 x CH, CH3, 3 x CCH2CH2CH2, 3 x CCH2CH2CH2, 3 x C(CH3)3), 
1.73-1.80 (2H, m, CH2), 1.91 (3H, s, CH3), 1.93 (3H, s, CH3), 2.03 (3H, s, CH3), 
2.38-2.43 (2, m, CH2CH2CONH), 2.44-2.49 (6H, m, 3 x CH2CH2CO), 2.53-2.60 
(2H, m, CH2), 2.63-2.69 (6H, m, 3 x CH2CH2CO), 2.77-2.82 (2H, m, 
CH2CH2CONH), 3.55-3.80 (14H, m, 4 x OCH2, 3 x COCH2NH), 3.90-3.97 (6H, 
m, 3 x CCH2CH2CH2O), 4.19-4.23 (2H, m, OCH2), 4.43-4.48 (2H, m, OCH2), 
7.02-7.07 (1H, m, 3 x COCH2NH), 7.09-7.18 (2H, m, Ar-CH), 7.74- 7.78 (1H, 
m, triazole CH), 8.03-8.12 (2H, m, Ar-CH); 13C NMR ((CD3)2SO, 125 MHz)           
δ 11.58 (CH3), 11.89 (CH3), 12.70 (CH3), 19.56 (CH3), 19.62 (CH3), 19.94 
(CH2), 20.39 (CH2CH2CONH), 21.44 (CH2), 22.08 (CH2), 22.45 (CH3), 22.54 
(CH3), 23.35 (CH2), 23.70 (CH2), 23.84 (CH2), 23.91 (CH3), 24.15 (CH2), 27.25                           
(2 signals, CH2CH2CO), 27.37 (CH3), 27.68 (CH, 27.82 (CH3.), 28.14 
(C(CH3)3), 30.22 (CH2), 32.01 (CH), 32.06 (CH), 33.64 (CH2CH2CO), 34.21 
(CH2), 35.45 (CH2CH2CONH), 36.60 (CH2), 36.69 (CH2), 38.76 (CH2), 46.71 
(CH2), 49.18 (OCH2), 49.47 (COCH2NH), 56.91 (CCH2CH2CH2), 64.26 
(CCH2CH2CH2), 67.60 (OCH2), 68.69 (OCH2), 68.84 (OCH2), 69.58 (OCH2), 
69.78 (OCH2), 78.08 (C(CH3)3), 110.88 (Ar-C), 114.81 (Ar-CH), 117.42 (Ar-C), 
120.94 (Ar-C), 121.86 (triazole CH), 122.18 (Ar-C), 125.03 (Ar-C), 126.44      




155.74 (CO), 162.93 (Ar-C), 164.04 (CO), 170.76 (CO), 172.11 (CO), 206.13 
(CO); [Found (ESI+) 1633.0436 [M+H]+, C87H138N7O22 requires 1632.9889]. 
Dend-(Ext. Tris-ALA)1-Vit-E. 3TFA (157) 
 
A solution of (155) (25 mg, 15 µmol) in DCM (2.5 mL) was treated with TFA       
(2.5 mL) at 0 °C and reaction mixture was stirred for 30 min and monitored by 
HPLC (Gradient 3) which showed complete disappearance of starting material. 
The solvent was evaporated under vacuum and the residue was                          
co-evaporated with Et2O (x 3) to remove excess TFA. This material (157) was 
freeze-dried from H2O to give (157) as a off-white solid (24 mg, 96%); 
Analytical HPLC (Gradient 3) Rt = 4.53 min; 1H NMR (CD3OD, 500 MHz)              
δ 0.86-0.91 (12H, m, 4 x c), 1.08-1.89 (38H, m, 9 x CH2, 3 x CH, CH3, 3 x 
CCH2CH2CH2, 3 x CCH2CH2CH2, CH2), 1.98 (3H, s, CH3), 2.01 (3H, s, CH3), 
2.11 (3H,s, CH3), 2.54 (2H, t, J = 7.25, CH2CH2CONH), 2.63-2.70 (8H, m, 3 x 
CH2CH2CO, CH2), 2.80-2.85 (6H, m, 3 x CH2CH2CO), 2.94 (2H, t, J = 7.25, 
CH2CH2CONH), 3.11-3.16 (2H, m, OCH2), 3.65-3.70 (4H, m, 2 x OCH2), 3.83-
3.87 (2H, m, OCH2), 3.88-3.92 (2H, m, OCH2), 4.02-4.06 (12H, m, 3 x 
COCH2NH2, 3 x CCH2CH2CH2O), 4.23-4.28 (2H, m, OCH2), 4.53-4.58 (2H,m, 
OCH2), 7.10 (2H, d, J = 9.0, Ar-CH), 7.81 (1H, s, triazole-CH), 8.16 (2H, d, J = 
8.5, Ar-CH); 13C NMR (CD3OD, 125 MHz) δ 12.02 (CH3), 12.29 (CH3), 13.18 
(CH3), 20.14 (CH3), 20.19 (CH3), 21.56 (CH2), 22.67 (CH2CH2CONH), 23.01 
(CH3), 23.04 (CH3), 23.09 (CH2), 23.59 (CH2), 23.76 (CH2), 25.42 (CH2), 25.91 
(CH2), 28.50 (CH2CH2CO), 29.15 (CH), 30.75 (CH), 31.76 (CH2), 33.89 (CH), 
35.29 (CH2CH2CO), 36.84 (CH2CH2CONH), 38.38 (CH2), 40.53 (CH2), 45.71            
(CH2), 48.08 (COCH2NH2), 51.38 (OCH2), 59.09 (CCH2CH2CH2), 66.03 
(CCH2CH2CH2), 68.99 (OCH2), 69.00 (OCH2), 70.45 (OCH2), 70.62 (OCH2), 
71.46 (OCH2), 71.72 (OCH2), 115.77 (Ar-CH), 118.94 (Ar-C), 122.93 (Ar-C), 




(Ar-C), 164.87 (Ar-C), 166.74 (CO), 174.09 (CO), 203.12 (CO); [Found (ESI+) 
688.9005 [M+2Na]2+, C72H113N7O22Na2 requires 688.9014]. 
Attempted synthesis of azido-PEG benzoic acid-Thy (159) 
 
A suspension of thymidine (158) (0.16 g, 0.66 mmols) in dioxane (15 mL) was 
treated with TEA (0.53 mL, 3.76 mmol) at 0 °C. EDC.HCl (0.63 g, 3.30 mmol), 
(142) (0.97 g, 3.29 mmol) and DMAP (6.44 mg, 0.05 mmol) were added to the 
reaction mixture which was stirred for 36 h at RT. The reaction was monitored 
by HPLC (Gradient 1). No change was observed. 
11-Azidoundecanoic acid (160)316 
 
A suspension of 11-bromoundecanoic acid (2 g, 7.5 mmol) and sodium azide 
(1.96 g, 30.2 mmol) in DMF (25 mL) was heated at 80 °C under N2 for 16 h. 
DMF was then removed under reduced pressure and the residue was taken in 
CHCl3 (30 mL). The organic layer was washed with H2O (30 mL) acidified with 
3 mL of 5% aq. HCl, H2O (30 mL), and dried over MgSO4. The organic extract 
was filtered, and the solvent was evaporated to give the crude product as a 
colourless oil (1.57 g). Purification by column chromatography on silica gel 
eluting with 5-15% EtOAc in petroleum ether gave (160) as a colourless oil    
(1.29 g, 78%); IR (film) 2885 (CH), 2115 (N3), 1730 (CO); 1H NMR (CDCl3,  
400 MHz) δ 1.26-1.38 (12H, 6 x CH2), 1.54-1.67 (4H, 2 x CH2), 2.34 (2H, t,        









A suspension of thymidine (158) (0.16 g, 0.66 mmols) in dioxane (15 mL) was 
treated with TEA (0.53 mL, 3.76 mmol) at 0 °C. EDC.HCl (0.63 g, 3.30 mmol), 
azidoundecanoic acid (160) (0.75 g, 3.29 mmol) and DMAP (6.44 mg, 0.05 
mmol) were added to the reaction mixture which was stirred for 48 h at RT. 
The reaction was monitored by HPLC (Gradient 1) which showed complete 
disappearance of thymidine and formation of a new species at 11.30 min.       
The crude product was purified by semi-preparative HPLC (Gradient 2) to give 
(161) as a yellowish oil (0.32 g, 73%); Analytical HPLC (Gradient 1) Rt = 11.30 
min; IR (film) 3315 (NH), 3066 (CH), 2928 (CH), 2856 (CH), 2099 (N3), 1737 
(ester CO), 1694 (amide/imide CO); 1H NMR (CDCl3, 400 MHz) δ 1.20-1.38 
(24H, m, 12 x CH2), 1.53-1.63 (8H, m, 4 x CH2), 1.89- 1.94 (3H, s, 5-CH3), 
2.07-2.15 (1H, m, CHH, 2’), 2.30-2.35 (4H, m, 2 x CH2), 2.42-2.47 (1H, m, 
CHH, 2’), 3.21-3.25 (4H, t, J = 6.94 , 2 x CH2N3), 4.19-4.24 (1H, m, 4’), 4.27-
4.31 (1H, m, CHH, 5’), 4.36-4.41 (1H, m, CHH, 5’), 5.17-5.19 (1H, m, 4’), 6.27-
6.33 (1H, m, 1’), 7.27-7.31 (1H, m, 6), 9.33 (1H, s, 3); 13C NMR (CDCl3, 100 
MHz) 12.74 (5-CH3), 24.83 (CH2), 24.89 (CH2), 26.76 (CH2), 28.90 (CH2), 
29.12 (CH2), 29.17 (CH2), 29.23 (CH2), 29.26 (CH2), 29.36 (CH2), 29.45 (CH2), 
34.00 (CH2), 34.15 (CH2), 34.23 (CH2), 37.75 (2’), 51.55 (CH2), 63.78 (5’), 
74.04 (3’), 82.45 (4’), 84.93 (1’), 111.57 (5), 134.71 (6), 150.42 (2), 163.84 (4), 








A solution of (161) (15 mg, 22 µmol) and (105) (76 mg, 91 µmol) in DMSO      
(2.5 mL) was treated with copper(I) trifluoromethanesulfonate benzene 
complex (23 mg, 71 µmol). The reaction was stirred for 24 h and monitored by 
analytical HPLC (Gradient 1) which showed complete disappearance of (161) 
and formation of new species was observed at 12.89 min. The reaction mixture 
was purified by semi-preparative HPLC (Gradient 2) to give (162) as white solid 
(28 mg, 54%); Analytical HPLC (Gradient 1) Rt = 12.89 min; 1H NMR (CDCl3, 
400 MHz) δ 1.19-1.1.47 (78H, m, 12 CH2, 6 x C(CH3)3), 1.55-1.65 (4H, m, 2 x 
CH2), 1.82-1.93 (7H, m, 2 x CH2, 5-CH3), 2.07-2.15 (1H, m, CHH, 2’), 2.30-
2.35 (4H, m, 2 x CH2), 2.42-2.47 (1H, m, 1H, m, CHH, 2’), 2.54-2.76 (28H, m, 
6 x CH2CH2CO, 2 x CH2CH2CONH, 6 x CH2CH2CO), 3.02-3.05 (4H, m, 2 x 
CH2CH2CONH), 4.00 (12H, s, 6 x COCH2NH), 4.19-4.24 (1H, m, 4’), 4.27-4.41 
(18H, m, 6 x CCH2O, 5’, 2 x CH2),  5.15-5.20 (1H, m, 3’), 5.37-5.72 (6H, m,      
6 x COCH2NH), 6.26-6.29 (1H, m, 1’), 6.68-6.74 (2H, m, 2 x CH2CH2CONH), 
7.27-7.32 (1H, m, 6), 7.56-7.65 (2H, m, 2 x triazole CH), 9.12 (1H, s, 3);           
13C NMR (CDCl3, 125 MHz) 12.61 (5-CH3), 20.29 (CH2CH2CONH), 24.66 
(CH2), 24.72 (CH2), 26.26 (CH2), 27.57 (CH2CH2CO), 28.26 (C(CH3)3), 28.78 
(CH2), 28.91 (CH2), 28.96 (CH2), 29.02 (CH2), 29.05 (CH2), 29.15 (CH2), 29.83 
(CH2), 33.98 (CH2), 34.07 (CH2), 34.18 (CH2CH2CO), 35.24 (CH2CH2CONH), 
37.61 (2’), 50.06 (COCH2NH), 51.23 (CH2), 58.05 (CCH2O), 62.18 (CCH2O), 
63.63 (5’), 73.95 (3’), 79.90 (C(CH3)3), 82.31 (4’), 84.84 (1’), 111.25 (5), 123.33 
(triazole CH), 123.37 (triazole CH), 134.67 (6), 145.00 (CO), 150.13 (2 or 4), 
155.95 (CO), 163.63 (2 or 4), 171.83 (CO), 172.50 (CO), 173.00 (CO), 173.22 
(CO), 204.73 (CH2CH2CO); [Found (ESI+) 1193.5967 [M+2Na]2+, 




Dend-(Tris-ALA)2-Thy .6TFA (163) 
 
A solution of (162) (25 mg, 10.67 µmol) in DCM (5 mL) was treated with TFA       
(5 mL) at 0 °C and the reaction mixture was stirred for 30 min and monitored 
by analytical HPLC (Gradient 1) which showed complete disappearance of 
starting material (162). The solvent was evaporated under vacuum and the 
residue was co-evaporated with Et2O (x3) to remove excess TFA. This material 
was freeze-dried from H2O to give (163) as a off-white solid (23 mg, 93%); 
Analytical HPLC (Gradient 1) Rt = 5.97 min; 1H NMR (CD3OD, 400 MHz)              
δ 1.24-1.37 (24H, m, 12 x CH2), 1.57-1.66 (4H, m, 2 x CH2), 1.83-1.93 (7H, m, 
2 x CH2, 5-CH3), 2.34-2.44 (6H, m, 2 x CH2, 2’), 2.60 (4H, t, J = 7.6, 2 x 
CH2CH2CONH), 2.66-2.73 (12H, m, 6 x CH2CH2CO), 2.82-2.90 (12H, m, 6 x 
CH2CH2CO), 2.95 (4H, t, J = 7.6, 2 x CH2CH2CONH), 4.05 (12H, s, 6 x 
COCH2NH2), 4.17-4.24 (1H, m, 4’), 4.28-4.45 (18H, m, 6 x CCH2O, 5’, 2 x 
CH2), 5.24.5.27 (1H, m, 3’), 6.21-6.25 (1H, m, 1’), 7.48-7.53 (1H, m, 6), 7.73-
7.79 (2H, m, 2 x triazole CH); 13C NMR (CD3OD, 100 MHz) 12.61 (5-CH3), 
22.22 (CH2CH2CONH), 25.84 (CH2), 25.94 (CH2), 27.43 (CH2), 28.28 
(CH2CH2CO), 30.00 (CH2), 30.07 (CH2), 30.25 (CH2), 30.37 (CH2), 30.40 
(CH2), 31.23 (CH2), 34.86 (CH2), 34.92 (CH2), 35.30 (CH2CH2CO), 36.50 
(CH2CH2CONH), 37.83 (2’), 48.08 (COCH2NH2), 51.40 (CH2), 59.14 (CCH2O), 
63.29 (CCH2O), 64.79 (5’), 75.58 (3’), 83.69 (4’), 86.59 (1’), 111.90 (5), 123.66 
(triazole CH), 137.31 (6), 147.55 (triazole C), 152.20 (2 or 4), 166.17 (2 or 4), 
173.52 (CO), 174.75 (CO), 174.88 (CO), 175.07 (CO), 203.18 (CO); [Found 










A solution of (142) (44 mg, 148 µmol) in DCM (5 mL) was treated with EDC.HCl 
(28 mg, 148 µmol) and DMAP (3 mg, 28 µmol) and stirred at 0 °C. 2,3,4,6-
tetra-O-benzyl-D-gluco-pyranose (162) (50 mg, 92 µmol) was added to the 
reaction mixture and stirred at RT for 36 h. the solvent was evaporated and 
the crude product was purified by semi-preparative HPLC (Gradient 2) to 
obtain (165) as an oil (83 mg, 70%, major β anomer); Analytical HPLC 
(Gradient 1) Rt = 10.07 min; 1H NMR (CDCl3, 400 MHz)  δ 3.38 (2H, t, J = 5.0, 
CH2), 3.64-3.84 (12H, m, 4 x CH2 + 4 x CH), 3.87-3.92 (2H, m, CH2), 4.17-4.22 
(2H, m, CH2), 4.46-4.93 (8H, m, 4 x CH2), 5.86 (0.95H, d, J = 8.0, anomeric 
CH (β)), 6.58 (0.05H, d, J = 4.0, anomeric CH (α)), 6.92-6.96 (2H, m, Ar-CH), 
7.13-7.32 (20H, m, Ar-CH), 7.99-8.03 (2H, m, Ar-CH); [Found (ESI+) 840.3484 
[M+Na]+, C47H51N3O10Na requires 840.3467].  
Dend-Tris-ALA-Boc-Glc-OBn (166) 
 
A solution of (165) (20 mg, 24 µmol) and (105) (41 mg, 49 µmol) in DMSO      
(1.5 mL) was treated with copper(I) trifluoromethanesulfonate benzene 
complex (12 mg, 24 µmol). The reaction was stirred for 36 h and monitored by 




starting material (165) and formation of new species at 12.53 min. The reaction 
mixture was purified by semi-preparative HPLC (Gradient 2) to give (166) as a 
white solid (22 mg, 54%, major β anomer); Analytical HPLC (Gradient 3)                  
Rt = 12.53 min; 1H NMR (CDCl3, 500 MHz) δ 1.49 (27H, s, 3 x C(CH3)3), 2.62-
2.69 (6H, m, 3 x CH2CH2CO), 2.73-2.81 (8H, m, 3 x CH2CH2CO, 
CH2CH2CONH), 3.11-3.17 (2H, m, CH2CH2CONH), 3.69-3.73 (3H, m, CH2, 
CH), 3.74-3.78 (2H, m, CH2), 3.79-3.87 (5H, m, CH2, 3 x CH), 3.90-3.94 (2H, 
m, CH2), 3.95-3.99 (2H, m, CH2), 4.08 (6H, br, 3 x NHCH2CO), 4.24-4.28 (2H, 
m, OCH2), 4.36 (6H, s, 3 x C(CH2)O), 4.51-4.72 (4H, m, 2 x OBnCH2), 4.79-
4.97 (4H, m, 2 x OBnCH2), 5.54 (3H, br, 3 x NHCH2CO), 5.90 (0.88H, d, J = 
7.5, anomeric CH (β)), 6.63 (0.12H, d, J = 3.5, anomeric CH (α)), 6.91 (1H, br, 
CH2CH2CONH), 6.97-7.02 (2H, m, Ar-CH), 7.18-7.22 (2H, m, 2 x Ar-CH), 7.24-
7.41 (18H, m, 18 x Ar-CH), 7.92 (1H, br, triazole-CH), 8.04-8.09 (2H, m, Ar-
CH); 13C NMR (CDCl3, 125 MHz) δ 20.07 (CH2CH2CONH), 27.70 
(CH2CH2CO), 28.42 (C(CH3)3), 34.32 (CH2CH2CO), 50.20 (NH2CH2CO), 58.31 
(C(CH2)O), 62.21 (C(CH2)O), 67.70 (CH2), 68.21 (CH2), 68.70 (CH2), 69.59 
(CH2), 70.64 (CH2), 70.80 (CH2), 73.60 (CH2), 75.11 (CH2), 75.14 (CH2), 75.60 
(CH), 75.83 (CH2), 77.27 (CH), 80.28 (CH), 81.05 (CH), 84.98 (CH), 94.65 
(anomeric CH), 114.40 (Ar-CH), 125.79 (triazole-CH), 127.81 (Ar-CH), 127.82 
(Ar-CH), 127.89 (Ar-CH), 127.97 (Ar-CH), 128.00 (Ar-CH), 128.11 (Ar-CH), 
128.16 (Ar-CH), 128.28 (Ar-CH), 128.47 (Ar-CH), 128.51 (Ar-CH), 128.52 (Ar-
CH), 128.59 (Ar-CH), 132.33 (Ar-CH), 137.88 (Ar-C), 137.92 (Ar-C), 138.10 
(Ar-C), 138.49 (triazole C or Ar-C), 144.14 (triazole C or Ar-C), 156.23 (Ar-C 
or CO), 163.09 (Ar-C or CO), 164.64 (Ar-C or CO), 171.98 (CO), 172.63 (CO). 










Attempted synthesis of Dend-Tris-ALA-Boc-Glc-OH (167) 
 
Method A249 
A solution of (166) (0.06 g, 0.03 mmol) in DCM: EtOH (10 mL, 2:1) was treated 
with Pd/C (11.6 mg, 20%) and the mixture was stirred under an atmosphere of 
H2 for 12 h at RT. The reaction was monitored by analytical HPLC. No change 
was observed. 
Method B 
Method A was repeated, but replacing the solvent with MeOH. 
Method C 
Method B was repeated, but replacing the Pd/C with Pd(OH)2 on carbon. 
H-Leu-Ala-Arg(Pmc)-Leu-Leu-Thr(tBu)-2-Chlorotrityl resin (171) 
 
2-Chlorotrityl resin (0.5 g, 1.3 mmol/g) was pre-swollen in a SPPS vessel using 




the first amino acid was accomplished by adding a solution of Fmoc-Thr(tBu)-
OH (0.775 g, 1.95 mmol) and DIEA (0.69 mL, 3.9 mmol) in DMF (2 mL). The 
vessel was agitated for 1 h and the solvent was removed under reduced 
pressure. The resin was washed with DMF (5 mL), then piperidine/DMF (3 mL, 
1:4 v/v) was added to the resin and the vessel was agitated for 5 min. The 
procedure was repeated and the vessel was shaken for 10 min. The solvent 
was removed under reduced pressure and the resin was washed with DMF     
(5 x 5 mL). Successful removal of the Fmoc group was confirmed by the Kaiser 
test. The remaining amino acids were coupled using an Activotec automated 
peptide synthesiser using 3 eq. of Fmoc-protected amino acid (Fmoc-Leu-OH, 
Fmoc-Arg(Pmc)-OH, or Fmoc-Ala-OH), 3 eq of PyBOP as coupling agent,          
6 eq of DIEA as base and DMF (6.0 mL) as solvent. The peptide resin was 
washed thoroughly with DMF (2 x 5.0 mL), DCM (2 x 5.0 mL), MeOH (5.0 mL) 
and Et2O (2 x 5.0 mL), and dried in vacuo to give (171) (1.3 g) of peptide resin. 
The final loading of the peptide was found to be 0.745 mmol/g by Fmoc loading 
test (see section 7.1).  
H2N-Leu-Ala-Arg(Pmc)-Leu-Leu-Thr(tBu)-OH (173) 
 
Peptide resin (171) (50 mg, 65 µmol) was swollen in a SPPS vessel with DCM   
(2 mL) for 15 min, and the step was repeated twice. 1% TFA in DCM (0.5 mL) 
was then added to the SPPS vessel which was agitated for 2 min, then the 
resin was filtered under reduced pressure and the filtrate was collected in a 
flask containing 10% pyridine in MeOH (2 mL). The above step was repeated 




mL), DCM (2 x 1.5 mL) and MeOH (3 x 1.5 mL). The filtrate was evaporated 
under reduced pressure to 5% of the original volume, then water (8 mL) was 
added to precipitate the product, which was collected by centrifugation. The 
final product was washed with fresh water (8 mL) and the process repeated 3 
times. (173) was obtained as a white solid after drying under vacuum (61 mg, 
69%); HPLC (Gradient 1, Rt- 8.55 min); [Found (ESI+) 1008.6231 [M+H]+, 
C14H20N3O5 requires 1008.6064]. 
H-Leu-Ala-Arg-Leu-Leu-Thr-OH. 2TFA (172) 
 
Peptide resin (171) (100 mg, 0.75 mmol/g) was placed in a 5 mL vial and was 
treated with TFA/TIS/H2O (2 mL, 95:2.5:2.5) for 3 h. The resin beads were 
filtered off, washed with TFA, and the combined filtrates were collected into a 
Falcon tube containing Et2O (5.0 mL) to precipitate the peptide. The resulting 
precipitate was collected by centrifugation and was washed repeatedly with 
Et2O to remove excess TFA. The precipitated material was dissolved in 0.1% 
aq. TFA, filtered using a 0.2 m syringe filter and the resulting solution was 
directly purified by semi-preparative HPLC (Gradient 1). The purified peptide 
was then freeze-dried from H2O to give (172) as a white solid (55 mg, 85%); 
Analytical HPLC (Gradient 1) Rt = 5.5 min; 1H NMR (CD3OD, 500 MHz) δ 0.86-
1.04 (18H, m, 6 x CH3), 1.18 (3H, d, J = 6.0, CH3), 1.41 (3H, d, J = 7.0, CH3), 
1.61-1.80 (12H, m, 3 x CH, 4 x CH2, CHH), 1.85-1.92 (1H, m, CHH), 3.21 (2H, 
t, J = 7.0, CH2), 3.90-3.92 [1H, m, CH), 4.32-4.50 [6H, m, 6 x CH); 13C NMR 
(CD3OD, 125 MHz) δ 17.99 (CH3), 20.55 (CH3), 21.86 (CH3), 21.99 (CH3), 
22.05 (CH3), 23.15 (CH3), 23.47 (CH3), 25.35 (CH3), 25.81 (CH), 25.88 (CH), 
25.96 (CH2), 30.19 (CH2), 41.70 (CH2), 41.72 (CH2), 41.97 (CH2), 42.03 (CH2), 
50.53 (CH), 52.83 (CH), 53.18 (CH), 53.40 (CH), 53.95 (CH), 58.97 (CH), 
68.44 (CH), 158.65 [NHC(NH)NH2], 170.57 (CO), 173.36 (CO), 173.47 (CO), 





Azido PEG benzoic acid spacer-H-Leu-Ala-Arg(Pmc)-Leu-Leu-Thr(tBu)-2-
Chlorotrityl resin (176) 
 
Peptide resin (171) (200 mg, 151 µmol) was swollen in DCM (3.0 mL) for 10 
min and then in DMF (3 x 3.0 mL) for 5 min each. A solution of (142) (89.1 mg,               
302 µM) in DMF (400 µL) was treated with HATU (115 mg, 302 µM) followed 
by DIEA (110 µL, 604 µM). After 3 min of preactivation, the mixture was added 
to the peptide resin. The resin was shaken for 24 h, then the solvent was 
removed under reduced pressure. The resin beads were washed with DMF      
(3 x 2.0 mL), DCM (3 x 2.0 mL), MeOH (2.0 mL) and DCM (2 x 2.0 mL). 
Successful attachment of (142) was confirmed by a negative Kaiser test. 
Azido PEG benzoic acid spacer-H-Leu-Ala-Arg-Leu-Leu-Thr-OH. TFA 
(177) 
 
Peptide resin (176) (73 mg, 55 µmol) was placed in a 3 mL vial and was treated 
with TFA/TIS/H2O (1 mL, 95:2.5:2.5 v/v/v) for 3 h. The resin beads were filtered 
off, washed with TFA, and the combined filtrates were collected into a Falcon 




precipitate was collected by centrifugation and was washed repeatedly with 
Et2O to remove excess TFA. The precipitated material was dissolved in 0.1% 
aq. TFA, filtered using a 0.2 m syringe filter and the resulting solution was 
purified by semi-preparative HPLC (Gradient 2). The purified peptide was 
freeze-dried from H2O to give (177) as white solid (34 mg, 57%); Analytical 
HPLC (Gradient 1) Rt = 7.89 min; 1H NMR (CD3OD, 500 MHz) δ 0.90-1.02 
(18H, m, 6 x CH3), 1.18 (3H, d, J = 6.5, CH3), 1.37 (3H, d, J = 7.0, CH3), 1.61-
1.93 (13H, m, 3 x CH, 5 x CH2), 3.15-3.23 (2H, m, CH2), 3.35-3.39 (2H, m, 
CH2N3), 3.66-3.70 (4H, m, OCH2), 3.71-3.75 (2H, m, OCH2), 3.87-3.90 (2H, m, 
OCH2), 4.19-4.28 (3H, m, OCH2, CH), 4.29-4.45 (6H, m, 6 x CH), 7.03 (2H, d, 
J = 7.0, Ar-CH), 7.87 (2H, d, J = 7.0, Ar-CH); 13C NMR (CD3OD, 125 MHz)         
δ 17.29 (CH3), 20.45 (CH3), 21.68 (CH3), 21.73 (CH3), 22.20 (CH3), 23.28 
(CH3), 23.55 (CH3), 23.60 (CH3), 25.74 (CH), 25.90 (CH), 26.07 (CH2), 26.10 
(CH), 29.74 (CH2), 41.37 (CH2), 41.57 (CH2), 41.92 (CH2), 51.51 (CH), 51.75 
(OCH2), 53.29 (CH), 53.61 (CH), 54.57 (CH), 54.98 (CH), 59.10 (CH), 68.63 
(CH), 68.82 (OCH2), 70.74 (OCH2), 71.16 (OCH2), 71.55 (OCH2), 71.84 
(OCH2), 115.37 (Ar-CH), 127.08 (Ar-C), 130.59 (Ar-CH), 158.56 (Ar-C), 163.46 
(CO), 170.37 (CO), 173.27 (CO), 174.14 (CO), 174.85 (CO), 174.92 (CO), 













Azido PEG Gallic acid spacer-H-Leu-Ala-Arg(Pmc)-Leu-Leu-Thr(tBu)-2-
Chlorotrityl resin (178)  
 
Peptide resin (171) (115 mg, 65.5 µmol) was swollen in DCM (3.0 mL) for 10 
min and then in DMF (3 x 3.0 mL) for 5 min. A solution of (147) (84.0 mg,         
131 µM) in DMF (400 µL) was treated with HATU (49.0 mg, 131 µmol) followed 
by DIEA (45.0 µL, 262 µmol). After 3 min of preactivation, the mixture was 
added to the peptide resin. The resin was shaken for 24 h, then the solvent 
was removed and the resin beads were washed with DMF (3 x 2.0 mL), DCM 
(3 x 2.0 mL), MeOH (2.0 mL) and DCM (2 x 2.0 mL). Successful attachment of 
(147) was confirmed by the negative Kaiser test.  
Azido PEG Gallic acid spacer-H-Leu-Ala-Arg-Leu-Leu-Thr-OH. TFA (179)  
 
Peptide resin (178) (50 mg, 37.7 µmol) was placed in a 3 mL vial and was 




filtered off, washed with TFA, and the combined filtrates were collected into a 
Falcon tube containing Et2O (5.0 mL) to precipitate the peptide. The resulting 
precipitate was collected by centrifugation and was washed repeatedly with 
Et2O. The precipitated material was dissolved in 0.1% aq. TFA, filtered using 
a 0.2 m syringe filter and the resulting solution was purified by semi-
preparative HPLC (Gradient 2). The purified peptide was then freeze-dried 
from H2O to give (179) as a off-white solid (29 mg, 54%); Analytical HPLC 
(Gradient 1) Rt = 8.48 min; 1H NMR (CD3OD, 500 MHz) δ 0.86-1.06 (18H, m, 
6 x CH3), 1.18 (3H, d, J = 6.5, CH3), 1.38 (3H, d, J = 7.0, CH3), 1.60-1.82 (12H, 
m, 3 x CH, 4 x CH2, CHH), 1.87-1.94 (1H, m, CHH), 3.16-3.19 (2H, m, CH2), 
3.34-3.38 (6H, m, 3 x CH2N3), 3.63-3.69 (12H, m, OCH2), 3.71-3.75 (6H, m,     
3 x OCH2), 3.81-3.85 (2H, m, OCH2), 3.87-3.92 (4H, m, OCH2), 4.21-4.36 (9H, 
m, 3 x OCH2, 3 x CH), 4.38-4.42 (2H, m, 2 x CH), 4.45-4.51 (2H, m, 2 x CH), 
7.25 (2H, s, Ar-CH); 13C NMR (CD3OD, 125 MHz) δ 17.44 (CH3), 20.49 (CH3), 
21.76 (CH3), 21.82 (CH3), 22.21 (CH3), 23.34 (CH3), 23.54 (CH3), 23.57 (CH3), 
25.77 (CH), 25.92 (CH), 26.00 (CH2), 26.11 (CH), 29.89 (CH2), 41.38 (CH2), 
41.63 (CH2), 41.70 (CH2), 41.94 (CH2), 51.26 (CH), 51.79 (OCH2), 53.32 (CH), 
53.48 (CH), 54.27 (CH), 54.82 (CH), 59.04 (CH), 68.58 (CH), 70.25 (OCH2), 
70.94 (OCH2), 71.15 (OCH2), 71.62 (OCH2), 71.65 (OCH2), 71.89 (OCH2), 
73.65 (OCH2), 108.37 (Ar-CH), 153.84 (Ar-C), 173.29 (CO), 173.90 (CO), 
174.85 (CO); [Found (ESI+) 1307.7079 [M+H]+, C56H95N18O18 requires 
1307.7077]. 
Dend-(Tris-ALA)1-LARLLT. 4TFA (175) 
 
Peptide resin (176) (20 mg, 15 µmol) was swollen in DCM (2.0 mL) for 10 min         
(x 3), then DMSO (2.0 mL) for 10 min (x 3). A solution of (105) (25 mg,                  




trifluoromethanesulfonate benzene complex (15 mg, 30 µmol) and the mixture 
was added to the reaction vessel containing the resin which was agitated for 5 
days. The solvent was removed and the resin washed with DMSO (5 x               
1.0 mL), DCM (3 x 2.0 mL), MeOH (2.0 mL) and DCM (2 x 2.0 mL). The resin 
was placed in a 3 mL vial and was treated with TFA/TIS/H2O (1 mL, 95:2.5:2.5 
v/v/v) for 3 h. The resin beads were filtered off, washed with TFA, and the 
combined filtrates were collected into a Falcon tube containing Et2O (3.0 mL) 
to precipitate the peptide-dendrimer. The resulting precipitate was collected by 
centrifugation and was washed repeatedly with Et2O. The precipitated material 
was dissolved in 0.1 % aq. TFA, filtered using a 0.2 m syringe filter and the 
resulting solution was purified by semi-preparative HPLC (Gradient 2). The 
product was freeze-dried from H2O to give (175) as a white solid (16 mg, 53%); 
Analytical HPLC (Gradient 1) Rt = 6.09 min; 1H NMR (CD3OD, 500 MHz)                 
δ  0.90-1.02 (18H, m, 6 x CH3), 1.18 (3H, d, J = 6.5, CH3), 1.38 (3H, t, J = 7.0, 
CH3), 1.63-1.78 (13H, m, 3 x CH, 5 x CH2), 2.59 (2H, t, J = 7.5, NHCOCH2CH2), 
2.67-2.70 (6H, m, 3 x CH2CH2CO), 2.84-2.87 (6H, m, 3 x CH2CH2CO), 2.92 
(2H, t, J = 7.5, NHCOCH2CH2), 3.19 (2H, t, J = 7.25, CH2), 3.63-3.69 (4H, m, 
CH2N + OCH2), 3.81-3.85 (2H, m, OCH2), 3.88 (2H, t, J = 5.0, OCH2), 4.04 
(6H, m, 3 x COCH2NH2), 4.16-4.21 (2H, m, OCH2), 4.23-4.35 (3H, m, 3 x CH), 
4.37-4.43 (8H, m, CCH2O, 2 x CH), 4.44-4.55 (4H, m, 2 x CH, OCH2), 7.01  
(2H, d, J = 9.0, Ar-CH), 7.79 (1H, s, triazole CH), 7.86 (2H, d, J = 9.0, Ar-CH); 
13C NMR (CD3OD, 125 MHz) δ 17.45 (CH3), 20.49 (CH3), 21.71 (CH3), 21.77 
(CH3), 22.15 (CH3), 22.23 (NHCOCH2CH2), 23.36 (CH3), 24.21 (CH3), 25.75 
(CH), 25.90 (CH), 26.02 (CH), 28.23 (CH2CH2CO), 29.85 (CH2), 35.27 
(CH2CH2CO), 36.50 (NHCOCH2CH2), 41.45 (CH2), 41.60 (CH2), 41.95 (CH2), 
51.32 (CH), 51.37 (CH2-N), 53.32 (CH), 53.52 (CH), 54.43 (CH), 59.11 (CH), 
63.27 (COCH2NH2), 68.57 (CH), 68.82 (OCH2), 70.45 (OCH2), 70.66 (OCH2), 
71.41 (OCH2), 71.69 (OCH2), 115.34 (Ar-CH), 124.40 (triazole CH), 130.62 
(Ar-CH), 173.55 (CO), 175.71 (CO), 203.19 (CO); [Found (ESI+) 752.4095 






Dend-(Ext. Tris-ALA)1-LARLLT. 4TFA (180) 
 
Peptide resin (176) (40 mg, 30 µmol) was swollen in DCM (3.0 mL) for 10 min     
(x 3), then DMSO (3.0 mL) for 10 min (x 3). A solution of (107) (55 mg,                 
60 µmol) in DMSO (200 µL) was treated with copper(I) 
trifluoromethanesulfonate benzene complex (30 mg, 60 µmol) and the mixture 
was added to the reaction vessel containing the resin and agitated for 5 days. 
Solvent was removed and the resin was washed with DMSO (5 x 1.0 mL), 
DCM (3 x 2.0 mL), MeOH (2.0 mL) and DCM (2 x 2.0 mL). The resin was 
placed in a 3 mL vial and was treated with TFA/TIS/H2O (1 mL, 95:2.5:2.5 
v/v/v) for 3 h. The resin beads were filtered off, washed with TFA, and the 
combined filtrates were collected into a Falcon tube containing Et2O (5.0 mL) 
to precipitate the peptide-dendrimer. The resulting precipitate was collected by 
centrifugation and was washed repeatedly with Et2O. The precipitated material 
was dissolved in 0.1 % aq. TFA, filtered using a 0.2 m syringe filter and the 
resulting solution was purified by semi-preparative HPLC (Gradient 2). The 
product was freeze-dried to obtain (180) as a off-white solid (23 mg, 38%); 
Analytical HPLC (Gradient 1) Rt = 6.16 min; 1H NMR (CD3OD, 500 MHz)              
δ  0.86-0.91 (6H, m, 2 x CH3), 0.95-1.05 (12H, m, 4 x CH3), 1.15-1.22 (3H, m, 
CH3), 1.35-1.41 (3H, m, CH3), 1.44-1.55 (6H, m, 3 x CH2CH2CH2O), 1.61-1.85 
(18H, m,  3 x CH, 4 x CH2, CHH, 3 x CH2CH2CH2O), 1.89-1.96 (1H, m, CHH), 
2.54 (6H, t, J = 7.5, NHCOCH2CH2), 2.63-2.70 (6H, m, 3 x CH2CH2CO), 2.79-
2.87 (6H, m, 3 x CH2CH2CO), 2.93 (6H, t, J = 7.3, NHCOCH2CH2), 3.21 (2H, 
t, J = 7.3, CH2), 3.62-3.71 (4H, m, 2 x OCH2), 3.80-3.85 (2H, m, OCH2), 3.89 
(2H, t, J = 5.3, OCH2), 3.99-4.07 (12H, m, 3 x COCH2NH2, 3 x CH2CH2CH2O), 
4.17-4.20 (2H, m, OCH2), 4.23-4.28 (1H, m, CH), 4.30-4.34 (2H, m, 2 x CH), 




OCH2), 6.97-7.05 (2H, m, Ar-CH), 7.80 (1H, s, triazole CH), 7.83-7.89 (2H, m, 
Ar-CH); 13C NMR (CD3OD, 125 MHz) δ 17.37 (CH3), 20.47 (CH3), 21.75 (CH3), 
22.18 (CH3), 22.66 (NHCOCH2CH2), 23.33 (CH3), 23.55 (CH3), 23.59 
(CH2CH2CH2O), 25.75 (CH), 25.91 (CH), 26.07 (CH2), 26.11 (CH), 28.50 
(CH2CH2CO), 29.77 (CH2), 31.77 (CH2CH2CH2O), 35.30 (CH2CH2CO), 36.82 
(NHCOCH2CH2), 41.41 (CH2), 41.59 (CH2), 41.94 (CH2), 48.15 (NHCH2CO), 
51.37 (OCH2), 51.47 (CH), 53.33 (CH), 53.62 (CH), 54.57 (CH), 54.83 (CH), 
57.48 (CCH2CH2CH2O), 59.11 (CH), 66.03 (CH2CH2CH2O), 68.61 (CH), 68.84 
(OCH2), 70.45 (OCH2), 70.66 (OCH2), 71.42 (OCH2), 71.69 (OCH2), 115.37 
(Ar-CH), 124.28 (triazole-CH), 127.21 (Ar-C), 130.63 (Ar-CH), 158.60 (Ar-C), 
163.37 (CO), 170.25 (CO), 173.32 (CO), 173.86 (CO), 174.11 (CO), 174.89 
(CO), 174.95 (CO), 175.67 (CO), 175.81 (CO), 203.15 (CO); [Found (ESI+) 
794.4517 [M+2H]2+, C74H124N16O22 requires 794.4533]. 
Dend-(Tris-ALA)3-LARLLT. 10TFA (181) 
 
Method A 
A solution of (148) (10 mg, 3.2 µmol) in DMF (2.0 mL) was treated with 
EDC.HCl (0.72 mg, 3.8 µmol) and HOBt.hydrate (0.8 mg, 5.4 µM) at 0 °C, then 
DIEA (0.66 µL) was added to the mixture. The reaction was stirred for 30 min, 
then peptide (173) (3.18 mg, 3.2 µmol) was added. The reaction was stirred at 
RT for 16 h and was monitored by HPLC (Gradient 1). No consumption of (148) 
was observed nor the appearance of any new peaks.  
Method B 
Method A was repeated but by replacing EDC.HCl and HOBt.hydrate with 
HATU. The reaction was monitored by HPLC (Gradient 1), however similar 





Peptide resin (171) (5.0 mg, 7.6 µmol) was swollen in DCM (2.0 mL) for 10 min 
(x 3), then in DMF (2.0 mL) for 10 min (x 3). A solution of (148) (36.0 mg,         
11.4 µmol) in DMF (500 µL) was preactivated with HATU (4.33 mg, 11.4 µmol) 
and DIEA (2 mL, 22.4 µmol) for 3 min before adding to the reaction vessel 
containing the peptide resin (171). The vessel for agitated for 16 h and the 
solvent was removed under reduced pressure. The resin was washed with 
DMF (5 x 1.0 mL), DCM (3 x 2.0 mL), MeOH (2.0 mL) and DCM (2 x 2.0 mL). 
The resin was placed in a 3 mL vial and was treated with TFA/TIS/H2O                
(1 mL, 95:2.5:2.5 v/v/v) for 3 h. The resin beads were filtered off, washed with 
TFA, and the combined filtrates were collected into a Falcon tube containing 
Et2O (3.0 mL) to precipitate the peptide-dendrimer. The resulting precipitate 
was collected by centrifugation and was washed repeatedly with Et2O. The 
precipitated material was dissolved in 0.1 % aq. TFA, filtered using a 0.2 m 
syringe filter and the resulting solution was purified by semi-preparative HPLC 
(Gradient 2). The product was freeze-dried from H2O to give (181) as a white 
solid (1 mg, 5%); Analytical HPLC (Gradient 1) Rt = 5.18 min. 
Method D 
Peptide resin (178) (50 mg, 37.8 µmol) was swollen in DCM (2.0 mL) for              
10 min (x 3), then in DMSO (2.0 mL) for 10 min (x 3). A solution of (105)                 
(190 mg, 226 µmol) in DMSO (600 µL) was treated with copper(I) 
trifluoromethanesulfonate benzene complex (114 mg, 226 µmol) and the 
mixture was added to the reaction vessel containing the resin and agitated for 
5 days. The solvent was removed and the resin was washed with DMSO             
(5 x 1.0 mL), DCM (3 x 2.0 mL), MeOH (2.0 mL) and DCM (2 x 2.0 mL). The 
resin was placed in a 3 mL vial and was treated with TFA/TIS/H2O (1 mL, 
95:2.5:2.5 v/v/v) for 3 h. The resin beads were filtered off, washed with TFA, 
and the combined filtrates were collected into a Falcon tube containing Et2O 
(5.0 mL) to precipitate the peptide-dendrimer. The resulting precipitate was 
collected by centrifugation and was washed repeatedly with Et2O. The 
precipitated material was dissolved in 0.1 % aq. TFA, filtered using a 0.2 m 




(Gradient 2). The product was freeze-dried from H2O to give (181) as a white 
solid (44 mg, 30%). Analytical HPLC (Gradient 1) Rt = 5.18 min. 
Method E 
A solution of peptide targeted core (179) (5 mg, 3.55 µmol) in DMSO (100 µL) 
was treated with (105) (18 mg, 21 µmol) and copper(I) 
trifluoromethanesulfonate benzene complex (11 mg, 21 µmol), and the 
reaction mixture was stirred for 36 h and monitored by analytical HPLC 
(Gradient 1) which showed the disappearance of the starting material and 
appearance of new species at 9.94 min. The reaction mixture was diluted with 
0.1% aq. TFA and the product was isolated by semi-preparative HPLC 
(Gradient 2) and freeze-dried from H2O to give Boc-protected peptide-targeted 
dendrimer (183) (9.5 mg, 69%). Analytical HPLC (Gradient 1) Rt = 9.94 min. 
The resulting product was dissolved in dry DCM (3 mL) and the reaction 
mixture was cooled to 0 °C. TFA (3 mL) was added dropwise and the reaction 
mixture was stirred for 30 min at RT and monitored by analytical HPLC 
(Gradient 1), which showed complete disappearance of (183). The solvent was 
evaporated under vacuum and the residue was co-evaporated with Et2O (x 3) 
to remove excess TFA. This material was freeze-dried from H2O to give (181) 
as a white solid (9 mg, 94%); Analytical HPLC (Gradient 1) Rt = 5.18 min; 
[Found (ESI+) 1915.9682 [M+2H]2+, C173H278N30O66 requires 1915.9654]. 
Method F 
The reaction carried was out in a microwave (MW) reaction vial (Biotage 
Initiator Microwave reactor) which was irradiated for 10 min (at constant power, 
10-15 W; temp = 70˚C). The reaction was allowed to reach RT and the vial 
was removed from the MW cavity. The reaction mixture was analysed by HPLC 
(Gradient 1) which showed complete disappearance of the starting material 
(179) and formation of a new species at 9.79 min. The product was isolated by 
semi-preparative HPLC and freeze-dried from H2O to give Boc protected 
peptide targeted dendrimer (183) (10.3 mg, 75%). Analytical HPLC       
(Gradient 1) Rt = 9.79 min. The resulting product was dissolved in dry DCM (3 




and the reaction mixture stirred for 30 min at RT and monitored by analytical 
HPLC (Gradient 1) which showed complete disappearance of (183) and 
appearance of new species at 5.18 min. The solvent was evaporated under 
reduced pressure and the residue was co-evaporated with Et2O (x 3) to 
remove excess TFA. This material was freeze dried from H2O to give final 
product (181) as a white solid (9.1 mg, 95%); Analytical HPLC (Gradient 1)       
Rt = 5.18 min; 1H NMR (CD3OD, 500 MHz) δ  0.92-1.03 (18H, m, 6 x CH3), 
1.19-1.23 (3H, m, CH3), 1.38-1.43 (3H, m, CH3), 1.66-1.85 (12H, m, 3 x CH + 
4 x CH2 + CHH), 1.92-1.95 (1H, m, CHH), 2.61 (6H, t, J = 7.5, NHCOCH2CH2), 
2.68-2.73 (18H, m, 9 x CH2CH2CO), 2.87-2.91 (18H, m, 9 x CH2CH2CO), 2.94 
(6H, t, J = 7.0, NHCOCH2CH2), 3.21 (2H, t, J = 7.0, CH2), 3.64-3.70 (12H, m, 
3 x CH2N + 3 x OCH2 ), 3.74-3.79 (2H, m, OCH2), 3.85-3.91 (10H, m, 5 x 
OCH2), 4.08 (18H, s, 9 x COCH2NH2), 4.18-4.23 (6H, m, 3 x OCH2), 4.26-4.31 
(1H, m, CH), 4.33-4.37 (2H, m, 2 x CH), 4.38-4.45 (20H, m, CCH2O + 2 x CH), 
4.46-4.52 (1H, m, CH), 4.54-4.59 (7H, m, 3 x OCH2 + CH), 7.29-7.33 (2H, m, 
Ar-CH), 7.79-7.83 (3H, m, triazole CH); 13C NMR (CD3OD, 125 MHz) δ 17.50 
(CH3), 20.50 (CH3), 21.78 (CH3), 22.23 (NHCOCH2CH2), 23.38 (CH3), 23.56 
(CH3), 23.60 (CH3), 25.75 (CH), 25.91 (CH), 26.09 (CH), 28.27 (CH2CH2CO), 
35.31 (CH2CH2CO), 36.46 (NHCOCH2CH2), 41.34 (CH2), 41.61 (CH2), 41.94 
(CH2), 48.14 (COCH2NH2), 51.25 (OCH2), 51.32 (OCH2), 53.36 (CH), 53.61 
(CH), 54.50 (CH), 54.85 (CH), 59.10 (αCH), 63.29 (CCH2O), 68.57 (CH), 69.97 
(OCH2), 70.44 (OCH2), 70.73 (OCH2), 71.28 (OCH2), 71.43 (OCH2), 71.57 
(OCH2), 71.65 (OCH2), 73.63 (OCH2), 108.08 (Ar-CH), 124.32 (triazole-CH), 
147.59 (triazole C or Ar-C), 153.66 (triazole C or Ar-C), 158.58 (Ar-C), 173.47 
(CO), 173.55 (CO), 174.94 (CO), 175.08 (CO), 203.26 (CO); [Found (ESI+) 









Dend-(Ext. Tris-ALA)3-LARLLT. 10TFA (182) 
 
Peptide resin (178) (50 mg, 37.8 µmol) was swollen in DCM (2.0 mL) for 10 
min (x 3), then DMSO (2.0 mL) for 10 min (x 3). A solution of (105) (209 mg,       
226 µmol) in DMSO (600 µL) was treated with copper(I) 
trifluoromethanesulfonate benzene complex (114 mg, 226 µmol) and the 
mixture was added to the reaction vessel containing the resin and which was 
agitated for 5 days. The solvent was removed and the resin was washed with 
DMSO (5 x 1.0 mL), DCM (3 x 2.0 mL), MeOH (2.0 mL) and DCM (2 x 2.0 mL). 
The resin was placed in a 3 mL vial and was treated with TFA/TIS/H2O (1 mL, 
95:2.5:2.5 v/v/v) for 3 h. The resin beads were filtered off, washed with TFA, 
and the combined filtrates were collected into a Falcon tube containing Et2O 
to precipitate the peptide-dendrimer. The resulting precipitate was collected by 
centrifugation and was washed repeatedly with Et2O. The precipitated material 
was dissolved in 0.1 % aq. TFA, filtered using a 0.2 m syringe filter and the 
resulting solution was analysed by HPLC (Gradient 1) and purified by semi-
preparative HPLC (Gradient 2). The product was freeze-dried from H2O to give 
(182) as a white solid (40 mg, 25%); Analytical HPLC (Gradient 1) Rt = 5.34 
min; 1H NMR (CD3OD, 500 MHz) δ  0.86-1.03 (18H, m, 6 x CH3), 1.18 (3H, d, 
J = 6.5, CH3), 1.38-1.43 (3H, m, CH3), 1.45-1.53 (18H, m, 6 x CCH2CH2CH2O), 
1.55-1.85 (31H, m, 3 x CH, 3 x CH2, 9 x CCH2CH2CH2O), 2.55 (6H, t, J = 7.0, 
NHCOCH2CH2), 2.61-2.71 (18H, m, 9 x CH2CH2CO), 2.77-2.87 (18H, m, 9 x 
CH2CH2CO), 2.93 (6H, t, J = 7.0, NHCOCH2CH2), 3.19 (2H, t, J = 7.0, CH2), 
3.58-3.70 (12H, m, 6 x OCH2), 3.72-3.77 (2H, m, OCH2), 3.80-3.84 (4H, m, 2 
x OCH2), 3.87-3.92 (6H, m, 3 x OCH2), 3.98-4.09 (36H, m, 9 x COCH2NH2, 9 
x CH2CH2CH2O), 4.14-4.21 (6H, m, 3 x OCH2), 4.24-4.34 (4H, m, 4 x CH), 
4.36-4.42 (2H, m, 2 x CH), 4.43-4.49 (1H, m, CH), 4.51-4.57 (7H, m, 3 x OCH2, 




(CH3), 20.50 (CH3), 21.81 (CH3), 22.21 (CH3), 22.68 (NHCOCH2CH2), 23.60 
(CCH2CH2CH2O), 25.76 (CH), 25.92 (CH), 26.07 (CH), 28.52 (CH2CH2CO), 
30.88 (CH), 31.77 (CCH2CH2CH2O), 35.33 (CH2CH2CO), 36.82 
(NHCOCH2CH2), 41.62 (CH2), 48.16 (COCH2NH2), 51.27 (OCH2), 51.32 (CH), 
53.38 (CH), 54.48 (CH), 54.81 (CH), 59.12 (CH), 66.05 (CCH2CH2CH2O), 
68.58 (CH), 70.01 (OCH2), 70.47 (OCH2), 70.77 (OCH2), 71.33 (OCH2), 71.46 
(OCH2), 71.60 (OCH2), 108.23 (Ar-CH), 124.30 (triazole CH), 153.70 (Ar-C), 
158.64 (Ar-C), 173.38 (CO), 173.89 (CO), 174.11 (CO), 175.63 (CO), 203.20 
(CO); [Found (ESI+) 796.4429 [M+4H]4+, C146H244N30O48 requires 796.4388]. 
5-(4-Aminophenyl)-10,15,20-triphenylporphyrin (190)289  
 
Step 1 
The conjugate (190) was synthesized according to the procedure of Luguya et 
al.289 modified as follows: A solution of (6) (0.5 g, 0.81 mmol) in TFA (30 mL) 
in an air-open round-bottom flask was treated with NaNO2 (0.1 g, 1.44 mmol) 
in a single portion. The reaction mixture was stirred at 18 °C for 3 min and then 
quenched with H2O (40 mL). The mixture was transferred to a separatory 
funnel and further diluted with H2O (40 mL) and DCM (80 mL). After separation, 
the aqueous phase was extracted with DCM (2 x 100 mL). The organic phases 
were combined, washed with sat. aq. NaHCO3 (2 x 100 mL), brine (100 mL), 
dried over MgSO4, filtered and the solvent was evaporated to give a residue           
(0.59 g), which was a mixture of unchanged (6), mono- and dinitrated 







A solution of the crude mixture from step 1 (0.59 g) in DCM (250 mL) and 
MeOH (60 mL) was treated with Pd/C 5% (0.09 g). NaBH4 (0.75 g, 19.8 mmol) 
was then added in small portions over 10 min, while stirring and keeping the 
flask open to the atmosphere. After 15 min of additional stirring, the reaction 
was quenched with the addition of H2O (75 mL), then transferred to a 
separatory funnel. The organic phase was separated, washed with brine          
(75 mL), dried over MgSO4, filtered and the solvent was evaporated. 
Purification by column chromatography on silica gel using toluene to elute 
unreacted (6), then 0-10% EtOAc in DCM gave (190) as a purple solid              
(0.16 g, 31%); 1H NMR (400 MHz, CDCl3 δ -2.75 (2H, br, internal 2 x N-H of 
the porphyrin), 6.97-7.02 (2H, m, Ar), 7.65-7.78 (9H, m, Ar), 7.94-8.01 (2H, m, 




A solution of (190) (22.6 mg, 0.04 mmol) in anhydrous DCM (1.5 mL) was 
treated with HOBt (7.54 mg, 0.05 mmol), dibenzocyclooctyne-acid (10.0 mg, 
0.03 mmol), EDC.HCl (6.88 mg, 0.04 mmol) and DIEA (10 μL, 0.04 mmol). The 
reaction mixture was stirred at RT overnight, then it was purified directly by 
column chromatography on silica gel eluting with 1-10% acetone in DCM to 
give (192) as a red solid (21 mg, 76%); Rf (DCM/acetone 9:1) = 0.75; MP > 
250 °C; HPLC: Analytical HPLC (Gradient 1) Rt = 11.91 min; UV-Vis (CHCl3), 
nm (%): 420 (100), 516 (8.4), 543 (4.88), 595 (3.51), 643 (2.98); 1H NMR          




1.89-1.95 (1H, m, CHHCH2CH2CH2CONH), 2.23-2.28 (3H, m, 
CHHCH2CH2CH2CONH), 3.56-3.62 (1H, m, CHH), 5.00-5.08 (1H, m, CHH), 
7.25-7.68 (9H, m, 9 x Ar-CH), 7.79-7.83 (9H, m, 9 x Ar-CH), 7.99 (2H, d, J = 
8.0, 2 x Ar-CH), 8.11 (2H, d, J = 8.0, 2 x Ar-CH), 8.20 (6H, d, J = 7.5, 6 x Ar-
CH), 8.79-8.84 (6H, m, 6 x Ar-CH); 13C NMR (125 MHz, (CD3)2SO, 60 °C),           
δ 24.33, 24.38, 30.27,  33.76, 36.07, 54.58, 117.30, 117.87, 119.56, 119.66, 
119.79, 121.35, 124.83, 126.48, 126.64, 127.33, 127.45, 127.65, 127.73, 
128.05, 128.30, 128.58, 129.12, 130.87, 132.06, 132.19, 133.89, 134.26, 
135.43, 137.38, 139.03, 141.01, 141.03, 148.19, 151.64, 171.04, 171.43. 
[Found (ESI+) 945.3966 [M+H]+, C65H49N6O2 requires 945.3912]. 
13’-(2-aminoethylamido)-15’,17’-dimethyl-chlorin e6 (191) 
 
Pheophorbide-a was prepared by extraction and purification of pheophytin-a 
from spirulina spp. followed by methanolysis of the phytol group.290 A solution 
of pheophorbide-a (30) (100 mg, 0.17 mmol) in anhydrous THF (25 mL) was 
treated with 1,2-diaminoethane (397 μL, 5.94 mmol). The resulting solution 
was stirred at RT overnight. The mixture was then diluted with DCM (100 mL) 
and washed with H2O (3 x 50 mL) and brine (3 x 50 mL). The organic phase 
was dried (Na2SO4) and the solvent was evaporated. The crude product (191) 









dimethylchlorin e6 (193) 
 
A solution of (191) (22.0 mg, 0.03 mmol) was treated with HOBt (5.0 mg, 0.04 
mmol), dibenzocyclooctyne-acid (10.0 mg, 0.03 mmol), EDC.HCl (7.0 mg, 0.04 
mmol) and DIEA (16.0 μL, 0.09 mmol) in anhydrous DCM (1.5 mL) and stirred 
at RT overnight. The crude product was purified directly by column 
chromatography on silica gel eluting with EtOAc to give (193) as a green solid 
(17 mg, 57%); Rf (EtOAc) = 0.23; Analytical HPLC (Gradient 1) Rt = 10.36 min; 
UV-Vis (CHCl3), nm (%): 404 (100), 489 (9.95), 609 (4.15), 665 (32.86);            
1H-NMR (500 MHz, (CD3)2SO, 60 °C) δ -2.15 - -1.70 (2 H, m internal N-H 
chlorin), 1.21 - 1.42 (4H, m, 2 x CH2), 1.58 - 1.75 (7H, m, 2 x CH3 + CHH), 1.82 
(1H, m, CHH), 1.93-2.04 (2H, m, CH2), 2.18 (2 H, dd, J = 13.6, 5.5, CHH + 
CHH), 2.24 - 2.37 (1H, m, CHH), 3.27-3.74 (20H, m, CHH + 2 x CH2 + 5 x 
CH3), 2.61-2.70 (1H, m, CHH), 3.86 (2H, q, J = 7.2, CH2), 4.45 (1H, d, J = 10.4, 
CH), 4.63 (1H, d, J = 7.1, CH), 5.01-5.10 (1H, m, CHH), 5.31 (1 H, d, J = 18.8, 
CHH), 5.53 (1H, d, J = 18.8, CHH), 6.21 (1H, d, J = 11.6, CHH), 6.46 (1H, d,    
J = 17.8, CHH), 7.25-7.66 (8H, m, DBCO aromatic protons), 7.73 (1H, br, N2-
H), 8.29 (1H, dd, J = 17.8, 11.6, CH), 8.94 (1H, br, N1-H), 9.13 (1H, br, CH), 
9.78 (1H, br, CH), 9.83 (1H, br, CH); 13C-NMR (125 MHz, (CD3)2SO, 60 °C), 
11.4, 12.1, 12.4, 18.0, 19.4, 23.4, 24.3, 24.8, 25.0, 25.1, 30.0, 31.1, 33.8, 34.2, 
34.4, 35.7, 37.5, 38.8, 48.7, 51.7, 52.2, 53.3, 55.3, 79.2, 79.4, 79.7, 94.9, 98.9, 
101.2, 103.6, 108.6, 114.9, 122.0, 122.6, 123.0, 125.5, 127.2, 128.0, 128.4, 
128.5, 129.2, 129.8, 130.2, 130.5, 130.8, 132.8, 134.4, 136.3, 138.9, 144.6, 
148.9, 152.4, 168.4, 168.6, 172.1, 172.6, 173.1, 173.5, 174.3; [Found (ESI+) 




LARLLT TPP-DBCO (195) 
 
A solution of azido-peptide (177) (15 mg, 13.9 µmol) and (192) (26 mg, 28 
µmol) in DMSO (500 µL) was stirred at room temperature for 8 h, shielded from 
light. Reaction was monitored by analytical HPLC (Gradient 1) which showed 
disappearance of starting material (177) and appearance of new species at      
10.08 min. The crude product was purified by semi-preparative HPLC 
(Gradient 2) and was freeze-dried to give (195) as a dark green solid (19 mg, 
68%); Analytical HPLC (Gradient 1) Rt = 10.08 min; UV-Vis (0.1% aq TFA),    
nm (%): 412 (100), 521 (13.5), 539 (9.75), 584 (8.35), 642 (7.69); fluorescence 
λmax. (0.1% aq TFA, λexc. = 420 nm) 690 nm; [Found (ESI+) 1907.9407 
[M+2H]2+, C109H123N18O14 requires 1907.9461]; 
LARLLT Ce6-DBCO (196) 
 
A solution of azido-peptide (177) (10 mg, 0.01 mmol) and (193) (19.68                 
mg, 0.02 mmol) in DMSO (1.0 mL) was stirred at RT for 8 h. Reaction was 
monitored by analytical HPLC (Gradient 1) which showed disappearance of 
starting material (177) and appearance of new species at 8.83 min. The crude 
product was purified by semi-preparative HPLC (Gradient 2) and was freeze-
dried to give (196) as a dark blue solid (12.7 mg, 66%); Analytical HPLC 




(10.73), 606 (3.81), 662 (31.47); fluorescence λmax. (0.1% aq TFA, λexc. = 420 
nm) 667 nm; [Found (ESI+) 995.0128 [M+2Na]2+, C103H137N19O19Na requires 
995.0061]. 
LARLLT Verteporfin-DBCO (197) 
 
A solution of azido-peptide (177) (10 mg, 0.01 mmol) and (194) (27.6 mg,     
0.02 mmol) in DMSO (1.0 mL) was stirred at RT for 8 h. Reaction was 
monitored by analytical HPLC (Gradient 1) which showed disappearance of 
starting material (177) and appearance of new species at 9.33 min. The crude 
product was purified by semi-preparative HPLC (Gradient 2) and was freeze-
dried to give (197) as a dark blue solid (14.5 mg, 73%); Analytical HPLC 
(Gradient 1) Rt = 9.33 min; UV-Vis (0.1% aq TFA), nm: 421 (100), 575 (17.21), 
628 (8.09), 687 (39.98); fluorescence λmax. (0.1% aq TFA, λexc. = 420 nm)        
693 nm; [Found (ESI+) 992.4846 [M+2Na]2+, C103H130N18O20Na requires 
992.4747]. 
Imidazole-1-sulfonyl azide. HCl (204a)308, 317 
 
An ice-cooled suspension of NaN3 (4.8 g, 73 mmol) in MeCN (100 mL) was 
treated with sulfuryl chloride (5.9 mL, 73 mmol) added dropwise. The reaction 
mixture was stirred at RT overnight. Imidazole (10 g, 146 mmol) was added in 




RT for 3 h. The mixture was diluted with EtOAc (200 mL), washed with H2O    
(2 x 200 mL), sat. aq. NaHCO3 (2 x 200 mL), dried over MgSO4 and filtered. A 
solution of HCl in EtOH [obtained by drop-wise addition of AcCl (7.8 mL, 109 
mmol) to ice-cooled dry EtOH (40 mL) was added dropwise to the filtrate with 
stirring. The mixture was chilled in an ice-bath, filtered and the residue washed 
with EtOAc (3 x 50 mL) to give (204a) as colourless needles (9.3 g, 61%);        
Mp = 94-96 °C (lit. 96-98 °C)317; 1H NMR (D2O, 400 MHz) δ 7.57 (1H, s, H-4), 
7.97 (1H, s, H-5), 9.45 (1H, s, H-2). 
Fmoc-azido Lysine (205)308 
 
A solution of Fmoc-L-Lysine-OH (5.50 g, 14.93 mmol) in water was treated 
with aq. HCl (1.2 mL, 14.9 mmol), and the reaction mixture was diluted with 
H2O/ MeOH (1:2, 65 mL). A solution of imidazole-1-sulfonyl azide 
hydrochloride (204a) (3.75 g, 17.9 mmol), NaHCO3 (8.11 g, 96.54 mmol) and 
CuSO4.5H2O (37.3 mg, 0.149 mmol) in water (1 mL) was added and the 
mixture was stirred for 16 h at RT. The reaction mixture was concentrated to 
50 mL, then it was diluted with more H2O (150 mL), and acidified to pH 2.0 by 
dropwise addition of 5 M aq. HCl. The aqueous layer was extracted with EtOAc 
(3 x 50 mL) and dried over MgSO4. The organic layer was filtered and the 
solvent was evaporated to give the crude product. Purification by column 
chromatography on silica gel eluting with (Toluene / EtOAc / AcOH 85:10:5 
v/v/v) gave (205) as a yellowish gum (3.61 g, 68%); 1H NMR (CDCl3, 400 MHz) 
δ 1.26-1.77 (5H, m, CHCHHCH2CH2CH2N3), 1.93-2.04 (1H, m, 
CHCHHCH2CH2CH2N3), 3.17-3.34 (2H, m, CHCH2CH2CH2CH2N3), 4.22 (1H, 




NH), 7.29-7.34 (2H, m, Fmoc CH), 7.38-7.44 (2H, m, Fmoc CH), 7.53-7.63 
(2H, m, Fmoc CH), 7.76 (2H, d, J = 7.2, Fmoc CH); 13C-NMR (CDCl3,               
100 MHz) δ 22.58 (CHCH2CH2CH2CH2N3/CHCH2CH2CH2CH2N3/ 
CHCH2CH2CH2CH2N3), 28.48 (CHCH2CH2CH2CH2N3 / CHCH2CH2CH2CH2N3/ 
CHCH2CH2CH2CH2N3), 31.96 (CHCH2CH2CH2CH2N3 / CHCH2CH2CH2CH2N3/ 
CHCH2CH2CH2CH2N3), 47.31 (Fmoc CH), 51.20 (CHCH2CH2CH2CH2N3), 
53.61 (CHCH2CH2CH2CH2N3), 67.34 (Fmoc-OCH2), 120.18 (Ar-CH), 125.15 
(Ar-CH), 127.24 (Ar-CH), 127.93 (Ar-CH), 141.51 (Ar-C), 143.76 (Ar-C), 
143.92 (Ar-C), 156.26 (CO), 176.35 (CO); [Found (ESI+) 395.1697 [M+H]+, 
C21H23N4O4  requires 395.1719]. 
H-Arg-Arg-Met-Lys-Trp-Lys-Lys(N3)-Gly-NH2 (Penetratin (9-15) (200)  
 
Rink Amide MBHA Resin (250 mg, 0.59 mmol/g) was pre-swollen in a SPPS 
vessel using DCM (5 mL) for 15 min, and the procedure was repeated twice. 
The Fmoc group from the resin was removed by adding piperidine/DMF         
(3.0 mL, 1:4 v/v) to the resin and the vessel was agitated for 5 min. The 
procedure was repeated and the vessel was agitated for 10 min. Successful 
removal of Fmoc group was confirmed by Kaiser test. Preloading of the first 
amino acid was accomplished by adding a solution of of Fmoc-Gly (178 mg, 
0.60 mmol), DIC (93.9 µL, 0.60 mmol) and DIEA (160 µL, 0.90 mmol) in DMF 




reduced pressure. The resin was washed with DMF (5 x 5 mL) and was 
followed by an acetylation step (Ac2O/DIEA/DMF = 2.5 mL, 1/1/8 v/v/v, 1 x 10 
min), then the Fmoc group was removed using the similar procedure as above. 
The remaining amino acids were coupled using a Activotec automated peptide 
synthesiser using 3 eq. of Fmoc-protected amino acid (Fmoc-Lys(N3)-OH, 
Fmoc-Arg(Pmc)-OH, Fmoc-Met-OH, Fmoc-Trp(Boc)-OH, Fmoc-Lys(Boc)-OH, 
or Fmoc-Gly-OH), 3 eq. of PyBOP as coupling agent, 6 eq. of DIEA as base 
and DMF (4.3 mL) as solvent. The last step of the synthesis was Fmoc de-
protection using the procedure same as above. The peptide resin (206) was 
washed thoroughly with DMF (2 x 5.0 mL), DCM (2 x 5.0 mL), MeOH (5.0 mL) 
and Et2O (2 x 5.0 mL), and dried in vacuo. to have 1.1 g of peptide-resin (206). 
Resin (50 mg, 0.03 mmol) was placed in a 10 mL vial and was treated with 
TFA/TIS/H2O (1 mL, 95:2.5:2.5 v/v/v) for 4 h. The resin beads were filtered off, 
washed with TFA, and the combined filtrates were collected into a Falcon tube 
containing Et2O (5mL) to precipitate the peptide. The resulting precipitate was 
collected by centrifugation and was washed repeatedly with Et2O to remove 
excess TFA. The precipitated material was dissolved in 0.1% aq. TFA, filtered 
using 0.2 µm syringe filter and the resulting solution was directly purified by 
semi-preparative HPLC (Gradient 2). The purified peptide was then freeze-
dried to give (200) as a white solid (33 mg, 65%); Analytical HPLC          















(Tat (48-57)-GYKG (201)  
 
The protected peptide resin (207) was synthesized as for (200) on a 0.15 mmol 
scale. Cleavage of a sample of resin (50 mg, 0.03 mmol) as previously gave 
peptide (201) as a white solid (54 mg, 67%); Analytical HPLC (Gradient 1)         
Rt- 4.52 min; [Found (ESI+) 609.7098 [M+3H]3+, C74H138N39O16  requires 
609.7056]. 
H-Leu-Gly-Ala-Ser-Trp-His-Arg-Pro-Asp-Lys-Gly-Gly-Arg-Lys-Lys-Arg-
Arg-Gln-Arg-Arg-Arg-Gly-Tyr-Lys(N3)-Gly-NH2 (vMIP-II- Tat (48-57)-GYKG 
chimera (202)  
 




scale. Cleavage of a sample of resin (50 mg, 0.03 mmol) as previously gave 
peptide (202) as a white solid (61 mg, 47%); Analytical HPLC (Gradient 1)            
Rt- 5.41 min; [Found (ESI+) 758.6892 [M+4H]4+, C128H219N57O30  requires 
758.6835]. 
H-Leu-Leu-Ile-Ile-Leu-Arg-Arg-Arg-Ile-Arg-Lys-Gln-Ala-His-Ala-His-Ser-
Lys(N3)-NH2 (PVec) (203)  
 
The protected peptide resin (209) was synthesized as for (206) on a 0.15 mmol 
scale. Cleavage of a sample of resin (50 mg, 0.03 mmol) as previously gave 
peptide (203) as a white solid (39.5 mg, 59%); Analytical HPLC (Gradient 1)         
Rt- 4.58 min; [Found (ESI+) 745.8039 [M+3H]3+, C98H179N40O20 requires 
745.8076]. 
H-Arg-Arg-Met-Lys-Trp-Lys-Lys(Tris-ALA)-Gly-NH2 (Penetratin (9-15)-
Tris-ALA (210)  
 




and then in DMSO for 3 min (3 x 2 mL). A solution of (105) (20 mg, 24 µmol) 
in DMSO (500 µL) was treated with copper(I) trifluoromethanesulfonate 
benzene complex (12 mg, 24 µmol) and the mixture was added to the reaction 
vessel containing the resin which was agitated for 5 days. The solvent was 
removed and the resin was washed with DMSO (5 x 2 mL), DCM (3 x 2 mL), 
MeOH (3 x 2 mL) and DCM (3 x 2 mL). The resin was placed in a 3 mL vial 
and was treated with TFA/TIS/H2O (1 mL, 95:2.5:2.5 v/v/v) for 4 h. The resin 
beads were filtered off, washed with TFA, and the combined filtrates were 
collected into a Falcon tube containing Et2O (3 mL) to precipitate the peptide 
conjugate. The resulting product was collected by centrifugation and was 
washed repeatedly with Et2O to remove excess TFA. The peptide conjugate 
was dissolved in 0.1% aq. TFA, filtered using 0.2 µm syringe filter and the 
resulting solution was purified by semi-preparative HPLC (Gradient 2). The 
purified peptide was then freeze-dried to give (210) as a white solid (13 mg, 
43%); Analytical HPLC (Gradient 1) Rt = 4.33 min; [Found (ESI+) 552.3047 
[M+3H]3+, C72H122N25O18S requires 552.3035]. 
H-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Gly-Tyr-Lys(Tris-ALA)-Gly-
NH2 (Tat (48-57)-GYKG-Tris-ALA) (211) 
 
The peptide-ALA conjugate (211) was synthesized as for (210) using peptide 
resin (206) (20 mg, 12 µmol). The purified peptide obtained was freeze-dried 
to give (211) as a white solid (18 mg, 41%); Analytical HPLC (Gradient 1)            







Arg-Gln-Arg-Arg-Arg-Gly-Tyr-Lys(Tris-ALA)-Gly-NH2 (vMIP-II- Tat (48-
57)-GYKG chimera-Tris-ALA) (212) 
 
The peptide-ALA conjugate (212) was synthesized as for (210) on a 12 µmol 
scale. The purified peptide obtained was freeze-dried to give (212) as a white 
solid (29 mg, 46%); Analytical HPLC (Gradient 1) Rt = 4.31 min; [Found (ESI+) 
893.7541 [M+4H]4+, C152H255N61O40 requires 893.7443]. 
H-Leu-Leu-Ile-Ile-Leu-Arg-Arg-Arg-Ile-Arg-Lys-Gln-Ala-His-Ala-His-Ser-
Lys(Tris-ALA)-NH2 (pVEC-Tris-ALA) (213) 
 
Peptide resin (209) (50 mg, 30 µmol) was swollen in DCM (2 mL) for 10 min 
and then in DMSO for 3 min (3 x 2 mL).  A solution of (105) (50 mg, 60 µmol) 
in DMSO (500 µL) was treated with copper(I) trifluoromethanesulfonate 
benzene complex (30 mg, 60 µmol) and the mixture was added to the reaction 
vessel containing the resin which was agitated for 5 days. Solvent was 
removed and the resin was washed with DMSO (5 x 2 mL), DCM (3 x 2 mL), 
MeOH (3 x 2 mL) and DCM (3 x 2 mL). The resin was transferred to a 5 mL 
vial and was treated with TFA/TIS/H2O (1 mL, 95:2.5:2.5 v/v/v) for 4 h. The 




collected into a Falcon tube containing Et2O (3 mL) to precipitate the peptide 
conjugate. The resulting product was collected by centrifugation and was 
washed repeatedly with Et2O to remove excess TFA. The peptide conjugate 
was dissolved in 0.1% aq. TFA, filtered using 0.2 µm syringe filter and the 
resulting solution was purified by semi-preparative HPLC (Gradient 2). The 
purified peptide was then freeze-dried to give (213) as a white solid (37 mg, 
31%); Analytical HPLC (Gradient 1) Rt = 5.23 min; [Found (ESI+) 925.5547 
[M+3H]3+, C122H215N44O30 requires 925.5545]. 
H-Leu-Leu-Ile-Ile-Leu-Arg-Arg-Arg-Ile-Arg-Lys-Gln-Ala-His-Ala-His-Ser-
Lys(Ex.TRIS-ALA)-NH2 (pVEC-Ex.Tris-ALA) (214) 
 
Peptide resin (209) (35 mg, 21 µmol) was swollen in DCM (2 mL) for 10 min 
and then in DMSO for 3 min (3 x 2 mL).  A solution of (105) (39 mg, 42 µmol) 
in DMSO (500 µL) was treated with copper(I) trifluoromethanesulfonate 
benzene complex (30 mg, 42 µmol) and the mixture was added to the reaction 
vessel containing the resin which was agitated for 5 days. The solvent was 
removed and the resin was washed with DMSO (5 x 2 mL), DCM (3 x 2 mL), 
MeOH (3 x 2 mL) and DCM (3 x 2 mL). The resin was transferred to a 5 mL 
vial and was treated with TFA/TIS/H2O (1 mL, 95:2.5:2.5 v/v/v) for 4 h. The 
resin beads were filtered off, washed with TFA, and the combined filtrates were 
collected into a Falcon tube containing Et2O (3 mL) to precipitate the peptide 
conjugate. The resulting product was collected by centrifugation and was 
washed repeatedly with Et2O to remove excess TFA. The peptide conjugate 
was dissolved in 0.1% aq. TFA, filtered using 0.2 µm syringe filter and the 
resulting solution was purified by semi-preparative HPLC (Gradient 2). The 




39%); Analytical HPLC (Gradient 1) Rt = 5.22 min; [Found (ESI+) 1429.8704 
[M+2H]2+, C128H226N44O30 requires 1429.8750]. 
pVEC TPP-DBCO (215) 
 
A solution of peptide (203) (10 mg, 3.31 µmol) and (192) (6.26 mg, 6.62 µmol) 
in DMSO (500 µL) was stirred at room temperature overnight, shielded from 
light. The reaction was monitored by analytical HPLC (Gradient 1) which 
showed disappearance of starting material (203) and appearance of a new 
species at 7.62 min. The crude product was purified by semi-preparative HPLC 
(Gradient 2) and was freeze-dried to give (215) as a dark green solid (9.1 mg, 
69%); Analytical HPLC (Gradient 1) Rt = 7.63 min; UV-vis (MeOH), nm (%): 
415 (100), 513 (12.96), 547 (9.50), 590 (8.23), 646 (7.81); fluorescence λmax. 
(MeOH, λexc. = 420 nm) nm (%) 653 (100), 716 (35.31); [Found (ESI+) 











7.3 Biological assays 
7.3.1 Materials and Methods 
All the reagents were purchased from Sigma-Aldrich. Cell culture materials 
were obtained from Life Sciences Technologies (Paisley, UK). Phenol red and 
phenol red-free Dulbeco’s Minimum Essential Medium (DMEM) was 
purchased from Gibco BRL Invitrogen Corporation (Life Technologies, UK). 
MilliQ water (Millipore, MA, USA) was used to prepare phosphate-buffered 
saline (PBS) to minimise transition metal levels. ALA was purchased from 
Carbosynth. 
Light source  
PDT studies carried out at Bath were conducted using a broad spectrum 4kW 
lamp (Sellas, Germany) which emits primarily UVA irradiation and has a 
significant emission in the range of 350-400 nm and some near visible radiation 
at wavelengths longer than 400 nm. The above lamp was suitable for ALA-
PDT studies, as the absorption maximum of PpIX (405 nm) overlaps with the 
emission of the lamp near the visible region (Figure 103). It also overlaps with 
the Soret band absorptions of (196) and (197). 
 





For PDT experiments carried out at University College London (Prof. A. J. 
MacRobert) 96 well plates (TPP® cell culture plates, Sigma Aldrich) were 
illuminated from below with a LumiSource lamp (PCI Biotech). The lamp 
delivered, through four fluorescent tubes, blue light in the spectrum range of 
375-450 nm.  
7.3.2 Stock solutions 
Stock solutions of all prodrugs under investigation, including ALA were 
prepared in DMSO at a concentration of 100 mM.  Aliquots were kept at  -20˚C 
until required.  
MTT stock solution was prepared at a final concentration of 5 mg/mL in PBS 
and was filtered through a 0.22 µm filter for sterilization. The stock solutions 
were stored in small aliquots at -20 °C.  
7.3.3 Cell lines 
Studies carried out at Bath:  
Fluorescence time-course studies and cytotoxicity studies were carried out in 
the MDA-MB-231 cell line. Cell culturing was carried out in 10% FCS DMEM 
(high glucose Dulbecco’s modified Eagle’s medium) with 30 mM NaHCO3,         
2 mM L-glutamine, and 50 IU/mL of each of penicillin/ streptomycin (P/S). The 
FCS stock was heat-inactivated at 56 °C for 45 min before use. Cells were 
passaged once every 5 days and seeded at a density of 8 x 103 cells per well 
in media (200 µL), and grown for 24 h prior to the treatment with compounds 
for 4 or 24 h, depending on the experimental requirement. 
Studies carried out at UCL:  
Cytotoxicity studies and fluorescence microscopy were undertaken in         
MDA-MB-231 and MCF-7 cell lines. Both the cell lines were grown in 10% FCS 
DMEM containing 1% of penicillin streptomycin. Cells were seeded into 96 well 
plates at a density of 6 x 103 cells per well and grown for 24 h prior to treatment 





Stock cells were passaged by trypsinisation once or twice a week. As a general 
rule, stock cell flasks were maintained in culture until they reached a 
confluency of 70-80%, after which they were trypsinised as detailed below: 
The medium was removed from the flask and the cells were then washed with 
PBS (2 x 10 mL). Trypsin (0.25% w/v, 2 mL) was then added to the flask and 
the cells were incubated at 37 °C for 3 min, or until detached. 10 % w/v DMEM 
(4 mL) was added to the flask in order to inactivate the trypsin. The cells were 
then centrifuged for 5 min at 1200 rpm (Jouan B3.11 centrifuge). The 
supernatant was then removed and the cell pellet was resuspended in fresh 
medium (10% w/v DMEM). A small aliquot of the cell suspension (0.1 mL) was 
mixed with trypan blue dye (0.1 mL) and then counted under a microscope 
using a Neubauer-improved haemocytometer purchased from Marienfeld 
(Germany). Cells were then diluted with fresh medium at the required density 
and incubated at 37 °C.  
7.3.5 Statistical Analysis 
Results were expressed as mean +/- standard deviation (SD). Data were 
analysed using paired and unpaired t-tests. The p value of <0.05 was 
considered as a significant difference between groups of data. GraphPad 
Prism 7.01 and Microsoft Excel 2013 software was used to carry out statistical 
analysis. 
The ranges given to the number of experiments for each graph presented in 
the Results section (i.e. n = 3, 4 or 6), indicates the number of independent 







7.3.6 Time-course fluorescence studies 
Cells were seeded into clear 96-well cell culture micro-plates (CELLSTAR®, 
Greiner Bio-one, United Kingdom) at a density of 8 x 103 cells per well for          
24 h. The culture medium was removed and each well was washed with PBS        
(2 x 100 µL). Varying concentrations of ALA and ALA-containing prodrugs in 
phenol red (100 µL) and serum-free medium (100 µL) were then added to 
designated series of wells in triplicates under subdued lighting. Each plate 
contained control wells with cells but without added drug to determine the 
background reading. Each plate was covered with aluminium foil and placed 
in the incubator at 37 °C CO2 for 4-24 h. The fluorescence signal from each 
well was measured at 4, 8 and 24 h interval with a CLARIOstar high 
performance microplate reader (CLARIOstar® BMG LABTECH, United 
Kingdom) using 410 nm excitation and 635 nm emission wavelengths with slit 
widths set to 10 nm.  
7.3.7 Photodynamic treatment 
Studies carried out at Bath:  
Cells were seeded into 96-well black cell culture micro-plates (CELLSTAR®, 
Greiner Bio-one, United Kingdom) at a density of 8 x 103 cells per well for         
24 h. The culture medium was removed and each well was washed with PBS       
(2 x100 µL). Varying concentrations of ALA and ALA-containing prodrugs in 
phenol red and serum-free medium (100 µL) were then added to designated 
series of wells in triplicates under subdued lighting. Each plate contained 
control wells with cells but without added drug to determine the background 
reading. Each plate was covered with aluminium foil and placed in the 
incubator for 4 h at 37 °C under an atmosphere of 5% CO2. After 4 h, drug 
samples were removed and PBS (100 µL) was added to each well. The plates 
were irradiated from above using the broad spectrum 4kW lamp for 30, 60 and 
90 sec (6, 12 and 18 J/cm2) by moving a box covered with foil across the plate 
to expose the appropriate wells (Figure 104). After the irradiation, the PBS was 
replaced with serum-free medium and plates were incubated for further 48 h 





Figure 104. PDT activity on a protected 96-well plate been carried under UVA lamp. 
Studies carried out at UCL:  
Cells were seeded in 96 well plates for 24 h, after which medium was removed 
and cells were washed with PBS. Freshly prepared solutions of compounds at 
varying concentrations were then added to designated wells and the plates 
were covered with foil to protect them from light and incubated for further a      
24 h. The plates were then irradiated from below with the by LumiSource lamp 
by keeping them on top of the light source area for specified times                          
(7 and 10 min). An opaque box was used to shelter throughout the duration of 
light exposure. The plates were further incubated for 48 h and cell viability was 
assessed by MTT assay. In each well plate, some wells were incubated with 
only culture medium (without any compound) and were used as controls.  
7.3.8 MTT assay 
Studies carried out at Bath:  
Prior to the experiment, a solution of MTT in serum free medium (SFM) was 
prepared at a final concentration of 0.5 mg/mL from the stock solution. 96 well 
plates were removed from the incubator and SFM from each well was replaced 
with MTT/SFM solution (100 µL). The plates were then incubated for a further 
3 h. The MTT/SFM solution was removed and DMSO (100 µL) was added to 




platform (Stuart Scientific UK) under dim lighting. The DMSO solutions were 
then transferred to a new 96 well plate (transparent) and read with a Dynatech 
plate reader MR-5000 (Dynatech, Guernsey, Channel Islands) at 570 nm using 
DMSO as a blank control. The mean values obtained from the raw data for 
each condition were expressed as percentage enzymatic activity. 
Studies carried out at UCL:  
A stock solution of MTT at a concentration of 1 mg/mL was prepared and        
100 µL was added to each well. The plates were covered with foil and 
incubated for 2 h. The solution was removed and formazan crystals were 
dissolved in DMSO. The absorbance was read with a plate reader (MR 700 
Dynatech) with a 570 nm band pass filter. The results obtained from the 
analysis above were averaged out for each concentration from each plate and 
then normalised. These were then plotted as % cell viability against normalised 
controls. Normalised standard deviations were also calculated and displayed 
as error bars on the graphs generated.  
7.3.9 Fluorescence Microscopy 
Fluorescence microscopy was carried out at UCL in Prof. A. J. MacRobert’s 
laboratory. 
In order to investigate the cellular uptake of the EGFR-targeted porphyrin 
(195), fluorescence microscopy was performed using an upright 
epifluorescence microscope (Olympus IMT-2) equipped with a 16 bit cooled 
512 x 512 CCD camera. Fluorescence excitation was delivered by a 405 nm 
laser diode module and the emission filter was centred at 660 ± 15 nm. Cells 
were seeded seeding in a Fluorodish and incubated with a final concentration 
of 10 µM of (195). The images were obatined at 10 X magnification and phase 





Overall summary and Future work 
The current project focussed on the synthesis and application of targeted-
dendrimeric ALA prodrugs for photodynamic therapy. 
Chapter 2 focussed on developing and optimising a synthetic route to first and 
second generation ALA dendrons with three or six ALA units suitable for further 
ligation by CuAAC. An initial attempt using Z-protection of Tris-derived building 
blocks led to problems of O- to N- acyl group migration, and subsequent 
acylation with 4-pentynoic acid gave the final Tris-conjugate (105) in low yield 
(7%). The main highlight of this chapter was the development of an alternative 
synthetic route involving a silyl protection strategy (using TIPS-Cl) of the Tris 
and ext. Tris building blocks (97) and (98). This not only avoided the O- to N- 
acyl group migration, but also in subsequent steps gave the first generation 
alkynyl-ALA dendrons (105) and (107) in good yields (89% and 77% 
respectively). The synthesis of a second generation ALA dendron with six ALA 
units (125) was carried out on a trial scale using 5-aminoisophthalic acid as 
the dendron core. This was successful, however further optimisation of the 
route to larger ALA dendrons is required.  
In Chapter 3, the core prodrug units with one (based on 4-hydroxybenzoic acid) 
or three azido arms (based on gallic acid) were synthesised. These azido units 
were then conjugated with the first generation ALA dendrons (105) and (107) 
via CuAAC. Optimised reaction conditions were obtained when the 
stoichiometry of the alkyne to azide in the reaction was (2:1) and with CuSO4 
as the copper source in DMSO/H2O/t-BuOH. These reaction conditions were 
used to synthesise non-targeted ALA dendrimers with three or nine ALA units 
in excellent yields. The synthetic procedure was also adapted successfully to 
synthesise simple biomolecule-targeted ALA prodrugs which involved 
attachment of vitamin E and thymidine to ALA dendrons via CuAAC, using 
Cu(I) trifluoromethanesulfonate benzene complex. Biological evaluation to 
monitor the PpIX release from these conjugates and PDT activity may now be 
carried out in relevant cancer cell lines. An attempt to conjugate a benzyl-
protected glucose derivative with an ALA dendron was also successful, but 




involve exchanging the hydroxyl protecting groups with ones which would be 
stable towards click reaction conditions, but at the same time are removable 
under mild conditions that are compatible with the ALA esters, avoiding 
hydrogenolysis. 
Chapter 4 focussed on investigating different synthetic strategies for 
attachment of an EGFR-targeting peptide (LARLLT) to the clicked ALA 
dendrons developed in Chapter 3. An attempt to initially couple a partially 
protected peptide to a dendrimer in solution under different amide coupling 
conditions (EDC.HCl/HOBt.hydrate or HATU) did not show the formation of 
any new species on HPLC. An alternative strategy of attaching the clicked ALA 
dendron to the peptide on resin was successful, however HPLC purification 
gave the final product in low yield (5%). Subsequent attempts focussed on 
modifying the synthetic strategy and included the attachment of the azido core 
to the targeting peptide, followed by click coupling on-resin or in solution. On-
resin click coupling with the previously developed click coupling conditions of 
CuSO4 and sodium ascorbate in DMSO/H2O were not successful, probably 
due to shrinking of the polystyrene resin under aqueous conditions. Alternative 
copper(I) sources were therefore investigated including copper(I) iodide and 
copper(I) trifluoromethanesulfonate benzene complex, and the click coupling 
of azido-peptides on resin with ALA dendrons was then found to proceed 
effectively in DMSO for 5 days. The best results were obtained when the 
reaction was carried out with copper(I) trifluoromethanesulfonate benzene 
complex which on full deprotection and cleavage from the resin showed the 
presence of a single major species and no unconjugated peptide. The 
identities of the final targeted conjugates with three or nine ALA units were 
confirmed by 1H, 13C NMR and mass spectrometry. The reaction time of five 
days could be significantly decreased to 36 h for the targeted nine ALA 
derivative (181) when the CuAAC reaction was performed with a fully 
deprotected azido peptide and alkynyl dendron. The final conjugate was 
obtained in 69% yield. A final attempt to further reduce the reaction time was 
carried out, and the coupling reaction to produce (183) in solution was carried 
out under microwave conditions. The final conjugate was then obtained in 75% 




Biological data obtained from time-course fluorescence studies and PDT 
experiments in an EGFR-overexpressing cell line (MDA-MB-231) showed 
enhanced ALA-induced PpIX fluorescence at different time intervals and 
higher phototoxicity for the peptide-targeted 9-ALA dendrimer (181) in 
comparison to equimolar doses of ALA and ALA dendrimers (with 3 or 9 copies 
of ALA). Further studies involving evaluation of these targeted dendrimers in 
other EGFR-overexpressing cell lines and exploring attachment of other 
targeting peptides to the ALA dendrimer are now required to further validate 
the application of this model for ALA delivery.  
In Chapter 5, EGFR targeting-peptide (177) was successfully attached to 
different classical photosensitiser derivatives (190), (191) and (13) via SPAAC 
which avoided the use of any copper catalyst. The resulting peptide-
photosensitiser conjugates (195)-(197) were obtained in good yield. PDT 
studies for  porphyrin derivative (190) were carried out in MDA-MB-231 (EGFR 
overexpressing) and MCF-7 (non-EGFR overexpressing) cells which showed 
an enhanced PDT effect in MDA-MB-231 cells, whereas no such effect was 
observed in the MCF-7 cell line. Biological evaluation involving Ce6 conjugate 
(196) and verteporfin conjugate (197) also showed enhanced PDT effects 
across different concentrations and time intervals in MDA-MB-231 cells.  
Chapter 6 focussed on the synthesis of a group of novel CPP-ALA conjugates 
(210)-(214) via CuAAC. Four CPPs were selected for the current work, with 
each of them containing a functionalised amino acid with a reactive azido 
group which could take part in CuAAC with the ALA dendrons (105) and (107). 
The CPP-ALA conjugates were obtained in good yields and will now be tested 
in relevant cell lines. Conjugation of pVEC derivative (203) with DBCO-
porphyrin derivative (192) was also attempted using SPAAC, and here 
biological evaluation in both MDA-MB-231 and MCF-7 cells showed significant 
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